

# ICAR 2011



## PROGRAMME

### Promosso da

**SIMIT** Società Italiana di Malattie Infettive e Tropicali  
e da

**INMI** Istituto Nazionale Malattie Infettive **ISS** Istituto Superiore di Sanità

**SIV** Società Italiana di Virologia **SIVIM** Società Italiana di Virologia Medica

**SIICA** Società Italiana di Immunologia, Immunologia Clinica e Allergologia

**SIMaST** Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

**ANLAIDS** Associazione Nazionale per la lotta contro l'AIDS

**ARCIGAY** Associazione Lesbica e Gay Italiana

**LILA** Lega Italiana per la Lotta contro l'AIDS **NADIR** Fondazione Nadir Onlus

**Firenze • March 27-29, 2011**  
**Palazzo dei Congressi**

**Sotto l'Alto Patronato del Presidente della Repubblica**

*Ministero della Salute*



*Università degli Studi di Firenze*



*Agenzia Italiana del Farmaco*  
**AIFA**





## PRESIDENTI

Francesco Mazzotta (*Coordinatore*)  
 Francesco Leoncini  
 Carlo Federico Perno

## SEGRETERIA SCIENTIFICA

Sergio Lo Caputo  
 Francesca Ceccherini-Silberstein  
 Laura Sighinolfi  
 Gaetana Sterrantino

## COMITATO DI PROGRAMMA

Andrea Antinori  
 Giampiero Carosi  
 Alessandra Cerioli  
 Florio Ghinelli  
 Adriano Lazzarin  
 Francesco Leoncini  
 Francesco Mazzotta  
 Carlo Federico Perno  
 Evangelista Sagnelli  
 Stefano Vella

## LOCAL COMMUNITY LIASONS

Francesca Romana Ponziani (*Fondazione Aviralia*)  
 Stefano Corso (*Lila*)  
 Guido Bastianelli (*Anlaidis*)

## SEGRETERIA ORGANIZZATIVA

T.M.T. Srl  
 Via Mecenate 12 - 20138 Milano  
 Tel. +390258012822  
 Fax +390258028245  
 E-mail: [segreteria@icar2011.it](mailto:segreteria@icar2011.it)  
 Web site: [www.icar2011.it](http://www.icar2011.it)



## Tracks Supervisors

*Subtracks Coordinators*

### BASIC SCIENCES

Florio Ghinelli, Evangelista Sagnelli, Stefano Vella

#### Virology

*A. Caruso, M. Clementi, G. Palù, M.C. Re*

#### Immunopathogenesis

*A. Cossarizza, A. De Maria, C. Mastroianni, G. Tambussi*

#### Diagnostic

*M. Capobianchi, P. Maggi, V. Svicher, M. Zazzi*

### CLINICAL SCIENCES

Andrea Antinori, Giampiero Carosi, Adriano Lazzarin

#### Antiretroviral Therapy (I)

*A. Ammassari, M. Borderi, S. Rusconi, V. Tozzi*

#### Antiretroviral Therapy (II)

*S. Bonora, A.M. Cattelan, G. Marchetti, C. Torti*

#### Co-infections and co-morbidity

*A. Matteelli, G. D'Ettorre, S. Di Giambenedetto, E. Vaccher*

### EPIDEMIOLOGY AND SOCIAL SCIENCES

Alessandra Cerioli

#### Epidemiology and Social Sciences

*F. Crespi, G. Ippolito, P. Patané, F. von Schloesser*

## Organi di Governo di ICAR

### SPC (Scientific Programme Committee)

Nicola Abrescia

Massimo Andreoni

Gioacchino Angarano

Andrea Antinori

Orlando Armignacco

Vincenzo Barnaba

Giampiero Carosi

Roberto Cauda

Alessandra Cerioli

Massimo Clementi

Antonella d'Arminio Monforte

Giovanni Di Perri

Barbara Ensoli

Massimo Galli

Florio Ghinelli

Giuseppe Ippolito

Adriano Lazzarin

Francesco Leoncini

Alberto Matteelli

Francesco Mazzotta

Giorgio Palù

Carlo Federico Perno

Gianni Rezza

Giuliano Rizzardini

Evangelista Sagnelli

Fredy Suter

Stefano Vella

Filippo von Schloesser

Vincenzo Vullo

### CLSc (Community Liasons SubCommittee)

Alessandra Cerioli

Fiore Crespi

Paolo Patané

Filippo von Schloesser

### DIREZIONE DI PROGRAMMA

Giampiero Carosi (Coordinatore)

Andrea Antinori (Segretario)

Alessandra Cerioli

Adriano Lazzarin

Francesco Mazzotta

Carlo Federico Perno

Evangelista Sagnelli

## FACULTY

**Isabella Abbate**

INMI L. Spallanzani - IRCCS, Roma

**Nicola Abrescia**

A.O. D. Cotugno, Napoli

**Adriana Ammassari**

INMI L. Spallanzani - IRCCS, Roma

**Massimo Andreoni**

Università di Roma "Tor Vergata", Roma

**Gioacchino Angarano**

Università degli Studi di Bari, Bari

**Andrea Antinori**

INMI L. Spallanzani - IRCCS, Roma

**Guido Antonelli**

Università di Roma "Sapienza", Roma

**Francesco Antonucci**

INMI L. Spallanzani - IRCCS, Roma

**Orlando Armignacco**

A.O. Ospedale Belcolle, Viterbo

**Sergio Babudieri**

Università degli Studi di Sassari, Sassari

**Claudia Balotta**

Università degli Studi di Milano, Milano

**Fausto Baldanti**

Policlinico San Matteo, Pavia

**Vincenzo Barnaba**Università degli Studi di Roma  
"La Sapienza", Roma**Alessandro Bartoloni**

A.O.U. Careggi, Firenze

**Teresa Bini**

A.O. San Paolo - Polo Universitario, Milano

**Marta Boffito**Chelsea and Westminster Hospital  
London, UK**Isabella Bon**A.O. Policlinico Sant'Orsola-Malpighi,  
Bologna**Paolo Bonfanti**

A.O. Ospedale "A. Manzoni", Lecco

**Stefano Bonora**

Università degli Studi di Torino, Torino

**Marco Borderi**A.O. Policlinico Sant'Orsola - Malpighi,  
Bologna**Michele Breveglieri**

Arcigay, Verona

**Raffaele Bruno**Fondazione IRCCS, Policlinico San  
Matteo, Pavia**Bruno Cacopardo**

Università degli Studi di Catania, Catania

**Paolo Cadrobbi**

Istituto Oncologico Veneto, Padova

**Andrea Calcagno**

A.O. Amedeo di Savoia, Torino

**Filippo Canducci**

Università Vita-Salute S. Raffaele, Milano

**Amedeo Capetti**

A.O. Polo Universitario L. Sacco, Milano

**Maria Rosaria Capobianchi**

INMI L. Spallanzani - IRCCS, Roma

**Marcello Caremani**Ospedale Santa Maria Sopra i Ponti,  
Arezzo**Giampiero Carosi**

Università degli Studi di Brescia, Brescia

**Antonella Castagna**IRCCS Fondazione Centro San Raffaele  
del Monte Tabor, Milano**Francesco Castelli**Azienda Ospedaliera Spedali Civili di  
Brescia**Anna Maria Cattelan**

Azienda ULSS 18, Rovigo

**Roberto Cauda**

Università Cattolica del Sacro Cuore, Roma

**Francesca Ceccherini-Silberstein**Università degli Studi di Roma "Tor  
Vergata", Roma**Benedetto Celesia**

ARNAS Garibaldi, Catania

**Alessandra Cerioli**

LILA, Bologna

**Antonio Chirianni**

A.O. D. Cotugno, Napoli

**Antonella Cingolani**

Università Cattolica del Sacro Cuore, Roma

**Paola Cinque**

Fondazione San Raffaele, Milano

**Massimo Clementi**Università Vita-Salute San Raffaele,  
Milano**Mario Clerici**

Università degli Studi di Milano, Milano

**Andrea Cossarizza**Università di Modena e Reggio Emilia,  
Modena**Fiore Crespi**

ANLAIDS Onlus, Roma

**Antonella d'Arminio Monforte**

Università degli Studi di Milano, Milano

**Andrea De Luca**

Università Cattolica del Sacro Cuore, Roma

**Andrea Francesco De Maria**Istituto Scientifico per la Ricerca sul  
Cancro, Genova**Francesco Giuseppe De Rosa**

Università degli Studi di Torino, Torino

**Anita De Rossi**

Università degli Studi di Padova, Padova

**Gabriella D'Etto**

Università di Roma "Sapienza", Roma

**Antonio Di Biagio**

A.O.U. San Martino, Genova

**Simona Di Giambenedetto**

Università Cattolica del Sacro Cuore, Roma

**Giovanni Di Perri**

Università degli Studi di Torino, Roma

**Giampiero D'Offizi**

INMI L. Spallanzani – IRCCS, Roma

**Barbara Ensoli**

Centro Nazionale AIDS, Istituto Superiore di Sanità, Roma

**Gaetano Filice**

Università degli Studi di Pavia, Pavia

**Pietro Filippini**

Seconda Università di Napoli, Napoli

**Massimo Galli**

Università degli Studi di Milano, Milano

**Giovan Battista Gaeta**

Seconda Università di Napoli, Napoli

**Cristina Gervasoni**

A.O. Polo Universitario L. Sacco, Milano

**Florio Ghinelli**

A.O.U. Arcispedale Sant'Anna, Ferrara

**Valeria Ghisetti**

Università degli Studi di Torino, Torino

**Mauro Giacca**

International Centre for Genetics, Engineering and Biotechnology, Trieste

**Nicola Gianotti**

IRCCS Fondazione San Raffaele, Milano

**Carlo Giaquinto**

Università degli Studi di Padova, Padova

**Enrico Girardi**

INMI L. Spallanzani – IRCCS, Roma

**Andrea Gori**

Università degli Studi di Milano-Bicocca, Milano

**Paolo Grossi**

Università degli Studi dell'Insubria, Varese

**Giovanni Guaraldi**

Università di Modena e Reggio Emilia, Modena

**Andrew Hill**

Liverpool University, Liverpool, UK

**Giuseppe Ippolito**

INMI L. Spallanzani – IRCCS, Roma

**Ralf Jürgens**

The Global Fund to Fight AIDS, Tuberculosis and Malaria, Mille-Isles, Quebec, Canada

**Adriano Lazzarin**

Università Vita-Salute San Raffaele, Milano

**Francesco Leoncini**

A.O.U. Careggi, Firenze

**Jay Levy**

Department of Medicine, University of California, San Francisco, USA

**Sergio Lo Caputo**

Azienda Sanitaria di Firenze, Firenze

**Daniela Lorenzetti**

Anlaidis, Roma

**Giuseppina Liuzzi**

INMI L. Spallanzani - IRCCS Roma

**Lucia Lopalco**

Fondazione Centro San Raffaele del Monte Tabor – IRCCS, Milano

**Paolo Maggi**

A.O. Policlinico di Bari, Bari

**Franco Maggiolo**

A.O. Ospedali Riuniti di Bergamo, Bergamo

**Mauro Magnani**

Università degli Studi di Urbino, Urbino

**Simone Marcotullio**

NADIR Onlus, Roma

**Renato Maserati**

Fondazione IRCCS – Policlinico San Matteo, Pavia

**Claudio Mastroianni**

Università di Roma "Sapienza" – Polo Pontino, Latina

**Alberto Matteelli**

Università degli Studi di Brescia, Brescia

**Francesco Mazzotta**

Azienda Sanitaria di Firenze, Firenze

**Lorenzo Minoli**

Università degli Studi di Pavia, Pavia

**Masaaki Miyazawa**

University School of Medicine, Osaka, Japan

**Julio Montaner**

B.C. Centre for Excellence in HIV/AIDS, Vancouver, Canada

**Mauro Moroni**

Università degli Studi di Milano, Milano

**Cristina Mussini**

A.O.U. Policlinico di Modena, Modena

**Pasquale Narciso**

INMI L. Spallanzani – IRCCS, Roma

**Paola Nasta**

A.O. Spedali Civili di Brescia, Brescia

**Pierluigi Navarra**

Policlinico Universitario "A. Gemelli", Roma

**Emanuele Nicastrì**

INMI L. Spallanzani – IRCCS, Roma

**Anna Orani**  
SIMIT, Lecco

**Lucia Palmisano**  
Istituto Superiore di Sanità, Roma

**Giorgio Palù**  
Università degli Studi di Padova, Padova

**Giuseppe Pantaleo**  
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

**Saverio Parisi**  
Università degli Studi di Padova, Padova

**Giustino Parruti**  
Ospedale Spirito Santo, Pescara

**Paolo Patané**  
Arcigay, Catania

**Carlo Federico Perno**  
Università degli Studi Roma "Tor Vergata", Roma

**Nicola Petrosillo**  
INMI L. Spallanzani - IRCCS, Roma

**Guido Poli**  
Università Vita-Salute San Raffaele, Milano

**Anton Pozniak**  
Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

**Massimo Puoti**  
A.O. Ospedale Niguarda Ca' Granda, Milano

**Tiziana Quirino**  
A.O. Ospedale di Circolo di Busto Arsizio, Busto Arsizio

**Enzo Raise**  
Azienda USL 12 Veneziana, Venezia

**Marina Ravizza**  
A.O. San Paolo - Polo Universitario, Milano

**Maria Carla Re**  
Università degli Studi di Bologna, Bologna

**Giovanni Rezza**  
Istituto Superiore di Sanità, Roma

**Agostino Riva**  
Università degli Studi di Milano, Milano

**Giuliano Rizzardini**  
A.O. Polo Universitario L. Sacco, Milano

**Stefano Rusconi**  
Università degli Studi di Milano, Milano

**Evangelista Sagnelli**  
Seconda Università di Napoli, Napoli

**Teresa Santantonio**  
Università degli Studi di Foggia, Foggia

**Loredana Sarmati**  
Università Tor Vergata, Roma

**Laura Sighinolfi**  
A.O.U. Arcispedale Sant'Anna, Ferrara

**Guido Silvestri**  
Yerkes National Primate Research Center, Emory University, Atlanta USA

**Barbara Suligoi**  
Istituto Superiore di Sanità, Roma

**Gaetana Sterrantino**  
A.O.U. Careggi, Firenze

**Fredy Suter**  
A.O. Ospedali Riuniti di Bergamo, Bergamo

**Valentina Svicher**  
Università degli Studi di Roma "Tor Vergata", Roma

**Giuseppe Tambussi**  
Ospedale San Raffaele, Milano

**Philip Tarr**  
University of Basel, Basel, Switzerland

**Carlo Torti**  
Università degli Studi di Brescia, Brescia

**Valerio Tozzi**  
INMI L. Spallanzani - IRCCS, Roma

**Maria Paola Trotta**  
INMI L. Spallanzani - IRCCS, Roma

**Ombretta Turriziani**  
Università degli Studi di Roma "La Sapienza", Roma

**Emanuela Vaccher**  
Centro di Riferimento Oncologico, Aviano

**Jan van Lunzen**  
University Medical Center Hamburg-Eppendorf, Germany

**Stefano Vella**  
Istituto Superiore di Sanità, Roma

**Pier Luigi Viale**  
Università degli Studi di Bologna, Bologna

**Alessandra Viganò**  
A.O. Polo Universitario L. Sacco, Milano

**Paolo Viganò**  
A.O. Ospedale Civile di Legnano, Legnano

**Claudio Viscoli**  
Università degli Studi di Genova, Genova

**Filippo von Schloesser**  
Nadir Onlus, Roma

**Vincenzo Vullo**  
Università degli Studi di Roma "La Sapienza", Roma

**Mauro Zaccarelli**  
INMI L. Spallanzani - IRCCS, Roma

**Maurizio Zazzi**  
Università degli Studi di Siena, Siena

**Giuliano Zuccati**  
Università degli Studi di Firenze, Firenze



*Il terzo Convegno ICAR 2011 si caratterizza per due elementi, aggiuntivi a quelli classici degli ICAR finora organizzati.*

*Il primo è la presenza nel calendario del Congresso dell'InternationalAids Society (IAS), che si svolgerà nel luglio 2011 a Roma.*

*Esso costituisce un'opportunità, in quanto è possibile collegare gli eventi ICAR con quelli di IAS, creando uno spazio in ICAR per promuovere IAS, e in IAS per presentare i migliori lavori emersi a Marzo in ICAR.*

*È un modo per dare notevole visibilità alla realtà scientifica italiana, creando continuità con un evento mondiale come IAS.*

*Il secondo elemento è la vicinanza con il recente CROI, che si è tenuto alla fine di febbraio.*

*ICAR è un'importante occasione per creare tra i due eventi internazionali uno spazio nel quale discutere e presentare le novità della ricerca italiana confrontandole con quella internazionale.*

*Il CROI, infatti, abitualmente rappresenta il punto fermo della ricerca biomedica sull'AIDS, su cui impostare le attività dell'intero anno.*

*In sostanza, quindi, in un Convegno istituzionale come ICAR, si potranno svolgere gli aggiornamenti post-CROI, evitando di disperderli sul territorio nazionale.*

*Oltre a questi elementi, di per sé innovativi, ICAR 2011 si focalizzerà, come ogni anno, su tematiche biomediche cercando di dare spazio ad aree disciplinari non pienamente sviluppate in altri incontri.*

*Attenzione sarà data alla diagnostica innovativa e al suo inserimento nei percorsi diagnostico terapeutici della pratica clinica. Infine ci saranno gli spazi dedicati alle novità terapeutiche ed ai Corsi pre-congressuali destinati in particolar modo ai giovani.*

Francesco Mazzotta

Francesco Leoncini

Carlo Federico Perno



# Pre-Conference Advanced Courses

## Sunday 27 March

The Pre-Conference Advanced Courses will take place at the Palazzo dei Congressi at the following times: from 13.30 to 16.30



### HIV-HEPATITIS VIRUS CO-INFECTION

Coordinators: *G. Filice* (Pavia), *G.B. Gaeta* (Naples),  
*M. Puoti* (Milan)

- 13.30 Introduction: overview on epidemiology**  
B. Cacopardo (Catania)
- 13.45 Update on pathogenesis of HIV-hepatitis co-infection**  
V. Svicher (Rome)
- 13.55 Clinical choices for treatment and follow up**
- **HBV co-infection** – F. Antonucci (Rome)
  - **HCV co-infection** – P. Nasta (Brescia)
- 14.35 Discussion**
- 14.45 Diagnostic tools for the staging of the disease:**
- **Laboratory in the definition of the viral framework and fibrosis** – T. Santantonio (Foggia)
  - **Ultrasound based diagnosis** – M. Caremani (Arezzo)
- 15.25 Discussion**
- 15.35 Therapy for coinfecting patients**  
R. Bruno (Pavia)
- 15.55 Liver transplantation in coinfecting patients**  
P. Grossi (Varese)
- 16.15 Discussion and conclusions**

## ADVANCED DIAGNOSTIC

Coordinators: *F. Ceccherini-Silberstein* (Rome),  
*O. Turriziani* (Rome), *V. Ghisetti* (Turin)

### RELIABILITY AND UTILITY OF ULTRASENSITIVE VIRAL LOAD QUANTIFICATION IN CLINICAL PRACTICE

- 13.30**     **Importance of ultrasensitive viral load quantification in clinical practice**  
L. Sarmati (Rome)
- 13.45**     **Comparative technology and reliability of ultrasensitive methods**  
F. Canducci (Milan)
- 14.00**     *Discussion*

### PROVIRAL DNA: TECHNOLOGY AND CLINICAL PRACTICE AT DEBATE

- 14.10**     **Clinical importance of proviral DNA assessment**  
L. Sarmati (Rome)
- 14.20**     **Quantification of all different viral DNA forms**  
M. Magnani (Urbino)
- 14.35**     **Viral tropism based on DNA samples**  
I. Bon (Bologna)
- 14.50**     *Discussion*

### ULTRA-DEEP SEQUENCING DEVELOPMENT AND UTILITY IN CLINICAL PRACTICE

- 15.00**     **Clinical importance of ultra-deep sequencing**  
S. Rusconi (Milan)
- 15.15**     **Comparative methods: ultra-deep sequencing or allele specific PCR?**  
I. Abbate (Rome)
- 15.30**     *Discussion*

### CLINICAL IMPLICATIONS OF HIV-1 NEF PROTEIN MUTATIONS

- 15.40**     **Clinical role of nef protein mutations**  
N. Petrosillo (Rome)

### RAPID DIAGNOSIS OF HIV INFECTION

- 15.55**     **HIV rapid test? Reliability and utility**  
F. Baldanti (Pavia)
- 16.10**     **Discussion and conclusions**

## WOMEN AND HIV: IDENTIFICATION AND MANAGEMENT OF PECULIARITIES OF HIV INFECTED WOMEN

Coordinators: A.M. Cattelan (Padua), L. Palmisano (Rome),  
A. Orani (Lecco)

- 13.30**      **Females susceptibility to HIV infection**  
G. Liuzzi (Rome)
- 13.50**      **Sexually transmitted diseases and female population**  
G. Zuccati (Florence)
- 14.10**      *Discussion*
- 14.20**      **Screening of co-morbidities in HIV infected women**  
C. Mussini (Modena)
- 14.35**      **Management of toxicity to ART in HIV infected women**  
C. Gervasoni (Milan)
- 14.50**      *Discussion*
- 15.00**      **Distribution and metabolism of drugs and antiretrovirals in women**  
A. Calcagno (Turin)
- 15.15**      **Fertility and pregnancy in HIV infected women: an integrated approach**  
• **The infectious diseases clinician** – T. Bini (Milan)  
• **The gynecology specialist** - M. Ravizza (Milan)
- 15.45**      **HIV infection and females believes**  
A. Ammassari (Rome)
- 16.00**      **Women and HIV: clinical trials and cohort data**  
A. d'Arminio Monforte (Milan)
- 16.15**      **Discussion and conclusions**



17.00

## **OPENING CEREMONY**

*(Palazzo Vecchio  
Salone dei Cinquecento)*

*F. Mazzotta (Florence)*

*F. Leoncini (Florence)*

*C.F. Perno (Rome)*

**Authorities welcome**

18.00

## **LECTURES**

Chairmen: *A. Cerioli (Bologna), E. Sagnelli (Naples),  
S. Vella (Rome)*

**TREATMENT AS PREVENTION:  
HAART EXPANSION A POWERFUL STRATEGY  
TO REDUCE AIDS MORBIDITY,  
MORTALITY AND HIV INCIDENCE**

*J. Montaner (Vancouver)*

**HIV VACCINE: QUO VADIS?**

*B. Ensoli (Rome)*

**HIV PREVENTION IN PRISON:  
FROM EVIDENCE TO POLICY**

*R. Jürgens (Montreal)*

19.30

**Welcome Cocktail**

*(Palazzo Vecchio - Sala delle Armi)*

## Monday 28 March

---

08.00 **Registration** (Palazzo dei Congressi)

08.30 **LECTURES** (Auditorium)

Chairmen: *G. Palù* (Padua), *M. Moroni* (Milan)

**ADVANCED UNDERSTANDING OF HIV VIROLOGY AND VIROLOGICAL MONITORING OF THE INFECTION; BUT THERE REMAIN OUTSTANDING ISSUES**

*G. Antonelli* (Rome)

**HIV/AIDS: THE IMPORTANCE OF INNATE IMMUNITY**

*J. Levy* (San Francisco)

### ORAL COMMUNICATIONS

09.45 **SESSION I** (Auditorium)

---

#### VIROLOGY

Chairman: *A. De Rossi* (Padua)

##### INTRODUCTION

*M. Clementi* (Milan)

Moderators and Discussants:

*A. Caruso* (Modena), *M.C. Re* (Bologna), *V. Svicher* (Rome)

**CO1 THE LOWEST X4 GENO2 PHENO-FALSE POSITIVE RATE IS ASSOCIATED WITH GREATER CD4 DEPLETION**

*M.M. Santoro*<sup>\*1</sup>, *D. Armenia*<sup>1</sup>, *L. Fabeni*<sup>2</sup>, *M. Santoro*<sup>1</sup>, *C. Gori*<sup>2</sup>, *F. Forbici*<sup>2</sup>, *V. Cento*<sup>1</sup>, *V. Svicher*<sup>1</sup>, *A. Bertoli*<sup>1</sup>, *L. Dori*<sup>1</sup>, *M. Andreoni*<sup>1</sup>, *P. Narciso*<sup>2</sup>, *A. Antinori*<sup>2</sup>, *F. Ceccherini-Silberstein*<sup>1</sup>, *C.F. Perno*<sup>1,2</sup>

<sup>1</sup> *University of Tor Vergata, Rome, Italy*; <sup>2</sup> *I.N.M.I. "L. Spallanzani", Rome, Italy*

**CO2 A GLYCOMIMETIC COMPOUND INHIBITS DC-SIGN MEDIATED HIV INFECTION IN CELLULAR AND CERVICAL EXPLANT MODELS**

*A. Berzi*<sup>\*1</sup>, *S. Sattin*<sup>2</sup>, *J. Reina*<sup>2</sup>, *M. Sanchez-Navarro*<sup>3</sup>, *J. Rojo*<sup>3</sup>, *D. Trabattoni*<sup>1</sup>, *P. Antonazzo*<sup>4</sup>, *I. Cetin*<sup>4</sup>, *A. Bernardi*<sup>2</sup>, *M. Clerici*<sup>5</sup>

<sup>1</sup> *Department of Clinical Science L. Sacco, University of Milan, Milan, Italy*; <sup>2</sup> *Department of Organic and Industrial Chemistry, University of Milan, Milan, Italy*; <sup>3</sup> *Instituto de Investigacion Quimicas, University of Sevilla, Sevilla, Spain*; <sup>4</sup> *Unit of Obstetrics and Gynecology, Hospital L. Sacco, Milan, Italy*; <sup>5</sup> *Air of Immunology, University of Milan, Milan, Italy*

**CO3 SELECTIVE UPREGULATION OF DC-SIGN IN M2A POLARIZED MACROPHAGES FACILITATES IN VITRO HIV-1 INFECTION AND TRANSMISSION**

*G. Poli*<sup>\*1</sup>, *L. Cassetta*<sup>2</sup>, *M. Alfano*<sup>2</sup>, *E. Cassol*<sup>3</sup>

<sup>1</sup> *Università Vita-Salute San Raffaele, Milan, Italy*; <sup>2</sup> *IRCCS San Raffaele, Milan, Italy*; <sup>3</sup> *Harvard Medical School, Boston, USA*

- CO4** A STUDY OF HIV CORECEPTOR TROPISM IN PAIRED PLASMA, PBMC AND CEREBROSPINAL FLUID ISOLATES FROM NAÏVE SUBJECTS  
C. Andreoni\*<sup>1</sup>, S.G. Parisi<sup>2</sup>, L. Sarmati<sup>3</sup>, A.R. Buonomini<sup>3</sup>, G. D'Ettore<sup>1</sup>, C. Boldrin<sup>2</sup>, S. Andreis<sup>2</sup>, R. Scaggiante<sup>4</sup>, M. Cruciani<sup>5</sup>, O. Bosco<sup>5</sup>, V. Manfrin<sup>6</sup>, C. Mengoli<sup>2</sup>, G. Palù<sup>2</sup>, V. Vullo<sup>1</sup>, M. Andreoni<sup>3</sup>  
<sup>1</sup> *Cattedra di Malattie Infettive, La Sapienza, Rome, Italy;* <sup>2</sup> *Dipartimento di istologia, microbiologia e biotecnologie, università di Padova, Padua, Italy;* <sup>3</sup> *Cattedra di Malattie Infettive, Tor Vergata, Rome, Italy;* <sup>4</sup> *Unità di Malattie Infettive, Ospedale di Padova, Padua, Italy;* <sup>5</sup> *Centro di Medicina Preventiva, ULSS 20, Verona, Italy;* <sup>6</sup> *Unità di malattie Infettive, Vicenza, Italy*
- CO5** ACCUMULATION OF DEFECTIVE HI-1 VARIANTS IN A SUBTYPE SLOW-PROGRESSOR WITH HIGH RT SPECIFIC CD8+ MEMORY T-CELL RESPONSE  
S. Paolucci\*<sup>4</sup>, A. Foli<sup>2</sup>, S. Calarota<sup>1</sup>, R. Gulminetti<sup>3</sup>, F. Baldanti<sup>1</sup>  
<sup>1</sup> *SS Virologia Molecolare SC Virologia e Microbiologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;* <sup>2</sup> *Lab. Biotecnologie Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;* <sup>3</sup> *Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;* <sup>4</sup> *SS Virologia Molecolare SC Virologia e Microbiologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*
- CO6** THE ADAR EDITING ENZYMES ARE NOVEL HIV-1 PROVIRAL FACTORS  
M. Doria<sup>2</sup>, S. Tomaselli<sup>2</sup>, F. Neri<sup>2</sup>, S.A. Ciafre<sup>1</sup>, M.G. Farace<sup>1</sup>, A. Gallo<sup>2</sup>, A. Michienzi\*<sup>1</sup>  
<sup>1</sup> *Università di Roma "Tor Vergata", Rome, Italy;* <sup>2</sup> *Ospedale Bambin Gesù, Rome, Italy*

09.45

**SESSION II**

(Sala Verde)

**EPIDEMIOLOGY AND PREVENTION**Chairman: *G. Rezza* (Rome)**INTRODUCTION***B. Suligo* (Rome)

Moderators and Discussants:

*P. Patanè* (Catania), *E. Girardi* (Rome),*F. von Schlösser* (Rome)

- CO7** SIALON PROJECT (2008-2010): HIV PREVALENCE, UNDIAGNOSED INFECTIONS, DRUG USE AND UNPROTECTED ANAL INTERCOURSE AMONG MSM ATTENDING GAY VENUES IN SIX EUROPEAN CITIES (BARCELONA, BRATISLAVA, BUCHAREST, LJUBLJANA, PRAGUE AND VERONA)  
M. Breveglieri\*<sup>1</sup>, L. Gios<sup>1</sup>, M. Furegato<sup>1</sup>, J.P. Foschia<sup>1</sup>, E. Castellani<sup>1</sup>, D. Ramarli<sup>2</sup>, P. Coato<sup>2</sup>, M. Mirandola<sup>1</sup>  
<sup>1</sup> *Regional Centre for Health Promotion, Regione Veneto, Verona, Italy;* <sup>2</sup> *Dipartimento Patologia e Diagnostica, Università di Verona, Verona, Italy*
- CO8** 2007-2010: DAY CARE ACCOMODATION FOR PLWHA IN LOMBARDY REGION  
L. Rancilio\*<sup>1</sup>, A. Grassini<sup>1</sup>, G. Gaiera<sup>1</sup>  
<sup>1</sup> *Coordinamento Case Alloggio per persone con HIV/AIDS della Lombardia (C.R.C.A. Lombardia), Milan, Italy*
- CO9** IN A HAART NON-ADHERENT POPULATION, WOMEN REPORT SIGNIFICANTLY POORER ADHERENCE

**BEHAVIORS, HIGHER SYMPTOMS RATES, AND WORSE HEALTH STATUS WHEN COMPARED TO MEN**

A. Ammassari\*<sup>1</sup>, M.P. Trotta<sup>1</sup>, T. Bini<sup>2</sup>, C. Negri<sup>3</sup>, R. Bellagamba<sup>1</sup>, G. Gregis<sup>4</sup>, M. Tettoni<sup>5</sup>, A. Capetti<sup>6</sup>, C. Tommasi<sup>1</sup>, L. Trentini<sup>5</sup>, B. Argenterì<sup>6</sup>, M. Zaccarelli<sup>1</sup>, L. Comi<sup>2</sup>, S. Leone<sup>4</sup>, L. Dori<sup>7</sup>, P. Nasta<sup>8</sup>, A. Antinori<sup>1</sup>  
<sup>1</sup> INMI "L. Spallanzani", Rome, Italy; <sup>2</sup> Ospedale San Paolo, Milan, Italy; <sup>3</sup> Università di Milano, Milan, Italy; <sup>4</sup> Ospedale di Bergamo, Bergamo, Italy; <sup>5</sup> Università di Torino, Turin, Italy; <sup>6</sup> Ospedale Luigi Sacco, Milan, Italy; <sup>7</sup> Università Tor Vergata, Rome, Italy; <sup>8</sup> Ospedali Riuniti di Brescia, Brescia, Italy

**CO10 ACCESS TO HIV TESTING IN ITALY**

A. Colucci\*<sup>1</sup>, P. Gallo<sup>1</sup>, S. D'Amato<sup>2</sup>, M. Oldrini<sup>3</sup>, L. Rancilio<sup>3</sup>, M.G. Pompa<sup>4</sup>, A.M. Luzi on behalf of the Study Group<sup>1</sup>  
<sup>1</sup> Department of Infectious, Parasitic and Immune-Mediated Diseases, Italian National Institute of Health, Rome, Italy; <sup>2</sup> National AIDS Center, Italian Institute of Health, Rome, Italy; <sup>3</sup> Council for the fight against AIDS; <sup>4</sup> Italian Ministry of Health

**CO11 HIV INFECTION AND MIGRANTS: A PILOT STUDY BASED ON THE EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (ECDC) INDICATORS**

S. D'Amato\*<sup>1</sup>, O. Picconi<sup>1</sup>, S. Buttò<sup>1</sup>, S. Sipone<sup>1</sup>, M.G. Pompa<sup>2</sup>, B. Ensolì<sup>1</sup>  
<sup>1</sup> National AIDS Center, Istituto Superiore di Sanità, Rome, Italy; <sup>2</sup> Direzione Generale della Prevenzione Sanitaria, Ministero della Salute, Rome, Italy

**CO12 HIV POST-EXPOSURE PROPHYLAXIS IN ITALY (1996-2009)**

V. Puro\*<sup>1</sup>, G. De Carli<sup>1</sup>, E. Schifano<sup>1</sup>, P. Piselli<sup>1</sup>, N. Orchi<sup>1</sup>, S. Pittalis<sup>1</sup>, P. Scognamiglio<sup>1</sup>, C. Cimaglia<sup>1</sup>, A. Agresta<sup>1</sup>, G. Ippolito<sup>1</sup>, Italian Registry of Antiretroviral PEP  
<sup>1</sup> INMI "L. Spallanzani" IRCCS, Rome, Italy

**11.30 LECTURE (Auditorium)**

Chairman: C. Viscoli (Genoa)

**CLINICAL IMMUNOLOGY OF HIV INFECTION**

J. van Lunzen (Hamburg)

**ORAL COMMUNICATIONS****12.00 SESSION III (Auditorium)****IMMUNOLOGY**

Chairman: G. Poli (Milan)

**INTRODUCTION**

G. Silvestri (Atlanta)

Moderators and Discussants:

A. De Maria (Genoa), F. Suter (Bergamo), C.M. Mastroianni (Rome)

**CO13 TLR4 RESPONSIVENESS TO LPS STIMULATION IS UPREGULATED IN HIV-EXPOSED UNINFECTED INDIVIDUALS**

G. De Luca\*<sup>1</sup>, D. Trabattoni<sup>1</sup>, M. Biasin<sup>1</sup>, S. Lo Caputo<sup>2</sup>, L. Piacentini<sup>1</sup>, B. Tavano<sup>1</sup>, M. Borelli<sup>1</sup>, V. Rainone<sup>1</sup>, F. Mazzotta<sup>2</sup>, M. Clerici<sup>1</sup>  
<sup>1</sup> Università degli Studi di Milano, Milan, Italy; <sup>2</sup> Osp. S. Maria Annunziata, Florence, Italy

- CO14** IN VITRO EXPOSURE OF HEALTHY CD4+ T LYMPHOCYTES TO GP120 INDUCES CHANGES IN MIRNA EXPRESSION PROFILES  
C. Casoli\*<sup>1,2</sup>  
<sup>1</sup> Università di Milano, Dipartimento di Scienze Cliniche, sez. Malattie Infettive, Milan, Italy; <sup>2</sup> Gemib srl, Parma, Italy
- CO15** MITOCHONDRIAL DNA SUSTAINS INFLAMMATION DURING HIV INFECTION: IMPLICATIONS FOR THE TREATMENT OF THE DISEASE  
A. Cossarizza\*<sup>1</sup>, M. Pinti<sup>1</sup>, M. Nasi<sup>1</sup>, L. Gibellini<sup>1</sup>, L. Bertoncetti<sup>1</sup>, S. Manzini<sup>1</sup>, E. Roat<sup>1</sup>, S. De Biasi<sup>1</sup>, L. Bisi<sup>1</sup>, L. Manzini<sup>1</sup>, V. Borghi<sup>2</sup>, C. Mussini<sup>2</sup>  
<sup>1</sup> Univ. di Modena e Reggio Emilia, Modena - <sup>2</sup> Azienda Ospedaliero-Universitaria, Modena, Italy
- CO16** COMPARATIVE PROTEOMIC ANALYSIS OF DLBCL FROM HIV+ AND HIV- INDIVIDUALS BY 2D DIFFERENTIAL GEL ELECTROPHORESIS  
V. De Re\*<sup>1</sup>, M.P. Simula<sup>1</sup>, A. Pavan<sup>1</sup>, G. Toffoli<sup>1</sup>, A. Carbone<sup>1</sup>, V. Canzonieri<sup>1</sup>, M. Spina<sup>1</sup>, E. Vaccher<sup>1</sup>  
<sup>1</sup> Centro di Riferimento Oncologico, Aviano, Italy
- CO17** IL-7 RECEPTOR AND IL-15 RECEPTOR SINGLE NUCLEOTIDE POLYMORPHISMS INFLUENCE HIV-1 DISEASE PROGRESSION  
A. Riva\*<sup>1</sup>, L. Ferraris<sup>2</sup>, D. Misciagna<sup>2</sup>, M. Nasi<sup>3</sup>, S. Ghezzi<sup>4</sup>, C. Casoli<sup>2</sup>, G. Poli<sup>5</sup>, A. Cossarizza<sup>3</sup>, M. Galli<sup>2</sup>, M. Tarkowski<sup>2</sup>  
<sup>1</sup> III Divisione di Malattie Infettive, Ospedale L. Sacco, Milan, Italy; <sup>2</sup> Dipartimento di Scienze Cliniche, Sezione di Malattie Infettive e Immunopatogenesi, Università di Milano, Milan, Italy; <sup>3</sup> Dipartimento di Scienze Biomediche, Università di Modena e Reggio Emilia, Modena, Italy; <sup>4</sup> Unità di Immunopatogenesi dell'AIDS, Divisione di Immunologia, Università Vita-Salute, San Raffaele, Milan, Italy; <sup>5</sup> Unità di Immunopatogenesi dell'AIDS, Divisione di Immunologia, Università Vita e Salute, San Raffaele, Milan, Italy
- CO18** PROVIRAL HIV CHANGES CORRELATE WITH CD4+CD45RA+ T-CELL RECOVERY IN PATIENTS RECEIVING RALTEGRAVIR-INCLUDING REGIMENS  
N. Gianotti\*<sup>1</sup>, M. Malnati<sup>2</sup>, L. Galli<sup>1</sup>, A. Galli<sup>1</sup>, M. Tolazzi<sup>3</sup>, G. Cassina<sup>2</sup>, S. Nozza<sup>1</sup>, L. Della Torre<sup>1</sup>, A. Castagna<sup>1</sup>, G. Scarlatti<sup>3</sup>  
<sup>1</sup> Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; <sup>2</sup> Human Virology Unit, San Raffaele Scientific Institute, Milan, Italy; <sup>3</sup> Viral Evolution and Transmission Unit, San Raffaele Scientific Institute, Milan, Italy

12.00 **SESSION IV**

(SalaVerde)

**CLINICAL IMMUNOLOGY**

Chairman: A. Gori (Monza)

**INTRODUCTION**

G. Tambussi (Milan)

Moderators and Discussants:

G. D'Offizi (Rome), G. Marchetti (Milan),  
A. Bartoloni (Florence)

- CO19** CMV-SPECIFIC INTERLEUKIN-17-PRODUCING CD4+ T CELLS (TH17) ARE EXPANDED IN HIV-INFECTED PATIENTS LACKING IMMUNOLOGICAL RECOVERY DESPITE EFFECTIVE ANTIRETROVIRAL TREATMENT  
A. Bandera\*<sup>4</sup>, D. Trabattoni<sup>1</sup>, N. Squillace<sup>4</sup>, A. Muscatello<sup>4</sup>, M. Rossi<sup>4</sup>, C. Pinnetti<sup>4</sup>, M. Borelli<sup>1</sup>, M. Saresella<sup>2</sup>, M. Clerici<sup>3</sup>, A. Gori<sup>4</sup>



<sup>1</sup> Dipartimento di Scienze Precliniche, LITA Vialba, Università di Milano - Milan, Italy; <sup>2</sup>Laboratorio di Medicina Molecolare & Biotecnologie, Fondazione Don Gnocchi - Milan, Italy; <sup>3</sup> Dipartimento di Scienze e Tecnologie Biomediche, Università di Milano - Milano; <sup>4</sup> Divisione di Malattie Infettive, Ospedale S. Gerardo, Monza, Italy

**CO20**

**INCREASED BONE MARROW INTERLEUKIN-7 (IL7)/IL 7R BUT REDUCED IL-7 RESPONSIVENESS IN HIV INFECTED PATIENTS LACKING CD4+ GAIN ON ANTIVIRAL THERAPY**

A. Bandera<sup>3,4</sup>, D. Trabattoni<sup>1</sup>, N. Squillace<sup>4</sup>, A. Muscatello<sup>4</sup>, M. Rossi<sup>4</sup>, C. Pinnetti<sup>4</sup>, M. Borelli<sup>1</sup>, M. Saresella<sup>2</sup>, M. Clerici<sup>3</sup>, A. Gori<sup>4</sup>

<sup>1</sup> Dipartimento di Scienze Precliniche, LITA Vialba, Università di Milano - Milan, Italy; <sup>2</sup> Laboratorio di Medicina Molecolare & Biotecnologie, Fondazione Don Gnocchi - Milan, Italy; <sup>3</sup> Dipartimento di Scienze e Tecnologie Biomediche, Università di Milano - Milano; <sup>4</sup> Divisione di Malattie Infettive, Ospedale S. Gerardo, Monza, Italy

**CO21**

**EXPANSION OF ACTIVATED T LYMPHOCYTES (CD3+CD4+HLADR+ AND CD3+CD8+HLADR+) IN PATIENTS TREATED WITH HAART WITH VIRAL BLIPS OR LOW LEVELS OF RESIDUAL VIREMIA**

A.R. Buonomini<sup>\*1</sup>, L. Sarmati<sup>1</sup>, M. Viscione<sup>1</sup>, L. Dori<sup>1</sup>, G. Maffongelli<sup>1</sup>, D. Fraboni<sup>1</sup>, F. Buccisano<sup>1</sup>, S.G. Parisi<sup>3</sup>, R. Ferretto<sup>2</sup>, M. Andreoni<sup>1</sup>

<sup>1</sup> Cattedra di Malattie Infettive, Tor Vergata, Rome, Italy; <sup>2</sup> Ospedale di Schio, Vicenza, Italy; <sup>3</sup> Dipartimento di istologia, microbiologia e biotecnologie, Università di Padova, Padua, Italy

**CO22**

**IMMUNOLOGICAL EFFICACY OF MARAVIROC (MVC) AS INTENSIFICATION STRATEGY IN HIV-INFECTED PATIENTS (PTS) FAILING CD4 RECOVERY ON VIROLOGICALLY-SUPPRESSIVE HAART**

S. Rusconi<sup>\*1</sup>, E. Colella<sup>1</sup>, F. Adorni<sup>2</sup>, P. Vitiello<sup>1</sup>, E. Focà<sup>3</sup>, A. Capetti<sup>4</sup>, P. Meraviglia<sup>5</sup>, C. Abeli<sup>6</sup>, S. Bonora<sup>7</sup>, M. D'Annunzio<sup>8</sup>, A. Di Biagio<sup>9</sup>, M. Di Pietro<sup>10</sup>, L. Butini<sup>11</sup>, G. Orofino<sup>12</sup>, S. Farina<sup>13</sup>, G. D'Ettore<sup>14</sup>, D. Francisci<sup>15</sup>, A. Soria<sup>16</sup>, G. Parruti<sup>17</sup>, A.R. Buonomini<sup>18</sup>, C. Tommasi<sup>19</sup>, M.P. Trotta<sup>20</sup>, E. Merlini<sup>21</sup>, G. Marchetti<sup>21</sup>

<sup>1</sup> Dipartimento di Scienze Cliniche "Luigi Sacco", Sezione di Malattie Infettive e Immunopatologia, Università degli Studi di Milano, Milan, Italy; <sup>2</sup> ITB-CNR, Segrate, MI, Italy; <sup>3</sup> Clinica Malattie Infettive, Università degli Studi di Brescia, Spedali Civili, Brescia, Italy; <sup>4</sup> 1<sup>a</sup> Div. Malattie Infettive, Ospedale Luigi Sacco, Milan, Italy; <sup>5</sup> 2<sup>a</sup> Div. Malattie Infettive, Ospedale Luigi Sacco, Milan, Italy; <sup>6</sup> Div. Malattie Infettive, Ospedale di Circolo, Busto Arsizio, VA, Italy; <sup>7</sup> Clinica Malattie Infettive, Università degli Studi di Torino, Turin, Italy; <sup>8</sup> Clinica di Malattie Infettive, Ospedale Policlinico, Bari, Italy; <sup>9</sup> Clinica Malattie Infettive, Università degli Studi di Genova, Ospedale San Martino, Genoa, Italy; <sup>10</sup> Div. Malattie Infettive, Ospedale S. Maria Annunziata, Antella, Florence, Italy; <sup>11</sup> Servizio Regionale di Immunologia Clinica e Tipizzazione Tessutale, Università Politecnica delle Marche, Torrette di Ancona, AN, Italy; <sup>12</sup> Div. A Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy; <sup>13</sup> Istituto di Clinica Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy; <sup>14</sup> Div. Malattie Infettive, Ospedale Policlinico Umberto I, Rome, Italy; <sup>15</sup> Clinica di Malattie Infettive, Ospedale S. Maria della Misericordia, Perugia, Italy; <sup>16</sup> Div. Malattie Infettive, Ospedale San Gerardo, Monza, Italy; <sup>17</sup> Div. Malattie Infettive, Ospedale Santo Spirito, Pescara, Italy; <sup>18</sup> Clinica Malattie Infettive, Università Tor Vergata, Rome, Italy; <sup>19</sup> INMI "Lazzaro Spallanzani", IV Div. Malattie Infettive, Rome, Italy; <sup>20</sup> INMI "Lazzaro Spallanzani", III Div. Malattie Infettive, Rome, Italy; <sup>21</sup> Clinica Malattie Infettive e Tropicali, Università degli Studi di Milano, Ospedale San Paolo, Milan, Italy

**CO23**

**FIRST DEMONSTRATION OF A DIRECT VIRAL DAMAGE ON HUMAN VESSEL WALL DERIVED MESENCHYMAL STEM CELLS BIOLOGIC HOMEOSTASIS: A NEW ROLE OF HIV-1 INFECTION AND RECOMBINANT GP120 IN THE GENESIS OF ATHEROSCLEROTIC DEGENERATION AND ADIPOGENESIS INDUCTION**

M. Borderi\*<sup>1</sup>, D. Gibellini<sup>2</sup>, V. Colangeli<sup>1</sup>, L. Calza<sup>1</sup>, R. Manfredi<sup>1</sup>,  
C. Marsiglia<sup>3</sup>, G. Taliani<sup>3</sup>, M.C. Re<sup>2</sup>, P. Viale<sup>1</sup>

<sup>1</sup> U.O. Malattie Infettive, Bologna, Italy; <sup>2</sup> Istituto di Microbiologia,  
Bologna, Italy; <sup>3</sup> Clinica Malattie Infettive e Tropicali, Università La  
Sapienza, Rome, Italy

**CO24** THE COMPLEX INTERPLAY OF  
CYTOKINES/CHEMOKINES, ANTIVIRAL THERAPIES  
AND REACTIVATED HERPESVIRUSES IN THE  
GENITAL TRACT OF HIV-1-INFECTED INDIVIDUALS

A. Lisco\*<sup>1</sup>, A. Munawwar<sup>2</sup>, A. Introini<sup>1</sup>, C. Vanpouille<sup>1</sup>, S. Singh<sup>2</sup>, L. Margolis<sup>1</sup>  
<sup>1</sup> National Institutes of Health, Bethesda, MD, USA; <sup>2</sup> All India Institute of  
Medical Sciences, New Delhi, India

**SHORT COMMUNICATIONS  
AND POSTER SESSION**

**SHORT COMMUNICATIONS**

13.30 **PREVENTION AND SOCIAL ASPECTS** (Sala Onice)

Discussants: *M. Breveglieri* (Verona),  
*D. Lorenzetti* (Rome)

**SC01** HIVOICES  
F. Porcari\*<sup>1</sup>, E. Pullega<sup>1</sup>, S. Mattioli<sup>1</sup>  
<sup>1</sup> Arcigay, Bologna, Italy

**SC02** GAY SEX ON THE WEB IN MILAN: SOCIAL NEEDS AND  
RISKY BEHAVIORS  
R. Rossotti\*<sup>1</sup>, M. Chiara<sup>1</sup>, A. Orani<sup>1</sup>  
<sup>1</sup> SC Malattie Infettive e Tropicali, AO "A. Manzoni", Lecco, Italy

**SC03** THE GIOCASICURO PROJECT: RESULTS OF A  
COMPREHENSIVE INTERVENTION FOR THE PREVENTION  
AND DIAGNOSIS OF SEXUALLY TRANSMITTED INFECTIONS  
AMONG MEN WHO HAVE SEX WITH MEN IN ITALY  
I. Dal Conte\*<sup>1</sup>, V. Cucco<sup>4</sup>, G. Salamina<sup>2</sup>, A. Zamboni<sup>3</sup>, Members of  
Giocasicuro Project<sup>5</sup>  
<sup>1</sup> ASL TO2 Torino Ospedale Amedeo di Savoia, Turin, Italy; <sup>2</sup> ASLTO1,  
Dipartimento di Prevenzione, Turin, Italy; <sup>3</sup> Università degli Studi, Turin,  
Italy; <sup>4</sup> Coordinamento Torino Pride LGBT, Turin, Italy; <sup>5</sup> Giocasicuro,  
Turin, Italy

**SC04** FACILITATED ACCESS PROCEDURES FOR HIV AND HCV  
TESTING IN VULNERABLE GROUPS  
M.L. Cosmaro\*<sup>1</sup>, M. Oldrini<sup>1</sup>, L. Rancilio<sup>2</sup>, A.M. Villa<sup>3</sup>, M.R. Parisi<sup>4</sup>,  
A. Lazzarin<sup>4</sup>, L. Confalonieri<sup>5</sup>, G. Rizzardini<sup>5</sup>, G. Bandiera<sup>6</sup>, A. Rosso<sup>6</sup>,  
A. Morrone<sup>6</sup>  
<sup>1</sup> LILA Milano ONLUS, Milan, Italy; <sup>2</sup> CARITAS Ambrosiana, Milan, Italy;  
<sup>3</sup> Ambulatorio Opera San Francesco per i poveri, Milan, Italy; <sup>4</sup>  
Department of Infectious Disease-IRCCS San Raffaele Scientific Institute,  
Milan, Italy; <sup>5</sup> Department of Infectious Diseases, Luigi Sacco Hospital,  
Milan, Italy; <sup>6</sup> NIHMP National Institute for Health, Migration and  
Poverty, Rome, Italy

**SC05** TEST DAY IN THE ERA OF "SEEK, TEST AND TREAT" FOR HIV  
M. Lichtner\*<sup>1</sup>, R. Marocco<sup>1</sup>, V. Belvisi<sup>1</sup>, T. Tieghi<sup>1</sup>, P. Zuccala<sup>1</sup>,  
P. Clemenzi<sup>1</sup>, L. Di Giacomo<sup>2</sup>, V. Mercurio<sup>2</sup>, G. Colazingari<sup>2</sup>,  
C.M. Mastroianni<sup>1</sup>  
<sup>1</sup> Sapienza Università di Roma, Latina, Italy; <sup>2</sup> Ospedale SM Goretti,  
Latina, Italy

- SC06 ACUTE CASE DEFINITION FOR BEDSIDE DIAGNOSIS OF SUSPECTED/PROBABLE HIV-1 INFECTION IN THE COMMUNITY SETTING**  
M. Tavio\*<sup>1</sup>, R. Del Gobbo<sup>1</sup>, A. Mataloni Paggi<sup>1</sup>, A. Riva<sup>1</sup>, F. Burzacchini<sup>1</sup>, M. Simeone<sup>1</sup>, L. Scudeller<sup>1</sup>  
<sup>1</sup> *Divisione di Malattie Infettive, Ospedali Riuniti di Ancona, Ancona, Italy*
- SC06B HIGH PROPORTION OF HIV-1 SUBTYPE F1 TRANSMISSION NETWORKS AMONG ITALIAN HETEROSEXUAL MALES ASSOCIATED WITH INTRODUCTION EVENTS FROM SOUTH AMERICA**  
A. Lai\*<sup>1</sup>, G. Zehender<sup>1</sup>, A. De Luca<sup>2</sup>, V. Micheli<sup>3</sup>, P. Meraviglia<sup>4</sup>, P. Corsi<sup>5</sup>, P. Bagnarelli<sup>6</sup>, P. Aimi<sup>7</sup>, A. Zoncada<sup>8</sup>, F. Baldanti<sup>9</sup>, A. Gonnelli<sup>10</sup>, G. Colao<sup>11</sup>, D. Tacconi<sup>12</sup>, F. Simonetti<sup>1</sup>, M. Ciccozzi<sup>13</sup>, M. Zazzi<sup>14</sup>, C. Balotta<sup>1</sup>  
<sup>1</sup> *Department of Clinical Science, Infectious Diseases and Immunopathology Section, "L. Sacco" Hospital, University of Milan, Milan, Italy;* <sup>2</sup> *Second Infectious Diseases Unit, Siena University, Siena;* <sup>3</sup> *Laboratory of Microbiology, "L. Sacco" Hospital, Milan;* <sup>4</sup> *2nd Division of Infectious Diseases, "L. Sacco" Hospital, Milan;* <sup>5</sup> *U.O.C. Infectious Diseases Careggi, Florence;* <sup>6</sup> *Department of Biomedical Science, Section of Microbiology, Laboratory of Virology, University Politecnica delle Marche, Ancona;* <sup>7</sup> *U.O.C. Infectious and Tropical Diseases, Massa;* <sup>8</sup> *Infectious Diseases Section, Cremona;* <sup>9</sup> *Section of Virology S. Matteo, Pavia;* <sup>10</sup> *U.O.C. Clinical Infectious Diseases, Siena;* <sup>11</sup> *Section of Virology Careggi, Florence;* <sup>12</sup> *Infectious Diseases Section, Arezzo;* <sup>13</sup> *Epidemiology Unit, Department of Infectious, Parasite and Immune-Mediated Diseases, Italian Institute of Health, Rome;* <sup>14</sup> *Section of Microbiology, Department of Molecular Biology, University of Siena - Italy*

13.30 **CLINICAL AND HIV DIAGNOSTIC** (Passi Perduti)

Discussants: *P. Navarra* (Rome), *C. Giaquinto* (Padua)

- SC07 EFFICACY AND SAFETY OF ONCE DAILY MARAVIROC PLUS LOPINAVIR/RITONAVIR IN ANTIRETROVIRAL NAÏVE HIV-INFECTED PATIENTS**  
S. Nozza\*<sup>1</sup>, A. Antinori<sup>2</sup>, F. Mazzotta<sup>3</sup>, C. Calbi<sup>2</sup>, M. Di Pietro<sup>3</sup>, L. Galli<sup>1</sup>, C. Tommasi<sup>2</sup>, R. Fezza<sup>2</sup>, P. Narciso<sup>2</sup>, G. Tambussi<sup>1</sup>, A. Lazzarin<sup>1</sup>  
<sup>1</sup> *San Raffaele Scientific Institute, Milan, Italy;* <sup>2</sup> *INMI L. Spallanzani, Rome, Italy;* <sup>3</sup> *Ospedale S.M. Annunziata, Florence, Italy*
- SC08 MODULATORY EFFECTS OF THE NOVEL CCR5 ANTAGONIST MARAVIROC ON MICROGLIAL PRO INFLAMMATORY ACTIVATION ELICITED BY GP120**  
L. Lisi\*<sup>1</sup>, P. Navarra<sup>1</sup>, C. Dello Russo<sup>1</sup>  
<sup>1</sup> *Istituto di Farmacologia, Università Cattolica del Sacro Cuore, Rome, Italy*
- SC09 MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING**  
A. Calcagno\*<sup>1</sup>, S. Bonora<sup>1</sup>, M.C. Tettoni<sup>1</sup>, M. Bonasso<sup>1</sup>, B. Salassa<sup>1</sup>, G. Orofino<sup>4</sup>, C. Bramato<sup>1</sup>, L. Trentini<sup>1</sup>, M. Simiele<sup>2</sup>, L. Marinaro<sup>1</sup>, R. Bertucci<sup>1</sup>, D. Imperiale<sup>3</sup>, A. D'Avolio<sup>2</sup>, V. Ghisetti<sup>5</sup>, G. Di Perri<sup>1</sup>  
<sup>1</sup> *Department of Infectious Diseases, University of Torino, Turin, Italy;* <sup>2</sup> *Pharmacokinetics and Pharmacogenetics Laboratory, University of Torino, Turin, Italy;* <sup>3</sup> *Department of Neurology, Ospedale Maria Vittoria, ASLTO2, Turin, Italy;* <sup>4</sup> *Department of Infectious Diseases, "Divisione A", ASLTO2, Turin, Italy;* <sup>5</sup> *Molecular Biology and Virology Laboratory, Ospedale Amedeo di Savoia, ASLTO2, Turin, Italy*

- SC10** EFFICACY, SAFETY, DISCONTINUATION RATES AND PHARMACOKINETICS OF BOOSTED OR UNBOOSTED ATAZANAVIR WHEN COMBINED WITH A TENOFOVIR OR ABACAVIR CONTAINING BACKBONE  
M. Fabbiani\*<sup>1</sup>, A. Mondini<sup>1</sup>, I. Fantini<sup>1</sup>, S. Farina<sup>1</sup>, E. Ragazzoni<sup>1</sup>, L. Sidella<sup>1</sup>, M. Doino<sup>1</sup>, P. Navarra<sup>1</sup>, R. Cauda<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>  
<sup>1</sup> *Università Cattolica del Sacro Cuore, Rome, Italy*
- SC11** NEUROIMAGING OF HIV/AIDS PATIENTS TODAY  
R. Barbò\*<sup>1</sup>, C. Agostinis<sup>2</sup>, B. Marini<sup>3</sup>, M.R. Rottoli<sup>2</sup>  
<sup>1</sup> *Neuroradiologia, Humanitas Gavazzeni, Bergamo, Italy;*  
<sup>2</sup> *Neuroradiologia, Ospedali Riuniti, Bergamo, Italy;* <sup>3</sup> *Malattie Infettive, Ospedali Riuniti, Bergamo, Italy*
- SC12** ALEXITHYMIA AS A MAJOR CARDIOVASCULAR RISK FACTOR IN HIV-INFECTED PATIENTS  
F. Sozio<sup>1</sup>, F. Vadini<sup>1</sup>, T. Ursini<sup>1</sup>, E. Mazzotta<sup>1</sup>, E. Polilli<sup>1</sup>, G. Placido<sup>1</sup>, A. Agostinone<sup>1</sup>, L. Manzoli<sup>2</sup>, G. Parruti\*<sup>1</sup>  
<sup>1</sup> *U.O. Malattie Infettive, Pescara, Italy;* <sup>2</sup> *Dipartimento di Epidemiologia e Sanità Pubblica, Università di Chieti, Chieti, Italy*

---

13.30 **HIV TROPISM AND DNA RESISTANCE** (Sala 4)

---

Discussants: C. Balotta (Milan), S. Parisi (Padua)

- SC13** MONITORING OF DRUG RESISTANCE MUTATIONS IN PROVIRAL DNA OF PATIENTS RESPONDING TO ANTIRETROVIRAL THERAPY  
O. Turriziani\*<sup>1</sup>, C. Montagna<sup>1</sup>, F. Falasca<sup>1</sup>, M. Bucci<sup>1</sup>, A. Fantauzzi<sup>1</sup>, A. Esposito<sup>1</sup>, M. Paola<sup>1</sup>, I. Mezzaroma<sup>1</sup>, G. Antonelli<sup>1</sup>  
<sup>1</sup> *Sapienza University of Rome, Rome, Italy*
- SC14** DYNAMICS AND COMPARTMENTALIZATION OF CXCR4-USING HIV VARIANTS DURING THE EARLY PHASES OF HIV INFECTION, ESTABLISHED BY ULTRA-SENSITIVE NEXT GENERATION SEQUENCING  
G. Rozera\*<sup>1</sup>, I. Abbate<sup>1</sup>, C. Vlassi<sup>2</sup>, A. Bruselles<sup>1</sup>, B. Bartolini<sup>1</sup>, E. Giombini<sup>1</sup>, A. Corpolongo<sup>2</sup>, G. D'Offizi<sup>2</sup>, P. Narciso<sup>2</sup>, M.R. Capobianchi<sup>1</sup>  
<sup>1</sup> *Laboratory of Virology of INMI L.Spallanzani, Rome, Italy;* <sup>2</sup> *IV Division, Clinical Department of INMI L.Spallanzani, Rome, Italy*
- SC15** THE GENOTYPIC FALSE POSITIVE RATE DETERMINED BY POPULATION V3-SEQUENCING CAN PREDICT THE BURDEN OF X4 QUASISPECIES DETECTED BY PYROSEQUENCING  
V. Cento\*<sup>1</sup>, V. Svicher<sup>1</sup>, G. Rozera<sup>2</sup>, I. Abbate<sup>2</sup>, M.M. Santoro<sup>1</sup>, D. Armenia<sup>1</sup>, L. Fabeni<sup>2</sup>, G. Palamara<sup>3</sup>, A. Latini<sup>3</sup>, G. Rizzardini<sup>4</sup>, V. Micheli<sup>4</sup>, A.R. Buonomini<sup>5</sup>, M. Andreoni<sup>5</sup>, C.F. Perno<sup>1,2,5</sup>, M.R. Capobianchi<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>  
<sup>1</sup> *Department of Experimental Medicine and Biochemical Science, University of "Tor Vergata", Rome, Italy;* <sup>2</sup> *I.N.M.I. "L. Spallanzani", Rome, Italy;* <sup>3</sup> *"San Gallicano" Hospital, Rome, Italy;* <sup>4</sup> *"L. Sacco" Hospital, Milan, Italy;* <sup>5</sup> *University Hospital "Tor Vergata", Rome, Italy*
- SC16** VIRAL TROPISM BY GENO2PHENO AS A TOOL FOR PREDICTING CD4 DECREASE IN HIV-1 INFECTED NAIVEPATIENTS WITH HIGH CD4 COUNTS  
S. Nozza\*<sup>1</sup>, F. Canducci<sup>1</sup>, L. Galli<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, M. R. Capobianchi<sup>3</sup>, E. Ceresola<sup>1</sup>, A. Antinori<sup>3</sup>, S. Di Giambenedetto<sup>4</sup>, A. D'Arminio Monforte<sup>2</sup>, A. Castagna<sup>1</sup>  
<sup>1</sup> *San Raffaele Scientific Institute - Milan, Italy;* <sup>2</sup> *ICONA Foundation - Italy;* <sup>3</sup> *INMI Spallanzani - Rome, Italy;* <sup>4</sup> *Catholic University - Rome, Italy*

- SC17** **IMPACT OF MUTATIONS OUTSIDE V3 ON CORECEPTOR TROPISM PHENOTYPICALLY ASSESSED IN SUBTYPE B HIV-1- INFECTED PATIENTS**  
L. Monno<sup>1</sup>, A. Saracino<sup>\*2</sup>, L. Scudeller<sup>3</sup>, G. Punzi<sup>1</sup>, A. Lagioia<sup>1</sup>, G. Brindicci<sup>1</sup>, G. Angarano<sup>1</sup>  
<sup>1</sup>*Clinica Malattie Infettive, Università degli Studi di Bari, Bari, Italy;* <sup>2</sup>*Clinica Malattie Infettive, Università degli Studi di Foggia, Foggia, Italy;* <sup>3</sup>*IRCCS Policlinico San Matteo, Pavia, Italy*
- SC18** **SIGNATURE MUTATIONS IN V3 AND BRIDGING SHEET DOMAIN OF HIV-1 GP120 HIV-1 ARE SPECIFICALLY ASSOCIATED WITH DUAL TROPISM AND MODULATE THE INTERACTION WITH CCR5 N-TERMINUS**  
C. Alteri<sup>\*1</sup>, A. Artese<sup>2</sup>, J.M. Zhang<sup>3</sup>, F. Mercurio<sup>1</sup>, G. Costa<sup>2</sup>, F. Stazi<sup>1</sup>, L. Fabeni<sup>4</sup>, A. Bertoli<sup>1</sup>, F. Forbici<sup>4</sup>, R. Salpini<sup>1</sup>, S. Dimonte<sup>2</sup>, S. Alcaro<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C.F. Perno<sup>1</sup>, V. Svicher<sup>1</sup>  
<sup>1</sup>*Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy;* <sup>2</sup>*Department of Pharmacobiological Sciences, University of Catanzaro "Magna Graecia", Roccelletta di Borgia, CZ, Italy;* <sup>3</sup>*Department of Statistics, Yale University, New Haven, USA;* <sup>4</sup>*INMI L Spallanzani, Infectious Diseases Division, Rome, Italy*
- SC19** **DEVELOPMENT OF RECOMBINANT VIRUS ASSAYS FOR PHENOTYPIC EVALUATION OF THE SUSCEPTIBILITY TO INTEGRASE INHIBITORS AND HIV CORECEPTOR TROPISM**  
F. Saladini<sup>\*1</sup>, A. Rosi<sup>1</sup>, I. Vincenti<sup>1</sup>, G. Meini<sup>1</sup>, M. Zazzi<sup>1</sup>  
<sup>1</sup>*Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy*

13.30 **POSTER PRESENTATIONS** (Ballatoi)

Discussants: A. Riva (Milan), B. Celesia (Catania)  
A. Cingolani (Rome), S. Babudieri (Sassari)

BS = Basic Sciences  
CS = Clinical Sciences  
ES = Epidemiology and Social Sciences

- PP01** **GENETIC DIVERSITY AT ENDOPLASMIC RETICULUM AMINOPEPTIDASES 2 (ERAP2) IS COUPLED WITH INNATE RESISTANCE TO HIV-1 INFECTION**  
BS  
M. Borelli<sup>\*1</sup>, M. Biasin<sup>1</sup>, S. Lo Caputo<sup>2</sup>, L. Piacentini<sup>1</sup>, I. Saulle<sup>1</sup>, M. De Luca<sup>1</sup>, M. Sironi<sup>3</sup>, R. Cagliani<sup>3</sup>, D. Trabattoni<sup>1</sup>, F. Mazzotta<sup>2</sup>, M. Clerici<sup>1</sup>  
<sup>1</sup>*Università degli Studi di Milano, Milan, Italy;* <sup>2</sup>*S.M. Annunziata Hospital, Florence, Italy;* <sup>3</sup>*IRCCS E. Medea, Lecco, Italy*
- PP02** **INCREASED T-CELL ACTIVATION FOLLOWING PBMC IN VITRO STIMULATION WITH LIPOPOLYSACCHARIDE (LPS) IN HIV+ PATIENTS WITH DIFFERENT IMMUNE RECONSTITUTION ON SUPPRESSIVE HAART**  
BS  
C. Tincati<sup>\*1</sup>, G.M. Bellistri<sup>1</sup>, G. Ancona<sup>1</sup>, E. Merlini<sup>1</sup>, F. Bai<sup>1</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>  
<sup>1</sup>*Clinica di Malattie Infettive e Tropicali, Università degli Studi di Milano, Ospedale San Paolo - Milan, Italy*
- PP03** **HORMONAL STATUS AND NATURAL IMMUNITY IN HIV INFECTED PATIENTS**  
CS  
R. Rossi<sup>\*1</sup>, G. La Martire<sup>1</sup>, M. Lichtner<sup>2</sup>, P. Massetti<sup>1</sup>, I. Sauzullo<sup>1</sup>, F. Mengoni<sup>1</sup>, R. Marocco<sup>2</sup>, C. Mastroianni<sup>2</sup>, V. Vullo<sup>1</sup>  
<sup>1</sup>*Sapienza Università di Roma, Rome, Italy;* <sup>2</sup>*Sapienza Università di Roma Polo Pontino, Rome, Italy*

- PP04**  
CS  
**DO PEOPLE VIROLOGICALLY SUPPRESSED ARE REALLY IN OPTIMAL CLINICAL CONDITIONS?**  
R. Murri\*<sup>1</sup>, A. Cingolani<sup>1</sup>, A. De Luca<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>, G. Marasca<sup>1</sup>, G. De Matteis<sup>1</sup>, M. Fabbiani<sup>1</sup>, E. Jacoboni<sup>1</sup>, I. Mastroiosa<sup>1</sup>, E. Tamburrini<sup>1</sup>  
<sup>1</sup> *Università Cattolica S Cuore, Rome, Italy*
- PP05**  
BS  
**THYMIC- AND BONE MARROW-CELLULAR RESERVOIRS HARBOR PHYLOGENETICALLY DISTINCT HIV STRAINS AND DIFFERENT RESISTANCE PROFILES**  
F. De Luca\*<sup>1</sup>, A. Bandera<sup>2</sup>, V. Cento<sup>1</sup>, C. Alteri<sup>1</sup>, F. Stazi<sup>1</sup>, A. Bertoli<sup>1</sup>, M. Montano<sup>1</sup>, A. Soria<sup>2</sup>, M. Andreoni<sup>1</sup>, C.F. Perno<sup>1</sup>, A. Gori<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>  
<sup>1</sup> *University of Tor Vergata, Rome, Italy*; <sup>2</sup> *“San Gerardo” Hospital University of Milan-Bicocca, Monza, Italy*
- PP06**  
CS  
**HIV AVIDITY INDEX COMPARED TO OTHER VIROLOGICAL PARAMETERS IN RECENT AND ESTABLISHED HIV INFECTIONS: DIAGNOSTIC RELEVANCE**  
S. Faraoni<sup>1</sup>, M. Proia\*<sup>1</sup>, M.G. Milia<sup>1</sup>, T. Allice<sup>1</sup>, G. Gregori<sup>1</sup>, E. Burdino<sup>1</sup>, T. Ruggiero<sup>1</sup>, A. Signorino<sup>1</sup>, C. Galli<sup>2</sup>, S. Bonora<sup>3</sup>, G. Orofino<sup>3</sup>, V. Ghisetti<sup>1</sup>  
<sup>1</sup> *Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Turin, Italy*; <sup>2</sup> *Scientific Affairs, Abbott Diagnostic, Rome, Italy*; <sup>3</sup> *Department of Infectious Diseases, Amedeo di Savoia Hospital and University of Torino, Turin, Italy*
- PP07**  
CS  
**HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 VIRAL LOAD AND DRUG RESISTANCE ON DRIED BLOOD SPOTS**  
B. Matteoli\*<sup>1</sup>, A. Scaccino<sup>1</sup>, L. Bontempo<sup>1</sup>, L. Ceccherini-Nelli<sup>1</sup>  
<sup>1</sup> *Dipartimento di Patologia Sperimentale BMIE Università di Pisa, Pisa, Italy*
- PP08**  
CS  
**WHAT SCREENING FOR OSTEOPOROSIS IN PATIENTS WITH HIV INFECTION: FRAX SCORE VERSUS BONE SERUM MARKERS?**  
G. Maffongelli\*<sup>1</sup>, A.R. Buonomini<sup>1</sup>, L. Sarmati<sup>1</sup>, S. Gini<sup>1</sup>, L. Dori<sup>1</sup>, A. Ricciardi<sup>1</sup>, M. Mapfumo<sup>1</sup>, E. Gentilotti<sup>1</sup>, P. Sordillo<sup>1</sup>, M. Andreoni<sup>1</sup>  
<sup>1</sup> *Cattedra di Malattie Infettive, Tor Vergata, Rome, Italy*
- PP10**  
ES  
**HIV INCIDENCE AND CHARACTERISTICS OF NEWLY DIAGNOSED HIV INFECTIONS AMONG NON-NATIONALS IN ITALY, 2003-2009**  
L. Camoni\*<sup>1</sup>, V. Regine<sup>1</sup>, M.C. Salfa<sup>1</sup>, M. Raimondo<sup>1</sup>, B. Suligo<sup>1</sup> e i Referenti regionali del Sistema di sorveglianza delle nuove diagnosi di infezione da HIV<sup>2</sup>  
<sup>1</sup> *Istituto Superiore di Sanità, Rome, Italy*; <sup>2</sup> *A. Carboni (Lazio); R. Cassiani (Abruzzo); M. Chironna (Puglia); M. Cuccia (Catania); A.C. Finarelli (Emilia-Romagna); G. Greco (Calabria); G. Icardi (Liguria); M.S. Mura (Sassari); C. Pasqualini (Piemonte); A. Pavan (Lombardia); C. Piovesan (Veneto); G. Rossetti (Trento); R. Pristerà (Bolzano); N. Scola (Marche); L. Sudano (Valle d'Aosta); C. Zappetti (Friuli-Venezia Giulia)*
- PP11**  
ES  
**NEWLY DIAGNOSED OF HIV INFECTION AMONG YOUNG MEN WHO HAVE SEX WITH MEN**  
A. Palummieri\*<sup>1</sup>, N. Orchi<sup>1</sup>, G. De Carli<sup>1</sup>, A. Navarra<sup>1</sup>, C. Sias<sup>1</sup>, M. Giuliani<sup>2</sup>, P. Scognamiglio<sup>1</sup>, S. Pittalis<sup>1</sup>, S. Grisetti<sup>1</sup>, A. Corpolongo<sup>1</sup>, A. Sampaolesi<sup>1</sup>, V. Puro<sup>1</sup>, E. Girardi for the SENDIH group<sup>1</sup>  
<sup>1</sup> *National Institute for Infectious Diseases “L. Spallanzani”, Rome, Italy*; <sup>2</sup> *AIDS Center “San Gallicano” Institute, Rome, Italy*

13.30

**POSTERS***(Ballatoi)*

**CLINICAL MEDICINE AND DIAGNOSIS I**

Chairman: *P. Narciso* (Rome)

**INTRODUCTION**

*M. Zazzi* (Siena)

Moderators and Discussants:

*M. Capobianchi* (Rome),

*P. Maggi* (Bari), *S. Rusconi* (Milan)

- CO25** **HAART, LOW LEVEL RESIDUAL VIREMIA AND RISK OF VIROLOGICAL FAILURE**  
 G. Cologni\*<sup>1</sup>, C. Bernardini<sup>1</sup>, A. Callegaro<sup>1</sup>, L. Soavi<sup>1</sup>, S. Leone<sup>1</sup>, D. Valenti<sup>1</sup>, F. Suter<sup>1</sup>, F. Maggiolo<sup>1</sup>  
<sup>1</sup> *Ospedali Riuniti, Bergamo, Italy*
- CO26** **USEFULNESS OF QUANTITATIVE ULTRASONOGRAPHY (QUS) FOR BONE HEALTH ASSESSMENT IN HIV-INFECTED PATIENTS**  
 R. Marocco\*<sup>1</sup>, V. Belvisi<sup>1</sup>, T. Tieghi<sup>1</sup>, R. Cesareo<sup>2</sup>, C. Del Borgo<sup>1</sup>, G. De Meo<sup>2</sup>, V.S. Mercurio<sup>1</sup>, M. Lichtner<sup>1</sup>, C.M. Mastroianni<sup>1</sup>  
<sup>1</sup> *Infectious Diseases Unit, Sapienza University, SM Goretti Hospital, Latina, Italy;* <sup>2</sup> *SM Goretti Hospital Latina, Latina, Italy*
- CO27** **TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD-BRAIN-BARRIER DAMAGE**  
 A. Calcagno\*<sup>1</sup>, S. Bonora<sup>1</sup>, M. Simiele<sup>2</sup>, S. Audagnotto<sup>1</sup>, M. Siccardi<sup>2</sup>, D. Gonzalez de Requena<sup>2</sup>, A. Romito<sup>4</sup>, D. Imperiale<sup>3</sup>, A. D'Avolio<sup>2</sup>, G. Di Perri<sup>1</sup>  
<sup>1</sup> *Department of Infectious Diseases, University of Torino, Turin, Italy;* <sup>2</sup> *Pharmacokinetics and Pharmacogenetics Laboratory, University of Torino, Turin, Italy;* <sup>3</sup> *Department of Neurology, Ospedale Maria Vittoria, ASLTO2, Turin, Italy;* <sup>4</sup> *Immunology Laboratory, Ospedale Maria Vittoria, ASLTO2, Turin, Italy*
- CO28** **VALUE OF ANTIRETROVIRAL CNS PENETRATION-EFFECTIVENESS (CPE) 2010 RANKING IN PREDICTING CSF HIV REPLICATION ACCORDING WITH RATE OF VIRAL SUPPRESSION IN PLASMA**  
 G. Picchi\*<sup>1</sup>, M.L. Giancola<sup>1</sup>, P. Lorenzini<sup>1</sup>, F. Baldini<sup>1</sup>, L. Monno<sup>2</sup>, A. Ammassari<sup>1</sup>, A. d'Arminio Monforte<sup>3</sup>, P. Cinque<sup>4</sup>, V. Tozzi<sup>1</sup>, A. Antinori<sup>1</sup>  
<sup>1</sup> *INMI L. Spallanzani IRCCS, Rome, Italy;* <sup>2</sup> *Università di Bari, Bari, Italy;* <sup>3</sup> *A.O. San Paolo, Università di Milano, Milan, Italy;* <sup>4</sup> *HSR, Istituto San Raffaele, Milan, Italy*
- CO29** **HIV ASSOCIATED NEUROCOGNITIVE DISORDERS: DIFFERENCES IN DIAGNOSTIC TOOLS AND MANAGEMENT STRATEGIES ACROSS ITALIAN HIV CLINICS**  
 V. Tozzi\*<sup>1</sup>, P. Cinque<sup>2</sup>, M. Andreoni<sup>3</sup>, F. Starace<sup>4</sup>, R. Maserati<sup>5</sup>, G. Orofino<sup>6</sup>, G. Orlando<sup>7</sup>, S. Carbonara<sup>8</sup>, A. Giacometti<sup>9</sup>, S. Bonora<sup>10</sup>, G. Parruti<sup>11</sup>, E. Quiros<sup>12</sup>, G. D'Etto<sup>13</sup>, G. Marchetti<sup>14</sup>, P. Lorenzini<sup>1</sup>, N.F. Di Campli<sup>15</sup>, A. Antinori<sup>1</sup>  
<sup>1</sup> *INMI L. Spallanzani IRCCS, Rome, Italy;* <sup>2</sup> *HSR, Istituto San Raffaele, Milan, Italy;* <sup>3</sup> *Università Tor Vergata, Rome, Italy;* <sup>4</sup> *Dipartimento Salute Mentale e Dipendenze Patologiche, AUSL, Modena, Italy;* <sup>5</sup> *Policlinico San Matteo-Università di Pavia, Pavia, Italy;* <sup>6</sup> *Ospedale Amedeo di Savoia, Turin, Italy;* <sup>7</sup> *Ospedale Luigi Sacco, Milan, Italy;* <sup>8</sup> *Università di Bari, Bari, Italy;* <sup>9</sup> *Università di Ancona, Ancona, Italy;* <sup>10</sup> *Università di Torino, Turin, Italy;* <sup>11</sup> *Ospedale di Pescara, Pescara, Italy;* <sup>12</sup> *Università di Brescia, Brescia, Italy;* <sup>13</sup> *Università La Sapienza, Rome, Italy;* <sup>14</sup> *AO San Paolo-Università di Milano, Milan, Italy;* <sup>15</sup> *ViiV Healthcare, Verona, Italy*

- CO30** THE KINETICS AND MAGNITUDE OF HIV-1 RNA RESPONSES TO ART IN THE CEREBROSPINAL FLUID AND PLASMA OF PATIENTS STARTING THERAPY  
 M. Viscione\*<sup>1</sup>, L. Sarmati<sup>1</sup>, A.R. Buonomini<sup>1</sup>, G. Maffongelli<sup>1</sup>, G. D'Ettore<sup>2</sup>, G. Ceccarelli<sup>2</sup>, A. Bertoli<sup>1</sup>, V. Vullo<sup>2</sup>, C.F. Perno<sup>1</sup>, M. Andreoni<sup>1</sup>  
<sup>1</sup> *Cattedra di Malattie Infettive, Tor Vergata, Rome, Italy;* <sup>2</sup> *Cattedra di Malattie Infettive, La Sapienza, Rome, Italy*

15.00 **SYMPOSIUM** (Sala Verde)

## ANTIRETROVIRAL DRUGS MONITORING

Chairman: *P.L. Viale* (Bologna)

### INTRODUCTION

*G. Di Perri* (Turin)

### NEW CHALLENGES IN MANAGEMENT OF DRUG INTERACTIONS

*M. Boffito* (London)

### DOSING OPTIMISATION OF ANTIRETROVIRALS

*A. Hill* (Liverpool)

### PHARMACOKINETIC REQUIREMENTS IN DIFFERENT THERAPEUTICAL CIRCUMSTANCES

*S. Bonora* (Turin), *R. Maserati* (Pavia)

## ORAL COMMUNICATIONS

16.45 **SESSION VI** (Auditorium)

## CLINICAL MEDICINE AND DIAGNOSIS II

Chairman: *O. Armignacco* (Viterbo)

### INTRODUCTION

*M. Andreoni* (Rome)

Moderators and Discussants:

*G. D'Ettore* (Rome), *L. Minoli* (Pavia),

*A. Chirianni* (Naples)

- CO31** APPLICATION OF GENOTYPIC TROPISM TESTING IN CLINICAL PRACTICE: VIROLOGICAL RESPONSE IN MULTI-EXPERIENCED HIV-POSITIVE PATIENTS TREATED WITH MARAVIROC-BASED THERAPY.  
 S. Nozza\*<sup>1</sup>, V. Svicher<sup>2</sup>, F. Canducci<sup>1</sup>, C. Alteri<sup>2</sup>, E. Boeri<sup>1</sup>, R. D'Arrigo<sup>2</sup>, A. Pignataro<sup>1</sup>, M. Clementi<sup>1</sup>, C.F. Perno<sup>2</sup>, A. Lazzarin<sup>1</sup>  
<sup>1</sup> *San Raffaele Scientific Institute, Milan, Italy;* <sup>2</sup> *University of Roma Tor Vergata, Department of Experimental Medicine, Rome, Italy*



- C032 EX-VIVO PHENOTYPIC SUSCEPTIBILITY TO GSK-1349572 OF CLONAL VARIANTS SELECTED IN PATIENTS FAILING RALTEGRAVIR**  
F. Canducci\*<sup>1</sup>, E.R. Ceresola<sup>1</sup>, M. Sampaolo<sup>1</sup>, D. Saita<sup>1</sup>, A.R. Pignataro<sup>1</sup>, E. Boeri<sup>1</sup>, V. Spagnuolo<sup>2</sup>, S. Nozza<sup>2</sup>, A. Castagna<sup>2</sup>, A. Lazzarin<sup>1</sup>, M. Clementi<sup>1</sup>  
<sup>1</sup> Università Vita-Salute - Milan, Italy; <sup>2</sup> Istituto Scientifico San Raffaele - Milan, Italy
- C033 RILPIVIRINE IS COMING: HOW WILL IT IMPACT ON HIV-1-INFECTED ITALIAN POPULATION?**  
R. Rossotti\*<sup>1</sup>, L. Fonte<sup>2</sup>, G. Meini<sup>3</sup>, F. Maggiolo<sup>4</sup>, S. Di Giambenedetto<sup>5</sup>, M. Pecorari<sup>6</sup>, P. Corsi<sup>7</sup>, L. Monno<sup>8</sup>, A. Giacometti<sup>9</sup>, D. Francisci<sup>10</sup>, M. Setti<sup>11</sup>, R. Maserati<sup>12</sup>, P. Bonfanti<sup>1</sup>, A.Orani<sup>1</sup>, M. Zazzi<sup>3</sup>  
<sup>1</sup> Department of Infectious Diseases, AO "A. Manzoni", Lecco, Italy; <sup>2</sup> Direzione Medica di Presidio, AO "A. Manzoni", Lecco, Italy; <sup>3</sup> Section of Microbiology, Department of Molecular Biology, University of Siena, Siena, Italy; <sup>4</sup> Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy; <sup>5</sup> Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy; <sup>6</sup> Laboratory of Microbiology and Virology, Modena University Hospital, Modena, Italy; <sup>7</sup> Unit of Infectious Diseases, Careggi University Hospital, Florence, Italy; <sup>8</sup> Clinical Infectious Diseases, Bari University Hospital, Bari, Italy; <sup>9</sup> Institute of Clinical Infectious Diseases, Ancona University Hospital, Ancona, Italy; <sup>10</sup> Division of Infectious Diseases, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy; <sup>11</sup> Division of Clinical Immunology, Department of Internal Medicine, University of Genoa Medical School, Genoa, Italy; <sup>12</sup> HIV/AIDS Outpatient Clinic Infectious Diseases Department, Foundation "IRCCS Policlinico San Matteo Hospital", Pavia, Italy
- C034 DUAL/MIXED (BUT NOT X4) TROPIC-HIV-1 ISOLATES CAN REPLICATE IN HUMAN PRIMARY MACROPHAGES AND ARE INHIBITED BY CCR5-INHIBITORS**  
M. Surdo\*<sup>2</sup>, E. Balestra<sup>2</sup>, P. Saccomandi<sup>2</sup>, F. Di Santo<sup>2</sup>, V. Svicher<sup>2</sup>, S. Alteri<sup>2</sup>, V. Cento<sup>2</sup>, M. Pollicita<sup>2</sup>, F. Scopelliti<sup>2</sup>, M. Andreoni<sup>2</sup>, C. Aquaro<sup>1</sup>, F. Ceccherini-Silberstein<sup>2</sup>, C.F. Perno<sup>2</sup>  
<sup>1</sup> Dipartimento di Farmaco-Biologia, Rende, CS, Italy; <sup>2</sup> Dipartimento di Medicina Sperimentale e Scienze Biochimiche Università di Roma Tor Vergata, Rome, Italy
- C035 PREVALENCE OF ETRAVIRINE (ETR)-RESISTANCE ASSOCIATED MUTATIONS AT NNRTI FAILURE AND PREDICTORS OF RESISTANCE TO ETR IN A LARGE ITALIAN RESISTANCE DATABASE (ARCA)**  
S. Rusconi\*<sup>1</sup>, F. Adorni<sup>2</sup>, B. Bruzzone<sup>3</sup>, A. Di Biagio<sup>3</sup>, G. Meini<sup>4</sup>, A. Callegaro<sup>5</sup>, G. Punzi<sup>6</sup>, E. Boeri<sup>7</sup>, M. Pecorari<sup>8</sup>, L. Monno<sup>9</sup>, N. Gianotti<sup>10</sup>, L. Butini<sup>11</sup>, L. Galli<sup>12</sup>, E. Polilli<sup>13</sup>, M. Galli<sup>1</sup> on behalf of the ARCA Collaborative Group [dedicated to Raffaella Rosso, M.D.]  
<sup>1</sup> Sezione di Malattie Infettive e Immunopatologia, Dipartimento di Scienze Cliniche "Luigi Sacco", Università degli Studi di Milano, Milan, Italy; <sup>2</sup> ITB- CNR, Segrate, Milan, Italy; <sup>3</sup> Malattie Infettive & Microbiologia, Università degli Studi di Genova, Genoa, Italy; <sup>4</sup> Istituto di Microbiologia & Virologia, Università degli Studi di Siena, Siena, Italy; <sup>5</sup> Microbiologia & Virologia, Ospedali Riuniti di Bergamo, Bergamo, Italy; <sup>6</sup> Istituto di Virologia, Università degli Studi di Bari, Bari, Italy; <sup>7</sup> Virologia, Istituto Scientifico San Raffaele, Milan, Italy; <sup>8</sup> Virologia, Policlinico Universitario, Modena, Italy; <sup>9</sup> Clinica Malattie Infettive, Università degli Studi di Bari, Bari, Italy; <sup>10</sup> Clinica Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy; <sup>11</sup> Immunologia Clinica e Tipizzazione Tessutale, Università Politecnica delle Marche, Torrette di Ancona, Ancona, Italy; <sup>12</sup> Malattie Infettive, Ospedale Pediatrico Meyer, Florence, Italy; <sup>13</sup> Virologia, Ospedale Santo Spirito, Pescara, Italy; [dedicated to Raffaella Rosso, M.D.]
- C036 INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS**  
A. D'Avolio\*<sup>1</sup>, M. Simiele<sup>1</sup>, M. Siccardi<sup>1</sup>, L. Baietto<sup>1</sup>, S. Agati<sup>1</sup>, J. Cusato<sup>1</sup>, A. Calcagno<sup>1</sup>, M. Tettoni<sup>1</sup>, L. Trentini<sup>1</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>  
<sup>1</sup> Università degli Studi di Torino, Turin, Italy

## CLINICAL EPIDEMIOLOGY

Chairman: *G. Ippolito* (Rome)

### INTRODUCTION

*A. d'Arminio Monforte* (Milan)

Moderators and Discussants:

*C. Torti* (Brescia), *S. Di Giambenedetto* (Rome),

*G. Parruti* (Pescara)

- CO37** FINAL RESULTS OF AN OUTREACH PROGRAM OF HIV RAPID TESTING AMONG MARGINALIZED PEOPLE LIVING IN ROME, ITALY  
*P. Scognamiglio*\*<sup>1</sup>, *G. Chiaradia*<sup>1</sup>, *M.R. Sciarrone*<sup>1</sup>, *M.R. Capobianchi*<sup>1</sup>, *E. Rossi*<sup>2</sup>, *M. Barra*<sup>2</sup>, *I. De Vincentiis*<sup>2</sup>, *R. Sista*<sup>2</sup>, *M. Zaccarelli*<sup>1</sup>, *V. Puro*<sup>1</sup>, *L. Ceccarini*<sup>2</sup>, *G. Ippolito*<sup>1</sup>, *E. Girardi*<sup>1</sup>  
<sup>1</sup> *Istituto Nazionale Malattie Infettive "L.Spallanzani" IRCCS, Rome, Italy;* <sup>2</sup> *Fondazione "Villa Maraini" Onlus-Roma, Rome, Italy*
- CO38** INCREASING TREND IN HIV-1 INCIDENCE AMONG MEN WHO HAVE SEX WITH MEN IN ROME, ITALY  
*M. Giuliani*\*<sup>1</sup>, *M.F. Vescio*<sup>2</sup>, *A. Latini*<sup>1</sup>, *G. Impara*<sup>1</sup>, *F. Pimpinelli*<sup>3</sup>, *F. Ensolì*<sup>3</sup>, *G. Palamara*<sup>1</sup>, *G. Rezza*<sup>2</sup>, *A. Di Carlo*<sup>1</sup>  
<sup>1</sup> *UOC Dermatologia Infettiva, Istituto Dermatologico S.Gallicano (IRCCS), Rome, Italy;* <sup>2</sup> *Dipartimento Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanità, Rome, Italy;* <sup>3</sup> *Laboratorio di Patologia Clinica e Microbiologia. Istituto Dermatologico S. Gallicano (IRCCS), Rome, Italy*
- CO39** CHANGES IN SURVIVAL OF HIV-SEROCONVERTED PATIENTS ENROLLED IN THE IHS STUDY FROM 1985 TO 2007  
*M. Dorrucchi*\*<sup>1</sup>, *M. Giuliani*<sup>1</sup>, *G. Rezza*<sup>1</sup> and the Italian HIV-Seroconversion Study Group<sup>2</sup>  
<sup>1</sup> *Dipartimento di Malattie Infettive, Parassitarie e Immunomediate (MIPI), Istituto Superiore di Sanità, Rome, Italy;* <sup>2</sup> *Italian HIV-Seroconversion Study Group, Italy*
- CO40** HIV SURVEILLANCE SYSTEM AND LATE PRESENTERS IN EMILIA-ROMAGNA, 2006-2009  
*E. Massimiliani*\*<sup>1</sup>, *A. Mattivi*<sup>1</sup>, *L. Droghini*<sup>1</sup>, *A.C. Finarelli*<sup>1</sup> and the SorvHIV-RER workgroup<sup>2</sup>  
<sup>1</sup> *Servizio Sanità Pubblica, Assessorato Politiche per la Salute, Regione Emilia-Romagna, Bologna, Italy;* <sup>2</sup> *Clinica Malattie Infettive di Bologna, Cesena, Ferrara, Forlì, Imola, Modena, Parma, Piacenza, Reggio Emilia, Ravenna, Rimini, Emilia-Romagna, Italy*
- CO41** HEALTH-CARE DELIVERY CHARACTERISTICS OF CLINICAL CENTERS ARE CORRELATED WITH SURVIVAL OF ITALIAN HIV PATIENTS  
*R. Murri*\*<sup>1</sup>, *A. Ammassari*<sup>2</sup>, *M.P. Trotta*<sup>2</sup>, *A. Antinori*<sup>2</sup>, *P. Lorenzini*<sup>2</sup>, *A. D'Arminio Monforte*<sup>3</sup>  
<sup>1</sup> *Università Cattolica S Cuore, Rome, Italy;* <sup>2</sup> *INMI Spallanzani, Rome, Italy;* <sup>3</sup> *Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy*
- CO42** SINGLE AND DOUBLE DOSES OF 2009 PANDEMIC INFLUENZA A H1N1 VACCINE ARE EQUALLY IMMUNOGENIC IN HIV-INFECTED ADOLESCENTS AND YOUNG ADULTS  
*A. Viganò*\*<sup>1</sup>, *G. Bedogni*<sup>2</sup>, *E. Gianì*<sup>1</sup>, *V. Giacomet*<sup>1</sup>, *V. Manfredini*<sup>1</sup>, *S. Coletto*<sup>1</sup>, *S. Stucchi*<sup>1</sup>, *E. Pariani*<sup>3</sup>, *A. Amendola*<sup>3</sup>, *G.V. Zuccotti*<sup>1</sup>  
<sup>1</sup> *Pediatric Clinic, L. Sacco Hospital, University of Milan, Milan, Italy;* <sup>2</sup> *Clinical Epidemiology Unit, Liver Research Center, Trieste, Italy;* <sup>3</sup> *Department of Public Health, Microbiology and Virology, University of Milan, Milan, Italy;*

08.00 **Registration** (Palazzo dei Congressi)

08.30 **LECTURES** (Auditorium)

Chairmen: *A. Lazzarin* (Milan), *A. Antinori* (Rome)

### **HIV/AIDS IN DEVELOPED COUNTRIES: CLINICAL ASPECTS AND COMORBIDITIES**

*M. Galli* (Milan)

### **ANTIVIRAL THERAPY-PRESCRIPTIVE OR PROACTIVE?**

*A. Pozniak* (London)

## **ORAL COMMUNICATIONS**

09.45 **SESSION VIII** (Auditorium)

---

### **CLINICAL AND ANTIRETROVIRAL THERAPY I**

Chairman: *F. Castelli* (Brescia)

#### **Introduction**

*A. Castagna* (Milan)

Moderators and Discussants:

*N. Abrescia* (Naples), *E. Raise* (Venice), *V. Tozzi* (Rome)

**CO43** **ARTEMIS: 192-WEEK EFFICACY AND SAFETY OF ONCEDAILY DARUNAVIR/RITONAVIR (DRV/R) VS LOPINAVIR/R (LPV/R) IN TREATMENT-NAÏVE HIV-1-INFECTED ADULTS**

*A. Lazzarin*<sup>\*1</sup>, *C. Orkin*<sup>2</sup>, *E. De Jesus*<sup>3</sup>, *H. Khanlou*<sup>4</sup>, *A. Stoehr*<sup>5</sup>, *K. Supparatpinyo*<sup>6</sup>, *T. Van de Casteele*<sup>7</sup>, *E. Lathouwers*<sup>7</sup>, *M. Garau*<sup>8</sup>  
<sup>1</sup> *S. Raffaele Hospital, University of Milan, Milan, Italy*; <sup>2</sup> *Barts and The London NHS Trust, London, London, UK*; <sup>3</sup> *Orlando Immunology Center, Orlando, Orlando, USA*; <sup>4</sup> *AIDS Healthcare Foundation, Los Angeles, Los Angeles, USA*; <sup>5</sup> *Institute for Interdisciplinary Medicine, Hamburg, Hamburg, Germany*; <sup>6</sup> *Chiang Mai University, Chiang Mai, Chiang Mai, Thailand*; <sup>7</sup> *Tibotec BVBA, Beerse, Beerse, Belgium*; <sup>8</sup> *Medical affairs Janssen, Milan, Italy*

**CO44** **TREATMENT SIMPLIFICATION TO ATAZANAVIR/RITONAVIR PLUS LAMIVUDINE QD IN PATIENTS ON TWO NRTIS PLUS ATAZANAVIR/RITONAVIR WITH OPTIMAL VIROLOGIC CONTROL: 48 WEEKS SAFETY AND EFFICACY RESULTS FROM A PILOT STUDY (ATAZANAVIR AND LAMIVUDINE SIMPLIFICATION STUDY)**

*A. De Luca*<sup>1</sup>, *M. Doio*<sup>2</sup>, *M. Fabbiani*<sup>2</sup>, *L. Bracciale*<sup>2</sup>, *N. Ciccarelli*<sup>2</sup>, *S. Farina*<sup>2</sup>, *L. Sidella*<sup>2</sup>, *A. D'Avino*<sup>2</sup>, *A. Mondì*<sup>2</sup>, *R. Murri*<sup>2</sup>, *R. Cauda*<sup>2</sup>, *S. Di Giambenedetto*<sup>\*2</sup>  
<sup>1</sup> *University Hospital; Second Division of Infectious Diseases, Siena, Italy*; <sup>2</sup> *Catholic University, Rome, Italy*

**CO45 WITH CURRENT ARV TREATMENTS VIROLOGICAL FAILURE MOSTLY OCCURS IN THE CONTEXT OF OPTIMAL SELF-REPORTED ADHERENCE**

M.P. Trotta\*<sup>1</sup>, P. Pierro<sup>1</sup>, P. Marconi<sup>1</sup>, P. Sette<sup>1</sup>, M. Zaccarelli<sup>1</sup>, R.A. Acinapura<sup>1</sup>, C. Calbi<sup>1</sup>, V. Neri<sup>1</sup>, A. Antinori<sup>1</sup>, A. Ammassari<sup>1</sup>  
<sup>1</sup> INMI L. Spallanzani, Rome, Italy

**CO46 DID THE CHANGE OVER TIME IN HIV TREATMENT GUIDELINES AFFECT THE PROBABILITY OF ART INITIATION AT DIFFERENT LEVELS OF CURRENT CD4 COUNT? EVIDENCE FROM A COHORT OF HIV PATIENTS ENROLLED IN ITALY WHEN THEIR CD4 COUNT WAS >500 CELLS/MM3**

S. Lo Caputo\*<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, A. Antinori<sup>3</sup>, M. Galli<sup>4</sup>, P.L. Viale<sup>5</sup>, A. Lazzarin<sup>6</sup>, G. Carosi<sup>7</sup>, L. Sighinolfi<sup>8</sup>, M. Montroni<sup>9</sup>, A. D'Arminio Monforte<sup>10</sup>

<sup>1</sup> U.O. Malattie Infettive Azienda Sanitaria Firenze, Florence, Italy;

<sup>2</sup> University College London, UK and University of Minnesota USA,

London, UK; <sup>3</sup> INMI Lazzaro Spallanzani IRCCS, Rome, Italy; <sup>4</sup>

Dipartimento Scienze Cliniche- Università di Milano Ospedale Luigi

Sacco, Milan, Italy; <sup>5</sup> Clinica Malattie Infettive Ospedale Sant'Orsola

Università degli Studi Bologna, Bologna, Italy; <sup>6</sup> Clinica Malattie

Infettive Osp. San Raffaele, Milan, Italy; <sup>7</sup> Istituto Malattie Infettive

Università di Brescia, Brescia, Italy; <sup>8</sup> U.O. Malattie Infettive Azienda

Ospedaliera Universitaria Arcispedale S. Anna, Ferrara, Italy; <sup>9</sup> Clinica

Malattie Infettive Università degli Studi Ancona, Ancona, Italy; <sup>10</sup> Clinica

Malattie Infettive; Ospedale San Paolo, Milan, Italy;

**CO47 FACTORS INFLUENCING LIVER FIBROSIS AND NECROINFLAMMATION IN HIV/HCV COINFECTION AND HCV MONOINFECTION**

C. Sagnelli\*<sup>1,2</sup>, C. Uberti-Foppa<sup>1</sup>, L. Galli<sup>1</sup>, G. Pasquale<sup>2</sup>, S. De Pascalis<sup>2</sup>,

M. Fiore<sup>2</sup>, L. Albarello<sup>3</sup>, N. Coppola<sup>2</sup>, C. Doglioni<sup>3</sup>, A. Lazzarin<sup>1</sup>, E. Sagnelli<sup>2</sup>

<sup>1</sup> Clinic of Infectious Diseases, Vita-Salute University, San Raffaele

Scientific Institute, Milan, Italy; <sup>2</sup> Department of Public Medicine, Section

of Infectious Diseases, Second University of Naples, Naples, Italy;

<sup>3</sup> Department of Pathology, San Raffaele Scientific Institute, Milan, Italy

**CO48 ASSOCIATION OF KIR/HLA-LIGAND COMBINATIONS WITH DIFFERENT HCV/HIV-RELATED DISORDERS**

V. De Re\*<sup>1</sup>, L. Caggiari<sup>1</sup>, M. De Zorzi<sup>1</sup>, G. Toffoli<sup>1</sup>, A. Carbone<sup>1</sup>, M. Spina<sup>1</sup>, E. Vaccher<sup>1</sup>

<sup>1</sup> Centro di Riferimento Oncologico, Aviano, Italy

09.45

**SESSION IX**

(Sala Verde)

**CLINICAL AND ANTIRETROVIRAL THERAPY II**

Chairman: *V. Vullo* (Rome)

**INTRODUCTION**

*M. Borderi* (Bologna)

Moderators and Discussants:

*A. Di Biagio* (Genoa), *E. Vaccher* (Aviano), *A. Matteelli* (Brescia)

**CO49 HIGHER EXPRESSION OF ADIPONECTIN Q AND LOWER EXPRESSION OF ENHANCER BINDING PROTEIN ALPHA IN ADIPOSE TISSUE CHARACTERIZE HIV-1 INFECTED PATIENTS WITH LIPODYSTROPHY**

D. Misciagna\*<sup>1</sup>, M. Tarkowski<sup>1</sup>, P. Cellerino<sup>2</sup>, S. Martone<sup>1</sup>, L. Milazzo<sup>3</sup>, D. Foschi<sup>4</sup>, M. Galli<sup>1</sup>, A. Riva<sup>3</sup>

<sup>1</sup> Dipartimento di Scienze Cliniche, Sezione di Malattie Infettive e Immunopatogenesi, Università di Milano, Milan, Italy; <sup>2</sup>II Divisione di Chirurgia Generale, Ospedale L. Sacco, Milan, Italy; <sup>3</sup>III Divisione di Malattie Infettive, Ospedale L. Sacco, Milan, Italy; <sup>4</sup>Dipartimento di Scienze Cliniche, II Divisione di Chirurgia Generale, Università di Milano, Milan, Italy

**CO50**

**TDF THERAPY IS INDEPENDENTLY ASSOCIATED TO HYPERPARATHYROIDISM IN A SAMPLE OF 371 HIV INFECTED PATIENTS**

D. Pocaterra\*<sup>1</sup>, L. Carezzi<sup>1</sup>, M. Schiavini<sup>1</sup>, P. Meraviglia<sup>1</sup>, D. Minisci<sup>1</sup>, M. Bevilacqua<sup>2</sup>, P. Bonfanti<sup>3</sup>, G. Rizzardini<sup>1</sup>

<sup>1</sup>L. Sacco Hospital, Department of Infectious Diseases, Milan, Italy;

<sup>2</sup>L. Sacco Hospital, Endocrinologic Unit, Milan, Italy; <sup>3</sup>A. Manzoni Hospital, Department of Infectious Diseases, Lecco, Italy

**CO51**

**IS THERE A RELATION BETWEEN MYALGIA AND CENTRAL NERVOUS SYSTEM SYMPTOMS IN PATIENTS RECEIVING RALTEGRAVIR? RESULTS FROM THE SCOLTA PROJECT.**

G. Madeddu\*<sup>1</sup>, V. Soddu<sup>1</sup>, E. Ricci<sup>2</sup>, T. Quirino<sup>3</sup>, B. Menzaghi<sup>3</sup>, C. Bellacosa<sup>4</sup>, C. Grosso<sup>5</sup>, L. Carezzi<sup>6</sup>, L. Cordier<sup>6</sup>, M. Franzetti<sup>7</sup>, F. Vichi<sup>8</sup>, G. Penco<sup>9</sup>, C. Martinelli<sup>10</sup>, P. Maggi<sup>4</sup>, A. Di Biagio<sup>17</sup>, G. Pellicano<sup>11</sup>, L. Corsico<sup>12</sup>, G.V.L. De Socio<sup>13</sup>, E. Mazzotta<sup>14</sup>, G. Parruti<sup>14</sup>, M. Guastavigna<sup>15</sup>, G. Orofino<sup>15</sup>, M.S. Mura<sup>1</sup>, P. Bonfanti<sup>16</sup>

<sup>1</sup> Istituto di Malattie Infettive, Università di Sassari, Sassari, Italy;

<sup>2</sup> Divisione Malattie Infettive, Ospedali Luigi Sacco, Milan, Italy;

<sup>3</sup> Reparto di Malattie Infettive, Ospedale di Busto Arsizio, Busto Arsizio, Italy;

<sup>4</sup> Unità Operativa di Malattie Infettive, Policlinico di Bari, Bari, Italy;

<sup>5</sup> Reparto di Malattie Infettive, Ospedale Bufalini, Cesena, Italy;

<sup>6</sup> II Divisione Malattie Infettive, Ospedale Luigi Sacco, Milan, Italy;

<sup>7</sup> Clinica Malattie Infettive, Ospedale Luigi Sacco, Milan, Italy; <sup>8</sup> Unità

Operativa di Malattie Infettive, Ospedale Santa Maria Annunziata,

Florence, Italy; <sup>9</sup> Unità Operativa di Malattie Infettive, Ospedale Galliera,

Genoa, Italy; <sup>10</sup> Dipartimento di Malattie Infettive, AOU Careggi, Florence,

Italy; <sup>11</sup> UOC Malattie Infettive, Policlinico G. Martino, Messina; <sup>12</sup> ASL

MB, Servizio MTS, Sesto San Giovanni, Italy; <sup>13</sup> Clinica Malattie Infettive,

Ospedale S.Maria della Misericordia, Perugia, Italy; <sup>14</sup> Unità Operativa

di Malattie Infettive, Ospedale di Pescara, Pescara, Italy; <sup>15</sup> Divisione A

Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy; <sup>16</sup> Struttura

Complessa di Malattie Infettive, Ospedale A. Manzoni, Lecco, Italy;

<sup>17</sup> Clinica Malattie Infettive, Ospedale San Martino, Genoa, Italy

**CO52**

**INCIDENCE TRENDS AND OUTCOME OF NON-AIDS-DEFINING MALIGNANCIES (NADM) IN A COHORT OF HIV-INFECTED PATIENTS DURING THE PERIOD 1985-2008**

M. Franzetti\*<sup>1</sup>, F. Adorni<sup>2</sup>, B. Vergani<sup>1</sup>, S. Antinori<sup>1</sup>, M. Galli<sup>1</sup>, A. Ridolfo<sup>1</sup>

<sup>1</sup>Infectious Diseases Unit, Department of Clinical Sciences "L. Sacco",

University of Milan, Milan, Italy; <sup>2</sup>Institute of Biomedical Technologies,

National Research Council, Segrate, Milan, Italy

**CO53**

**HAART IS EFFECTIVE TO PREVENT CERVICO-VAGINAL CYTOLOGICAL ABNORMALITIES RELATED TO HPV HIGHLY ONCOGENIC STRAINS**

A. Busto<sup>1</sup>, A. Maddaloni<sup>1</sup>, M.G. Guida\*<sup>1</sup>, M. Sansone<sup>2</sup>, M. D'Abbraccio<sup>1</sup>,

M. De Marco<sup>1</sup>, M. Figoni<sup>1</sup>, P. Micheli<sup>1</sup>, N. Abrescia<sup>1</sup>

<sup>1</sup> AORN Monaldi-Cotugno-CTO, Naples, Italy; <sup>2</sup> Università Federico II,

Naples, Italy

**CO54**

**PREVALENCE OF HPV SUBTYPES AND ANAL DISPLASIA AMONG A GROUP OF HIV-POSITIVE PEOPLE WITH ANAL COMPLAINS**

I. Dal Conte\*<sup>1</sup>, M. Mistrangelo<sup>2</sup>, V. Ghisetti<sup>3</sup>, P. Cassoni<sup>4</sup>, M.G. Milia<sup>3</sup>,

M.L. Stella<sup>1</sup>, G. Gregori<sup>3</sup>, M. Morino<sup>2</sup>, G. Di Perri<sup>5</sup>

<sup>1</sup> STI Clinic-Amedeo di Savoia Hospital-ASLTO2, Turin, Italy;

<sup>2</sup> Department of Digestive and Colorectal Surgery, Centre of Minimal

Invasive Surgery, San Giovanni Battista Hospital, University of Turin,

Turin, Italy; <sup>3</sup> Microbiology and Virology Laboratory, Amedeo di Savoia

Hospital, ASL TO2, Turin, Italy; <sup>4</sup> Department of Biomedical Sciences

and Human Oncology, San Giovanni Battista Hospital, University of

Turin, Turin, Italy; <sup>5</sup> Infectious Diseases Department, Amedeo di Savoia

Hospital, University of Turin, Turin, Italy

## ACCESS SUSTENIBILITY OF ANTIRETROVIRAL THERAPY

Chairman: *G. Carosi* (Brescia)

Discussants: *P. Cadrobbi* (Padua), *F. Crespi* (Rome)

Speakers:

Coordinamento Assessori Regionali Sanità, *D. Scaramuccia* (Florence),  
Farmindustria, AIFA, *S. Marcotullio* (Rome), *G. Rizzardini* (Milan)

## SHORT COMMUNICATIONS AND POSTER SESSION

### SHORT COMMUNICATIONS

#### 13.00 COMPLICATION OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

(Sala 4)

Discussants: *T. Quirino* (Busto Arsizio), *N. Gianotti* (Milan)

#### SC20 IMPACT OF RENAL IMPAIRMENT AND COMBINED ANTIRETROVIRAL TREATMENT ON ARTERIAL STRUCTURE AND STIFFNESS

F. Sabbatini\*<sup>1</sup>, N. Squillace<sup>1</sup>, C. Giannattasio<sup>1</sup>, D. Dozio<sup>1</sup>, F. Cesana<sup>1</sup>,  
M. Rossi<sup>1</sup>, G. Lapadula<sup>1</sup>, M. Airoldi<sup>1</sup>, A. Gori<sup>1</sup>, A. Bandera<sup>1</sup>

<sup>1</sup> *Ospedale San Gerardo, Monza, Italy*

#### SC21 EAT VOLUME IS AN INDEPENDENT RISK FACTOR OF CARDIOVASCULAR DISEASE IN HIV-INFECTED PATIENTS

G. Guaraldi\*<sup>1</sup>, S. Zona<sup>1</sup>, P. Raggi<sup>2</sup>, G. Orlando<sup>1</sup>, F. Carli<sup>1</sup>, G. Ligabue<sup>1</sup>,  
R. Scaglioni<sup>1</sup>, G. Besutti<sup>1</sup>, R. Rossi<sup>1</sup>, M.G. Modena<sup>1</sup>

<sup>1</sup> *University of Modena and Reggio Emilia, Modena, Italy*; <sup>2</sup> *Emory University, Atlanta, GA, USA*

#### SC22 OSTEOPROTEGERIN AS A BIOMARKER OF SUBCLINICAL ATHEROSCLEROSIS IN HIV-INFECTED MAN

A. D'Abramo\*<sup>1</sup>, C. D'Agostino<sup>1</sup>, M. Carnevalini<sup>1</sup>, M. Iannetta<sup>1</sup>,  
L. Erario<sup>1</sup>, F. Cristofano<sup>1</sup>, V. Vullo<sup>1</sup>

<sup>1</sup> *"Sapienza" Università di Roma, Rome, Italy*

#### SC23 LEFLUNOMIDE PROTECTS AGAINST DYSLIPIDEMIA DEVELOPMENT INDUCED BY RITONAVIR IN MICE

F. Baldelli<sup>1</sup>, A. Mencarelli<sup>2</sup>, B. Renga<sup>2</sup>, C. D'Amore<sup>2</sup>, S. Cipriani<sup>2</sup>,  
E. Schiaroli\*<sup>1</sup>, L. Bernini<sup>1</sup>, D. Francisci<sup>1</sup>, S. Fiorucci<sup>2</sup>

<sup>1</sup> *Clinica di Malattie Infettive, Perugia, Italy*; <sup>2</sup> *Dipartimento di Medicina Clinica e Sperimentale, Perugia, Italy*

#### SC24 MICROBIAL TRANSLOCATION (MT)-INDUCED IMMUNE ACTIVATION ASSOCIATES TO ATHEROSCLEROSIS IN CART TREATED HIV POS PATIENTS

E. Merlini\*<sup>1</sup>, F. Bai<sup>1</sup>, E. Suardi<sup>1</sup>, G. M. Bellistri<sup>1</sup>, S. Negri<sup>1</sup>, M. Cristina<sup>2</sup>,  
T. Bini<sup>1</sup>, A. d'Arminio Monforte<sup>1</sup>, G. Marchetti<sup>1</sup>

<sup>1</sup> *Chair of Infectious Diseases, San Paolo Hospital, University of Milan, Milan*; <sup>2</sup> *Chair of Internal Medicine, San Paolo Hospital, University of Milan, Milan, Italy*

**SC25** CIRCULATING MARKERS OF ENDOTHELIAL DYSFUNCTION, FLOW-MEDIATED VASODILATION AND CIRCULATING ENDOTHELIAL CELLS IN HIV INFECTION: EFFECT OF ABACAVIR VERSUS TENOFOVIR  
D. Francisci<sup>1</sup>, E. Falcinelli<sup>2</sup>, B. Belfiori\*<sup>1</sup>, E. Petito<sup>2</sup>, T. Fierro<sup>2</sup>, F. Baldelli<sup>1</sup>, P. Gresele<sup>2</sup>

<sup>1</sup> Division of Infectious Diseases, Department of Experimental Medicine, University of Perugia, Perugia, Italy; <sup>2</sup> Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy

**SC26** BONE TURN-OVER MARKERS IN HIV POSITIVE PATIENTS AFTER HAART: TENOFOVIR (TDF) + EMTRICITABINE (FTC) + ATAZANAVIR/RITONAVIR (ATV/R) -VS- TDF + FTC + EFAVIRENZ (EFV). RESULTS OF INCA TRIAL

E. Focà\*<sup>1</sup>, D. Motta<sup>1</sup>, M. Borderi<sup>2</sup>, I. Izzo<sup>1</sup>, A. Calabresi<sup>1</sup>, R. Bellagamba<sup>3</sup>, R. Fezza<sup>3</sup>, P. Narciso<sup>3</sup>, L. Sighinolfi<sup>4</sup>, P. Maggi<sup>5</sup>, M. Mendeni<sup>1</sup>, G. Carosi<sup>1</sup>, D. Gotti<sup>1</sup>, A. Clò<sup>6</sup>, S. Morini<sup>6</sup>, B.M. Cesana<sup>7</sup>, E. Quiros-Roldan<sup>1</sup>, C. Torti<sup>1</sup>  
<sup>1</sup>Infectious Diseases Department, University of Brescia, Brescia, Italy; <sup>2</sup>Infectious Diseases Institute, University of Bologna, Bologna, Italy; <sup>3</sup>National Institute of Infectious Diseases, Rome, Italy; <sup>4</sup>Infectious Diseases Department, S. Anna Hospital, Ferrara, Italy; <sup>5</sup>Infectious Diseases Institute, Policlinico di Bari, Bari, Italy; <sup>6</sup>Microbiology Section, University of Bologna, Bologna, Italy; <sup>7</sup>Institute of Statistics in Medicine, University of Brescia, Brescia, Italy

13.00

## HIV CLINICAL DIAGNOSTIC

(Sala Onice)

Discussants: F.G. De Rosa (Turin), M. Zaccarelli (Rome)

**SC27** SUSTAINED VIROLOGICAL RESPONSE (SVR) TO ANTI-HEPATITIS C (HCV) THERAPY IS ASSOCIATED WITH A SIGNIFICANT INCREASE OF TRIGLYCERIDE (TGD) AND TOTAL CHOLESTEROL (TC) PLASMA LEVELS

P. Nasta\*<sup>1</sup>, S. Amadasi<sup>1</sup>, F. Borghi<sup>1</sup>, F. Gatti<sup>1</sup>, E. Chiari<sup>1</sup>, G. Carosi<sup>1</sup>  
<sup>1</sup> Istituto di Malattie Infettive e Tropicali, Brescia, Italy

**SC28** LIVER STEATOSIS IN HIV/HCV COINFECTED AND HCV-MONOFECTED PATIENTS: AN HISTOLOGICAL COMPARISON

C. Sagnelli\*<sup>1,2</sup>, C. Uberti-Foppa<sup>2</sup>, L. Galli<sup>2</sup>, G. Pasquale<sup>1</sup>, S. De Pascalis<sup>2</sup>, M. Fiore<sup>1</sup>, N. Coppola<sup>1</sup>, L. Albarello<sup>2</sup>, C. Doglioni<sup>2</sup>, A. Lazzarin<sup>2</sup>, E. Sagnelli<sup>1</sup>  
<sup>1</sup>Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy; <sup>2</sup>Clinic of Infectious Diseases and Department of Pathology, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy

**SC29** MULTI DRUG RESISTANT TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN THE URBAN SETTING OF MILAN (1996-2009): AN AKWARD HERITAGE OF THE RECENT PAST

F. Zanini\*<sup>1</sup>, M. Carugati<sup>1</sup>, C. Schirotti<sup>1</sup>, G. Lapadula<sup>2</sup>, A. Lombardi<sup>3</sup>, E. Mazzola<sup>4</sup>, L. Codecasa<sup>5</sup>, A. Gori<sup>2</sup>, F. Franzetti<sup>1</sup>  
<sup>1</sup> Clinica di Malattie Infettive, A.O. - Polo Universitario "L. Sacco", Milan, Italy; <sup>2</sup> Clinica di Malattie Infettive, A.O. "S. Gerardo", Monza, Italy; <sup>3</sup> Laboratorio di Microbiologia, A.O. - Polo Universitario "L. Sacco", Milan, Italy; <sup>4</sup> Laboratorio di Microbiologia, A.O. "Cà Granda" Niguarda, Milan, Italy; <sup>5</sup> Istituto "Villa Marelli", Centro di riferimento regionale per la tubercolosi in Lombardia, Milan, Italy

- SC30** CHARACTERISTICS OF ANTI-HBV TREATMENT IN A COHORT OF ITALIAN HBV-INFECTED PATIENTS IN RELATION TO HIV-INFECTION STATUS  
G. Antonucci\*<sup>1</sup>, E. Girardi<sup>1</sup>, C. Angeletti<sup>1</sup>, F. Mazzotta<sup>2</sup>, E. Sagnelli<sup>3</sup>, SIMIT Study Group<sup>4</sup>  
<sup>1</sup>INMI L. Spallanzani, Rome, Italy; <sup>2</sup>U.O. di Malattie Infettive Ospedale S. M. Annunziata, Florence, Italy; <sup>3</sup>Clinica Malattie Infettive Seconda Università, Naples, Italy; <sup>4</sup>SIMIT
- SC31** INCIDENCE OF C.TRACHOMATIS GENITAL INFECTIONS IN A COHORT OF HIV INFECTED WOMEN  
A. Apostoli<sup>1</sup>, A. Carvalho<sup>1</sup>, S. Odolini<sup>1</sup>, S. Benedetti<sup>1</sup>, S. Dal Zoppo<sup>1</sup>, I. Izzo<sup>1</sup>, V. Bergamaschi<sup>1</sup>, S. Caligaris<sup>1</sup>, A. Matteelli\*<sup>1</sup>  
<sup>1</sup>Department of Infectious Diseases, Spedali Civili, Brescia, Italy
- SC32** PORPHYRIA CUTANEA TARDA IN TWO ARV-SUPPRESSED PATIENTS WITH HIV/HCV COINFECTION  
R. Marocco\*<sup>1</sup>, M. Lichtner<sup>1</sup>, I. Mezzaroma<sup>2</sup>, A. Esposito<sup>2</sup>, V. Belvisi<sup>1</sup>, H. Martini<sup>2</sup>, P. Giovangrossi<sup>3</sup>, F. Equitani<sup>3</sup>, C.M. Mastroianni<sup>1</sup>  
<sup>1</sup>Sapienza Università di Roma, Polo Pontino, Rome, Italy; <sup>2</sup>Sapienza Università di Roma, Rome, Italy; <sup>3</sup>Ospedale SM Goretti, Latina, Italy
- SC33** MALIGNANT SYPHILIS CONFIRMED IN SKIN BIOPSY BY IMMUNOHISTOCHEMICAL STAINING IN AN HIV-INFECTED PATIENT  
G.V. De Socio\*<sup>1</sup>, S. Simonetti<sup>2</sup>, A. Sgrelli<sup>1</sup>, E. Cecchini<sup>1</sup>, M.V. Moretti<sup>1</sup>, F. Baldelli<sup>1</sup>  
<sup>1</sup>Clinica di Malattie Infettive, Perugia, Italy; <sup>2</sup>Clinica dermatologica, Perugia, Italy

13.00 **POSTER PRESENTATIONS** (Ballato)

Discussants: A. Capetti (Milan), M.P. Trotta (Rome),  
E. Nicastri (Rome), A. Viganò (Milan),  
P. Viganò (Legnano), P. Filippini (Naples)

CS = Clinical Sciences  
ES = Epidemiology and Social Sciences

- PP12** EXPANDED POSTEXPOSURE PROPHYLAXIS: THE IRAPEP EXPERIENCE  
ES  
G. De Carli\*<sup>1</sup>, S. Pittalis<sup>1</sup>, E. Schifano<sup>1</sup>, V. Puro<sup>1</sup>  
<sup>1</sup>Istituto Nazionale Malattie Infettive L. Spallanzani, Rome, Italy
- PP13** EFFICACY, SAFETY AND TOLERABILITY OF CO-FORMULATED EFV/FTC/TDF TREATMENT  
CS  
G. Sterrantino\*<sup>1</sup>, B. Borchi<sup>1</sup>, A. Farese<sup>1</sup>, C. Martinelli<sup>1</sup>, F. Leoncini<sup>1</sup>  
<sup>1</sup>Azienda Ospedaliera-Universitaria Careggi, Florence, Italy
- PP14** COMPARISON OF HIV-1 RECOMBINANT PHENOTYPIC ASSAYS AND VIRTUAL PHENOTYPE IN THE DEFINITION OF CORECEPTOR USAGE  
CS  
A. Monchetti<sup>1</sup>, G. Biagioni<sup>1</sup>, M. Ferreri<sup>1</sup>, K. Marinelli<sup>1</sup>, S. Menzo<sup>2</sup>, P. Bagnarelli\*<sup>1</sup>  
<sup>1</sup>Virology Unit, Department of Biomedical Sciences, University Politecnica Marche, Ancona, Italy; <sup>2</sup>Laboratory of Virology, INMI "L. Spallanzani", Rome, Italy
- PP15** FACTORS IMPACTING HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 CORECEPTOR TROPISM  
CS  
M. Altamura\*<sup>1</sup>, L. Scudeller<sup>2</sup>, A. Volpe<sup>1</sup>, A. Saracino<sup>3</sup>, N. Ladisa<sup>1</sup>, C. Santoro<sup>1</sup>, L. Monno<sup>1</sup>, G. Angarano<sup>1</sup>  
<sup>1</sup>Clinica Malattie Infettive, Università degli Studi di Bari, Bari, Italy; <sup>2</sup>IRCCS Policlinico San Matteo, Pavia, Italy; <sup>3</sup>Clinica Malattie Infettive, Università degli Studi di Foggia, Foggia, Italy



**PP16**  
CS

**THERAPEUTIC DRUG MONITORING OF ANTIRETROVIRAL DRUGS IN HIV-INFECTED PREGNANT WOMEN: PHARMACOKINETICS, TRANSPLACENTAL AND AMNIOTIC FLUID DIFFUSION, EFFICACY AND SAFETY**

J. Ivanovic\*<sup>1</sup>, R. Bellagamba<sup>1</sup>, F. Signore<sup>2</sup>, C. Vallone<sup>2</sup>, E. Nicastrì<sup>1</sup>, M. Tempestilli<sup>1</sup>, G. Pisani<sup>2</sup>, C. Tommasi<sup>1</sup>, A.L. Gallo<sup>1</sup>, P.L. Pucillo<sup>1</sup>, P. Narciso<sup>1</sup>

<sup>1</sup>National Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome, Italy; <sup>2</sup>Department of Obstetrics and Gynaecology, 'San Camillo-Forlanini' Hospital, Rome, Italy

**PP17**  
CS

**INCREASED USE OF NEW GENERATION ANTIRETROVIRAL DRUGS IN ITALIAN CHILDREN WITH PERINATAL HIV INFECTION**

E. Chiappini\*<sup>1</sup>, L. Galli<sup>1</sup>, P. Tovo<sup>2</sup>, C. Gabiano<sup>2</sup>, C. Lisi<sup>3</sup>, A. Viganò<sup>4</sup>, S. Bernardi<sup>5</sup>, S. Esposito<sup>6</sup>, R. Rosso<sup>7</sup>, C. Giaquinto<sup>8</sup>, R. Badolato<sup>9</sup>, A. Guarino<sup>10</sup>, A. Maccabruni<sup>11</sup>, M. Masi<sup>12</sup>, M. Cellini<sup>13</sup>, F. Salvini<sup>14</sup>, D. La Rovere<sup>15</sup>, M. Dedoni<sup>16</sup>, I. Dodi<sup>17</sup>, M. de Martino<sup>1</sup>

<sup>1</sup>Department of Science for Woman and Child Health, University of Florence, Florence, Italy; <sup>2</sup>Department of Pediatrics, University of Turin, Turin, Italy; <sup>3</sup>Department of Statistics, University of Florence, Florence, Italy; <sup>4</sup>Department of Pediatrics, University of Milan, L. Sacco Hospital, Milan, Italy; <sup>5</sup>Pediatric Clinic, "Bambino Gesù" Hospital, Rome, Italy; <sup>6</sup>Department of Maternal and Pediatric Sciences, Milan University, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagali e Regina Elena, Milan, Italy; <sup>7</sup>Infectious Diseases Clinic, University of Genoa, San Martino Hospital, Genoa, Italy; <sup>8</sup>Department of Pediatrics, Padua University, Padua, Italy; <sup>9</sup>Pediatric Clinic, Brescia University, Brescia, Italy; <sup>10</sup>Department of Pediatrics, "Federico II" University, Naples, Italy; <sup>11</sup>Department of Infectious Diseases, University of Pavia, Pavia, Italy; <sup>12</sup>Pediatric Clinic, "S. Orsola" Hospital, Bologna University, Bologna, Italy; <sup>13</sup>Department of Mother and Child, University of Modena, Modena, Italy; <sup>14</sup>Division of Pediatrics, University of Milan, S. Paolo Hospital, Milan, Italy; <sup>15</sup>Pediatric Infectious Disease Unit, Giovanni XXIII Hospital, Bari, Italy; <sup>16</sup>Pediatric Clinic, Cagliari University, Cagliari, Italy; <sup>17</sup>Pediatric Department, University Hospital of Parma, Parma, Italy

**PP18**  
CS

**NO CORRELATION BETWEEN RISK OF NEUROPSYCHIATRIC ADVERSE EVENTS AND CSF PENETRATION EFFECTIVENESS (CPE) SCORE IN THE MONET TRIAL OF DARUNAVIR/RITONAVIR (DRV/R), WITH OR WITHOUT NUCLEOSIDE ANALOGUES (NRTIS)**

D. Ripamonti\*<sup>1</sup>, A. Winston<sup>2</sup>, J. Arribas<sup>3</sup>, A. Hill<sup>4</sup>, Y. van Delft<sup>5</sup>, C. Moecklinghoff<sup>6</sup>

<sup>1</sup>Ospedali Riuniti di Bergamo - Bergamo, Italy; <sup>2</sup>St Mary's Hospital, London, UK; <sup>3</sup>Hospital la Paz, Madrid, Spain; <sup>4</sup>Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK; <sup>5</sup>Janssen-Cilag EMEA, Tilburg, The Netherlands; <sup>6</sup>Janssen-Cilag EMEA, Neuss, Germany

**PP19**  
CS

**MARAVIROC (MVC) REDUCES LIVER STIFFNESS PROGRESSION (LSP) IN HIV-HEPATITIS C (HCV) COINFECTED PATIENTS. PRELIMINARY DATA FROM A RANDOMIZED CONTROL STUDY (MAICOL)**

P. Nasta\*<sup>1</sup>, F. Gatti<sup>1</sup>, F. Borghi<sup>1</sup>, S. Amadasi<sup>1</sup>, E. Chiari<sup>1</sup>, G. Carosi<sup>1</sup>

<sup>1</sup>Istituto di Malattie Infettive e Tropicali, Brescia, Italy

**PP20**  
CS

**SIX-YEAR CHANGES OF ANTHROPOMETRIC, TOTAL AND APPENDICULAR FAT MASSES MEASURES IN HIV-INFECTED CHILDREN SWITCHING FROM STAVUDINE TO TENOFOVIR AND FROM PROTEASE INHIBITOR TO EFAVIRENZ**

V. Giacommet\*<sup>1</sup>, G. Bedogni<sup>2</sup>, A. Viganò<sup>1</sup>, S. Mora<sup>3</sup>, V. Manfredini<sup>1</sup>, S. Stucchi<sup>1</sup>, P. Erba<sup>1</sup>, F. Penagini<sup>1</sup>, F. Di Nello<sup>1</sup>, P. Brambilla<sup>4</sup>, G.V. Zuccotti<sup>1</sup>

<sup>1</sup>Pediatric Clinic, L. Sacco Hospital, University of Milan, Milan, Italy;

<sup>2</sup>Clinical Epidemiology Unit, Liver Research Center, Trieste, Italy;

<sup>3</sup>Laboratory of Paediatric Endocrinology, San Raffaele Scientific

Institute, Milan, Italy; <sup>4</sup>ASL Milano 2, Milan, Italy

- PP21**  
CS  
**HIV/HPV CO-INFECTION: MONITORING AND TREATMENT IN SUB-SAHARAN AFRICA: A PUBLIC HEALTH MODEL INTERVENTION**  
G. Guidotti<sup>1</sup>, C. Moscatelli\*<sup>1</sup>, L. Palombi<sup>2</sup>, M.C. Marazzi<sup>3</sup>, C. Carrilho<sup>4</sup>, E.S.F. Walle<sup>4</sup>, I. Zimba<sup>5</sup>, M. Magnano San Lio<sup>6</sup>, F. Erba<sup>2</sup>, M. Cunha<sup>4</sup>, U. Rovigatti<sup>7</sup>, I. Marchetti<sup>7</sup>, M.P. Cioni<sup>7</sup>, G. Bevilacqua<sup>7</sup>  
<sup>1</sup> Scuola di Dottorato in Scienze Molecolari-Università di Pisa, Pisa, Italy; <sup>2</sup> Università Di Roma Tor Vergata, Rome, Italy; <sup>3</sup>Università LUMSA Facoltà di Scienze della Formazione, Rome, Italy; <sup>4</sup>Department of Pathology, Universidade Eduardo Mondlane, Hospital Central de Maputo, Maputo, Mozambique; <sup>5</sup>DREAM Health Center of Benfica, Maputo, Mozambique; <sup>6</sup>Community of Sant'Egidio, Drug Resources Enhancement against AIDS and Malnutrition (DREAM), Rome, Italy; <sup>7</sup>Dipartimento di oncologia, dei trapianti e delle nuove tecnologie in medicina Università di Pisa, Pisa, Italy
- PP22**  
CS  
**POPULATION-BASED DATABASE TO STUDY THE INCIDENCE OF CANCER IN HIV-INFECTED PATIENTS IN BRESCIA**  
A. Calabresi\*<sup>1</sup>, A. Ferraresi<sup>1</sup>, C. Scarcella<sup>2</sup>, R.M. Limina<sup>3</sup>, F. Donato<sup>3</sup>, A. Vavassori<sup>1</sup>, E. Focà<sup>1</sup>, M. Mendeni<sup>1</sup>, F. Castelnuovo<sup>1</sup>, A. Scalzini<sup>1</sup>, G. Carosi<sup>1</sup>, C. Torti<sup>1</sup>, E. Quiros Roldan<sup>1</sup>  
<sup>1</sup>Department of Infectious Diseases, University and Spedali Civili of Brescia, Brescia, Italy; <sup>2</sup>Brescia Local Health Authority, Brescia, Italy; <sup>3</sup>Chair of Hygiene, University of Brescia, Brescia, Italy
- PP23**  
CS  
**SWITCHING TO BOOSTED OR UNBOOSTED ATAZANAVIR IMPROVES GLUCOSE TOLERANCE IN HIV INFECTED SUBJECTS: ATAGLU COHORT STUDY**  
G. D'Ettore<sup>1</sup>, G. Ceccarelli\*<sup>1</sup>, F. Gizzi<sup>1</sup>, S. Mewamba<sup>1</sup>, C. Rizza<sup>1</sup>, F. Tierno<sup>1</sup>, P. Massetti<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, V. Vullo<sup>1</sup>  
<sup>1</sup> Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy
- PP24**  
CS  
**TREATMENT SIMPLIFICATION TO ATAZANAVIR/RITONAVIR PLUS LAMIVUDINE IS CORRELATED TO AN INCREASE OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) (ATAZANAVIR AND LAMIVUDINE SIMPLIFICATION STUDY, ATLAS)**  
R. Murri\*<sup>1</sup>, A. De Luca<sup>1,2</sup>, M. Fabbiani<sup>1</sup>, L. Bracciale<sup>1</sup>, S. Farina<sup>1</sup>, N. Ciccarelli<sup>1</sup>, L. Sidella<sup>1</sup>, M. Doino<sup>1</sup>, A. D'Avino<sup>1</sup>, I. Fanti<sup>1</sup>, A. Mondì<sup>1</sup>, R. Cauda<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>  
<sup>1</sup>Università Cattolica S. Cuore, Rome, Italy; <sup>2</sup>Siena University Hospital, Siena, Italy; Second Division of Infectious Diseases
- PP25**  
CS  
**EVOLUTION OF BONE MINERAL DENSITY AND METABOLISM AND OF SUBCUTANEOUS FAT IN PATIENTS ENROLLED IN THE ATAZANAVIR/R + LAMIVUDINE SIMPLIFICATION STUDY (ATLAS)**  
A. De Luca\*<sup>1</sup>, M. Fabbiani<sup>1</sup>, M. Doino<sup>1</sup>, S. Farina<sup>1</sup>, A. Mondì<sup>1</sup>, N. Ciccarelli<sup>1</sup>, L. Sidella<sup>1</sup>, A. D'Avino<sup>1</sup>, I. Fanti<sup>1</sup>, L. Bracciale<sup>1</sup>, R. Cauda<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>  
<sup>1</sup>Università Cattolica Del Sacro Cuore, Rome, Italy
- PP26**  
CS  
**ITALIAN SURVEY ON THE DIAGNOSIS OF OSTEOPOROSIS IN HIV: PRELIMINARY RESULTS**  
F. Vescini\*<sup>1</sup>, F. Di Campli<sup>2</sup>, M. Borderi<sup>3</sup>, workgroup Italian SorBone<sup>4</sup>  
<sup>1</sup> Centro per la Diagnosi e Cura dell'Osteoporosi, San Donà di Piave, Italy; <sup>2</sup>ViiV Healthcare, Verona, Italy; <sup>3</sup>Infectious Diseases Unit, Bologna, Italy; <sup>4</sup>Italian SorBone workgroup, Italy
- PP27**  
CS  
**RENAL IMPAIRMENT IN HIV-INFECTED PATIENTS IS PROGRESSIVE AND INFLUENCED BY ANTIRETROVIRAL TREATMENT**  
F. Sabbatini\*<sup>1</sup>, N. Squillace<sup>1</sup>, A. Muscatello<sup>1</sup>, A. Soria<sup>1</sup>, G. Lapadula<sup>1</sup>, M. Airoidi<sup>1</sup>, V. Pastore<sup>1</sup>, M. Rossi<sup>1</sup>, A. Gori<sup>1</sup>, A. Bandera<sup>1</sup>  
<sup>1</sup> Ospedale San Gerardo, Monza, Italy

**PP28**  
CS

**VITAMIN D3 SUPPLEMENTATION DECREASES THE RISK OF DIABETES MELLITUS AMONG PATIENTS WITH HIV INFECTION**

G. Guaraldi\*<sup>1</sup>, S. Zona<sup>1</sup>, G. Orlando<sup>1</sup>, C. Federica<sup>1</sup>, G. Ligabue<sup>1</sup>, C. Stentarelli<sup>1</sup>, M. Menozzi<sup>1</sup>, E. Garlassi<sup>1</sup>, C. Giovanardi<sup>1</sup>, P. Tebas<sup>2</sup>  
<sup>1</sup> University of Modena and Reggio Emilia, Modena, Italy; <sup>2</sup> University of Pennsylvania, Philadelphia, USA

13.00 **POSTERS** (Ballatoi)

14.30 **LECTURE** (Auditorium)

Chairman: *R. Cauda* (Rome)

**IMMUNOLOGIC RESPONSE**

*G. Pantaleo* (Lausanne)

15.00 **SYMPOSIUM** (Auditorium)

---

**IMMUNOGENETICS OF HIV:  
MODULATION OF RESISTANCE  
AND SUSCEPTIBILITY TO INFECTION**

Chairman: *V. Barnaba* (Rome)

**INTRODUCTION**

*M. Clerici* (Milan)

**UNSUSPECTED MOLECULAR PARTNERS  
FOR THE HIV-1 TAT PROTEINE**

*M. Giacca* (Trieste)

**GENETIC SCREENING FOR HIV-RELATED  
COMPLICATIONS AS A CLINICALLY RELEVANT  
PREDICTION TOOL**

*P. Tarr* (Basel)

**MITOCHONDRIA GENOMICS: AN UPDATE**

*A. Cossarizza* (Modena)

**NATURAL REGULATORS OF CCR5  
INTERNALIZATION AND IMPLICATION FOR  
VACCINE AND THERAPEUTICS AGAINST HIV  
INFECTION**

*L. Lopalco* (Milan)

**HIG-LEVEL RAC2 EXPRESSION ASSOCIATED WITH  
NOVEL INTRON POLYMORPHISMS RESTRICTS  
HIV-1 REPLICATION IN EXPOSED SENONEGATIVE  
INDIVIDUALS**

*M. Miyazawa* (Osaka)

---

**OPEN QUESTIONS IN HIV MANAGEMENT  
AND HIGHLIGHTS FROM ICAR 2011**

Chairman: *G. Angarano* (Bari)

Discussants: *F. Maggiolo* (Bergamo), *P. Bonfanti* (Lecco)

Speakers: *A. Ammassari* (Rome), *P. Cinque* (Milan),  
*A. De Luca* (Rome), *C. Mussini* (Modena)

17.45 **ICAR 2011 AWARDS**

**Prize-giving Ceremony for the best contributions from  
young researchers:**

**Premio “G.B. Rossi”, ANLAIDS  
Premio “Raffaella Rosso”, SIMIT  
Premio Fondazione AVIRALIA  
Premio SIVIM  
Premio SIMIT**

**ICAR PERSPECTIVES: IAS, ICAR 2012**

18.15 **FINAL REMARKS**  
F. Mazzotta

## POSTERS

## BASIC SCIENCES

- PO 01** OCCULT HEPATITIS B INFECTION (OBI) IN HIV-INFECTED PATIENTS IN PALERMO, ITALY: PRELIMINARY DATA  
P. Di Carlo\*<sup>1</sup>, G. Mazzola<sup>1</sup>, D. Ingrassia<sup>1</sup>, G. Guadagnino<sup>1</sup>, F. Vitale<sup>1</sup>, F. Tramuto<sup>1</sup>  
<sup>1</sup> *Dipartimento di Scienze per la Promozione della Salute, Università degli Studi di Palermo, Palermo, Italy*
- PO 02** PREVALENCE AND TYPE SPECIFIC PAPILLOMAVIRUS LOAD IN HIV-POSITIVE WOMEN ANAL INFECTION  
C. Scagnolari<sup>1</sup>, F. Cannella\*<sup>1</sup>, A.M. Degener<sup>1</sup>, S. Verzaro<sup>1</sup>, E. Di Biase<sup>1</sup>, C. Selvaggi<sup>1</sup>, M. Indinnimeo<sup>2</sup>, V. Vullo<sup>3</sup>, G. D'Ettores<sup>3</sup>, A. Pierangeli<sup>1</sup>, G. Antonelli<sup>1</sup>  
<sup>1</sup> *Department of Molecular Medicine "Sapienza" University, Rome, Italy;*  
<sup>2</sup> *Chirurgic Department "Pietro Valdoni" "Sapienza" University, Rome, Italy;* <sup>3</sup> *Department of Public Health and Infectious Diseases "Sapienza" University, Rome, Italy*
- PO 03** DELAYED MATURATION OF IGG ANTI-HIV AVIDITY IN PATIENTS WITH PRIMARY/ACUTE HIV INFECTION TREATED WITH A RALTEGRAVIR - HAART BASED REGIMEN  
G. Orofino\*<sup>1</sup>, V. Ghisetti<sup>2</sup>, S. Carosella<sup>1</sup>, M. Guastavigna<sup>1</sup>, M. Farenga<sup>1</sup>, S. Faraoni<sup>2</sup>, T. Allice<sup>2</sup>, P. Caramello<sup>1</sup>  
<sup>1</sup> *Div. A Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy;*  
<sup>2</sup> *Dipartimento di Malattie Infettive, S.C. Microbiologia e Virologia, Ospedale Amedeo di Savoia, Turin, Italy*
- PO 04** RELATIONSHIP BETWEEN REGULATORY T CELLS, VIRAL LOAD AND CHRONIC IMMUNE ACTIVATION IN HIV-1 INFECTED CHILDREN  
K. Giancesin\*<sup>1</sup>, R. Freguja<sup>1</sup>, M. Zanchetta<sup>2</sup>, F. Carmona<sup>2</sup>, C. Giaquinto<sup>3</sup>, A. De Rossi<sup>1</sup>  
<sup>1</sup> *Dipartimento di Scienze Oncologiche e Chirurgiche, AIDS Reference Centre, Università degli Studi di Padova, Padua, Italy;* <sup>2</sup> *Istituto Oncologico Veneto, IRCCS, Padua, Italy;* <sup>3</sup> *Dipartimento di Pediatria, Università degli Studi di Padova, Padua, Italy*
- PO 05** PROSPECTIVE EVALUATION OF QUALITATIVE IMMUNE RECOVERY IN HIV SUBJECTS STARTING ANTIRETROVIRAL THERAPY (ART) WITH SEVERE IMMUNODEFICIENCY: IMMUNOPHENOTYPE, IMMUNE ACTIVATION, PROLIFERATION AND APOPTOSIS  
A. Soria\*<sup>1</sup>, A. Bandera<sup>1</sup>, M. Airoidi<sup>1</sup>, S. Leone<sup>2</sup>, M. Pacei<sup>3</sup>, M. Borrelli<sup>3</sup>, F. Maggiolo<sup>2</sup>, D. Trabattoni<sup>3</sup>, M. Clerici<sup>3</sup>, A. Gori<sup>1</sup>  
<sup>1</sup> *Ospedale San Gerardo, Università Milano-Bicocca, Monza, Italy;*  
<sup>2</sup> *Ospedali Riuniti, Bergamo, Italy;* <sup>3</sup> *LITA VIALBA Università degli Studi di Milano, Milan, Italy*
- PO 06** THE HIV-1 NEF PROTEIN DOWN-REGULATES THE NATURAL KILLER CELL ACTIVATING LIGAND PVR  
G. Matusali<sup>1</sup>, M. Potestà<sup>1</sup>, E. Olivetta<sup>2</sup>, A. Santoni<sup>3</sup>, C. Cerboni<sup>3</sup>, M. Doria\*<sup>1</sup>  
<sup>1</sup> *Ospedale Pediatrico Bambino Gesù, Rome, Italy;* <sup>2</sup> *Istituto Superiore di Sanità, Rome, Italy;* <sup>3</sup> *Sapienza University of Rome, Rome, Italy*
- PO 07** LONG TERM IMMUNE RECONSTITUTION IN HIV-POSITIVE RELAPSE/REFRACTORY LYMPHOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION  
S. Zanussi\*<sup>1</sup>, R. Manuele<sup>2</sup>, M. Rupolo<sup>2</sup>, C. Pratesi<sup>1</sup>, C. Caffau<sup>1</sup>, M.T. Bortolin<sup>1</sup>, R. Tedeschi<sup>1</sup>, M. Mazzucato<sup>3</sup>, L. Abbruzzese<sup>3</sup>, E. Vaccher<sup>4</sup>, M. Spina<sup>4</sup>, U. Tirelli<sup>4</sup>, G. Basaglia<sup>1</sup>, M. Michieli<sup>2</sup>, P. De Paoli<sup>5</sup>  
<sup>1</sup> *Microbiology, Immunology, Virology, Oncology Reference Centre, Aviano, PN, Italy;* <sup>2</sup> *Cellular Therapy and High-Dose Chemotherapy Unit, Oncology Reference Centre, Aviano, PN, Italy;* <sup>3</sup> *Stem Cell Collection and Processing Unit, Oncology Reference Centre, Aviano, PN, Italy;* <sup>4</sup> *Division of Medical Oncology A, Oncology Reference Centre, Aviano, PN, Italy;* <sup>5</sup> *Scientific Directorate, Oncology Reference Centre, Aviano, PN, Italy*
- PO 08** PERIPHERAL BLOOD T REGULATORY CELLS AND TH17 CELLS AND THEIR GENES EXPRESSION PROFILE IN HIV-1

**INFECTED PATIENTS AND HEALTHY CONTROLS**

M. Tarkowski\*<sup>1</sup>, P. Lewkowicz<sup>2</sup>, E. Jablonowska<sup>2</sup>, D. Misciniagi<sup>1</sup>, A. Riva<sup>1</sup>, M. Galli<sup>1</sup>

<sup>1</sup>Università degli Studi di Milano, Milan, Italy; <sup>2</sup>Medical University of Lodz, Lodz, Poland

**PO 09 INFLUENCE OF DIFFERENT ART REGIMENS ON IMMUNE PARAMETERS AND ACTIVATION: ABACAVIR, TENOFOVIR AND RALTEGRAVIR-BASED REGIMENS AND NK CELLS**  
F. Bozzano\*<sup>1</sup>, F. Marras<sup>2</sup>, A. Beltrame<sup>3</sup>, A. Alessandrini<sup>3</sup>, G. Pagano<sup>3</sup>, A. De Maria<sup>2</sup>

<sup>1</sup>Istituto G. Gaslini, Genoa, Italy; <sup>2</sup>Università degli Studi di Genova, Genoa, Italy; <sup>3</sup>Azienda Ospedaliera, Ospedale S. Martino, Genoa, Italy

**PO 10 LONG TERM CD4 RECOVERY IN FULLY SUPPRESSED SUBJECTS TREATED WITH FIRST LINE HAART IS INFLUENCED BY TIME TO REACH UNDETECTABILITY**

G. Travi\*<sup>1</sup>, S. Salpietro<sup>1</sup>, C. Pizzocolo<sup>1</sup>, L. Galli<sup>1</sup>, V. Spagnuolo<sup>1</sup>, F. Cossarini<sup>1</sup>, N. Gianotti<sup>1</sup>, S. Nozza<sup>1</sup>, A. Lazzarin<sup>1</sup>, A. Castagna<sup>1</sup>

<sup>1</sup>San Raffaele Scientific Institute, Milan, Italy

**PO 11 PHARMACOLOGICAL MODULATION OF APOPTOSIS OF PBMC BY DARUNAVIR AND MARAVIROC**

I. Sauzullo\*<sup>1</sup>, F. Mengoni<sup>1</sup>, A. Ermocida<sup>1</sup>, R. Rossi<sup>1</sup>, M. Lichtner<sup>2</sup>, A.P. Massetti<sup>1</sup>, C.M. Mastroianni<sup>2</sup>, V. Vullo<sup>1</sup>

<sup>1</sup>Sapienza Università di Roma, Rome, Italy; <sup>2</sup>Sapienza Università, Latina, Polo Pontino, Italy

**PO 12 EVALUATION OF CELLULAR ASSOCIATED HIV-1 DNA LEVELS IN HIV-1 INFECTED PATIENTS RECEIVING A LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL THERAPY**

C. Scagnolari\*<sup>1</sup>, K. Monteleone<sup>1</sup>, C. Selvaggi<sup>1</sup>, S. Verzaro<sup>1</sup>, A. Carducci<sup>2</sup>, F. Ceccherini-Silberstein<sup>3</sup>, M. Andreoni<sup>4</sup>, G. Antonelli<sup>1</sup>, E. Riva<sup>2</sup>

<sup>1</sup>Department of Molecular Medicine, Laboratory of Virology "Sapienza" University of Rome, Rome, Italy; <sup>2</sup>Microbiology and Virology Dept, University Campus Bio-Medico, Rome, Italy; <sup>3</sup>Department of Experimental Medicine, University of Rome Tor Vergata, Rome Italy; <sup>4</sup>Clinic Infectious Diseases, Clinic Infectious Diseases, University of Rome Tor Vergata, Rome, Italy

**CLINICAL SCIENCES**

**PO 13 EVALUATION OF A NEW REAL-TIME PCR METHOD FOR HIV-1 RNA QUANTIFICATION IN PATIENTS WITH LOW LEVEL OF VIREMIA**

M.G. Milia\*<sup>1</sup>, T. Alice<sup>1</sup>, G. Gregori<sup>1</sup>, E. Burdino<sup>1</sup>, T. Ruggiero<sup>1</sup>, B. Simoncelli<sup>1</sup>, A. Bottoni<sup>1</sup>, C. Galli<sup>2</sup>, S. Bonora<sup>3</sup>, G. Orofino<sup>3</sup>, G. Di Perri<sup>3</sup>, V. Ghisetti<sup>1</sup>

<sup>1</sup>Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Turin, Italy; <sup>2</sup>Scientific Affairs, Abbott Diagnostic, Rome, Italy; <sup>3</sup>Department of Infectious Diseases, Amedeo di Savoia Hospital and University of Torino, Turin, Italy

**PO 14 CARDIOVASCULAR RISK FACTORS IN PATIENTS ON LONG-TERM TREATMENT**

C. Bellacosa\*<sup>1</sup>, M. Altamura<sup>1</sup>, F.D. Lenoci<sup>1</sup>, A. Volpe<sup>1</sup>, F. Perilli<sup>2</sup>, A. Lillo<sup>2</sup>, G. Angarano<sup>1</sup>, P. Maggi<sup>1</sup>

<sup>1</sup>Malattie Infettive, Azienda Ospedaliera Policlinico, Bari, Italy; <sup>2</sup>Chirurgia Vascolare, Azienda Ospedaliera Policlinico, Bari, Italy

**PO 15 HLA-B\*5701 TYPING BY ALLELE SPECIFIC REAL-TIME PCR: COMPARISON WITH SEQUENCE BASED TYPING**

T. Alice<sup>1</sup>, M.G. Milia<sup>1</sup>, G. Gregori<sup>1</sup>, E. Burdino<sup>1</sup>, T. Ruggieri<sup>1</sup>, M. Malta<sup>1</sup>, E. Scuccimarra<sup>1</sup>, V. Ghisetti<sup>1</sup>

<sup>1</sup>Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Turin, Italy

**PO 16 IDENTIFICATION OF HLAB 5701 IN GENOMIC DNA EXTRACTED FROM PERIPHERAL BLOOD OF HIV-1 POSITIVE PATIENTS**

N. Cuomo<sup>1</sup>, A. Di Spirito<sup>1</sup>, G. Milone<sup>1</sup>, N. Melillo<sup>1</sup>, M. Dati<sup>1</sup>, C. Esposito\*<sup>1</sup>

<sup>1</sup>UOC Virologia, Naples, Italy

- PO 17** BONE MINERAL STATUS IN HIV INFECTED PATIENTS IN MEDITERRANEAN REGION: PRELIMINARY DATA  
 P. Di Carlo<sup>1</sup>, R. La Sala\*<sup>1</sup>, D. Bruno<sup>2</sup>, P. Colletti<sup>1</sup>, G. Mazzola<sup>1</sup>, M. Mineo<sup>1</sup>, M.A. Raimondo<sup>1</sup>, G.B. Rini<sup>2</sup>, L. Titone<sup>1</sup>, G. Caruso<sup>3</sup>  
<sup>1</sup>Policlinico Universitario "Paolo Giaccone", Palermo, Italy; <sup>2</sup>Department of Clinical Medicine and Emerging Pathologies, University of Palermo, Palermo, Italy; <sup>3</sup>Dipartimento di Biotecnologie mediche e Medicina legale, Sezione di scienze radiologiche, Università degli Studi di Palermo, Palermo, Italy
- PO 18** IMPACT OF AGING AND HIV-INFECTION ON NEUROCOGNITIVE PERFORMANCE  
 N. Ciccarelli\*<sup>1</sup>, M. Fabbiani<sup>1</sup>, E. Baldonero<sup>1</sup>, I. Fanti<sup>1</sup>, S. Farina<sup>1</sup>, A. D'Avino<sup>1</sup>, A. Mondini<sup>1</sup>, L. Sidella<sup>1</sup>, M. Doino<sup>1</sup>, M.C. Silveri<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>  
<sup>1</sup>Catholic University, Rome, Italy
- PO 19** AIDS DEMENTIA COMPLEX IN THE HAART ERA: CHARACTERIZATION AT DIAGNOSIS, MORTALITY AND PREDICTORS OF DEATH AT THE DEPARTMENT OF INFECTIOUS DISEASES IN BRESCIA (NORTHERN ITALY)  
 A. Bonito\*<sup>1</sup>, M. Mendeni<sup>1</sup>, D. Motta<sup>1</sup>, E. Focà<sup>1</sup>, I. Izzo<sup>1</sup>, S. Casari<sup>1</sup>, F. Castelnuovo<sup>1</sup>, A. Scalzini<sup>1</sup>, G. Paraninfo<sup>1</sup>, G. Carosi<sup>1</sup>, F. Buelli<sup>1</sup>, M. Magoni<sup>2</sup>, E. Quiros-Roldan<sup>1</sup>, C. Torti<sup>1</sup>  
<sup>1</sup>Infectious Diseases Dpt, University and Spedali Civili of Brescia, Brescia, Italy; <sup>2</sup>Institute of Hygiene, University of Brescia, Brescia, Italy
- PO 20** ALEXITHYMIA, A DISORDER OF THE REGULATORY MECHANISM OF EMOTION ELABORATION, AS A PREDICTOR OF NEUROCOGNITIVE IMPAIRMENT IN HIV INFECTED PATIENTS  
 F. Vadini<sup>1</sup>, A. Rossi<sup>1</sup>, F. Sozio<sup>1</sup>, P. Di Stefano<sup>1</sup>, T. Ursini<sup>1</sup>, A. Consorte<sup>1</sup>, G. Parruti\*<sup>1</sup>  
<sup>1</sup>U.O. Malattie Infettive, Pescara, Italy
- PO 21** MINIMAL EMERGENCE OF DARUNAVIR RESISTANCE AT TREATMENT FAILURE: ARE INTERPRETATION ALGORITHMS ADEQUATE?  
 G. Sterrantino\*<sup>1</sup>, M. Zaccarelli<sup>2</sup>, M. Zazzi<sup>3</sup>, A. De Luca<sup>4</sup>, V. Borghi<sup>5</sup>, P. Meraviglia<sup>6</sup>, P. Corsi<sup>1</sup>, S. Bonora<sup>7</sup>, G. Colao<sup>8</sup>, F. Baldanti<sup>9</sup>, S. Di Gianbenedetto<sup>10</sup>, T. Carli<sup>11</sup>, F. Maggiolo<sup>12</sup>, A. Antinori<sup>9</sup>, F. Leoncini<sup>1</sup>  
<sup>1</sup>Malattie Infettive, Azienda Ospedaliera Universitaria Careggi, Florence, Italy; <sup>2</sup>Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani", Rome, Italy; <sup>3</sup>Università di Siena, Dipartimento di Biologia Molecolare, Siena, Italy; <sup>4</sup>Istituto di Clinica Malattie Infettive, Rome, Italy; <sup>5</sup>Clinica Malattie Infettive, Modena, Italy; <sup>6</sup>Seconda Divisione Malattie Infettive Ospedale L. Sacco, Milan, Italy; <sup>7</sup>Malattie Infettive Amedeo di Savoia, Turin, Italy; <sup>8</sup>Virologia Careggi, Florence, Italy; <sup>9</sup>Virologia S. Matteo, Pavia, Italy; <sup>10</sup>Laboratorio Virologia Cattolica, Rome, Italy; <sup>11</sup>Malattie Infettive, Grosseto, Italy; <sup>12</sup>Malattie Infettive, Bergamo, Italy
- PO 22** ANALYSIS OF MAJOR AND MINOR IAS-USA PI MUTATIONS IN THE MONET TRIAL OF DARUNAVIR/RITONAVIR MONOTHERAPY VERSUS DRV/R +2NRTIS  
 A. d'Arminio Monforte\*<sup>1</sup>, G. Carosi<sup>2</sup>, A. Lazzarin<sup>3</sup>, F. Pulido<sup>4</sup>, J. Arribas<sup>5</sup>, A. Hill<sup>6</sup>, Y. van Delft<sup>7</sup>, C. Moecklinghoff<sup>8</sup>  
<sup>1</sup>San Paolo Hospital, Milan, Italy; <sup>2</sup>University of Brescia, Brescia, Italy; <sup>3</sup>S. Raffaele Hospital, University of Milan, Milan, Italy; <sup>4</sup>Hospital 12 de Octubre, Madrid, Spain; <sup>5</sup>Hospital la Paz, Madrid, Spain; <sup>6</sup>Liverpool University and Tibotec BVBA, Liverpool, UK; <sup>7</sup>Janssen-Cilag, Tilburg, The Netherlands; <sup>8</sup>Anssen-Cilag, Neuss, Germany,
- PO 23** HIGH RALTEGRAVIR PLASMA PHARMACOKINETICS INTRAPATIENTS VARIABILITY IN THE CLINICAL SETTING  
 M. Siccardi<sup>1</sup>, A. D'Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, L. Baietto<sup>1</sup>, M. Simiele<sup>1</sup>, M. Bracchi<sup>1</sup>, L. Marinaro<sup>1</sup>, S. Bonora\*<sup>1</sup>, G. Di Perri<sup>1</sup>  
<sup>1</sup>Università degli Studi di Torino / ASL TO2. Clinica Universitaria di Malattie Infettive, Torin, Italy
- PO 24** INTRACELLULAR PHARMACOKINETICS OF ATAZANAVIR-RITONAVIR (300 MG/100 MG) IS INFLUENCED BY SOLUTE CARRIER ORGANIC ANION TRANSPORTER (SLCO) 3A1 EXPRESSION

M. Siccardi<sup>1</sup>, A. D'Avolio<sup>1</sup>, L. Baietto<sup>1</sup>, M. Simiele<sup>1</sup>, S. Bonora\*<sup>1</sup>, D. Back<sup>2</sup>, A. Owen<sup>2</sup>, G. Di Perri<sup>1</sup>

<sup>1</sup> Università degli Studi di Torino / ASL TO2. Clinica Universitaria di Malattie Infettive, Turin, Italy; <sup>2</sup> Department of Pharmacology and Therapeutics. University of Liverpool, Liverpool, UK

**PO 25 PHARMACOKINETIC (PK) AND PHARMACODYNAMIC ANALYSES OF ONCE- AND TWICE-DAILY DARUNAVIR/RITONAVIR (DRV/R) IN THE ODIN TRIAL**

A. Lazzarin\*<sup>1</sup>, F. Mazzotta<sup>2</sup>, I. Mezzaroma<sup>3</sup>, V. Sekar<sup>4</sup>, G. De La Rosa<sup>4</sup>, T. Van de Castele<sup>5</sup>, P. Vis<sup>4</sup>, R.M.W. Hoetelmans<sup>5</sup>, M. Garau<sup>6</sup>

<sup>1</sup>S. Raffaele Hospital, University of Milan, Milan, Italy; <sup>2</sup>S.M. Annunziata Hospital, Firenze, Florence, Italy; <sup>3</sup>Department of Clinical Medicine, Sapienza, University of Roma, Rome, Italy; <sup>4</sup>Tibotec Inc, Titusville, NJ, USA; <sup>5</sup>Tibotec BVBA, Beerse, Belgium; <sup>6</sup>Medical Affairs Janssen, Milan, Italy

**PO 26 HEALTH-RELATED QUALITY OF LIFE (HRQOL) ASSESSMENT WITH ONCE- AND TWICE-DAILY DARUNAVIR/RITONAVIR (DRV/R) IN THE ODIN TRIAL**

A. Lazzarin\*<sup>1</sup>, F. Mazzotta<sup>2</sup>, I. Mezzaroma<sup>3</sup>, T. Van de Castele<sup>4</sup>, G. De La Rosa<sup>5</sup>, P. De Doncker<sup>4</sup>, R. Termini<sup>6</sup>

<sup>1</sup> S.Raffaele Hospital, University of Milan, Italy, Milan; <sup>2</sup>S.M. Annunziata Hospital, Firenze, Florence, Italy; <sup>3</sup>Department of Clinical Medicine, Sapienza, University of Roma, Rome, Italy; <sup>4</sup>Tibotec BVBA, Beerse, Belgium, Beerse; <sup>5</sup>Tibotec Inc, Titusville, USA; <sup>6</sup>Medical Affairs Janssen Italy, Milan, Italy

**PO 27 LOW-LEVEL VIRAEMIA DURING TREATMENT WITH DARUNAVIR/R MONOTHERAPY VERSUS DRV/R + 2NRTIS IN THE MONET TRIAL**

G. Carosi\*<sup>1</sup>, A. Lazzarin<sup>2</sup>, A. d'Arminio Monforte<sup>3</sup>, N. Clumeck<sup>4</sup>, J. Arribas<sup>5</sup>, P. Pulick<sup>6</sup>, G. Fatkenheuer<sup>7</sup>, A. Hill<sup>8</sup>, Y. van Delft<sup>9</sup>, C. Moecklinghoff<sup>10</sup>

<sup>1</sup> University of Brescia, Brescia, Italy; <sup>2</sup>S. Raffaele Hospital, University of Milan, Milan, Italy; <sup>3</sup>San Paolo Hospital, Milan, Italy; <sup>4</sup>CHU Saint-Pierre/Maladies Infectieuses, Brussels, Belgium, Brussel; <sup>5</sup>Arribas, J., Hospital la Paz, Madrid, Spain; <sup>6</sup>P., Hospital for Infectious Diseases, Warsaw, Poland; <sup>7</sup>Universität Köln, Köln, Germany; <sup>8</sup>Pharmacology Research Laboratories, Liverpool University, Liverpool, UK; <sup>9</sup>Janssen-Cilag, Tilburg, The Netherlands; <sup>10</sup>Janssen-Cilag, Neuss, Germany

**PO 28 CHANGES IN PATIENT-REPORTED OUTCOMES DURING THE SENSE TRIAL: FIRST-LINE TREATMENT WITH 2 NRTIS PLUS ETRAVIRINE OR EFAVIRENZ**

A. Castagna\*<sup>1</sup>, A. Lazzarin<sup>1</sup>, G. Carosi<sup>2</sup>, M. Andreoni<sup>3</sup>, C. Orkin<sup>4</sup>, A. Streinu-Cercel<sup>5</sup>, S. Erscou<sup>5</sup>, M. Nelson<sup>6</sup>, A. Hill<sup>7</sup>, Y. van Delft<sup>8</sup>, S. Marks<sup>8</sup>

<sup>1</sup>S. Raffaele Hospital, University of Milan, Italy, Milano; <sup>2</sup>Brescia Civili Hospital, University of Brescia, Brescia, Italy; <sup>3</sup>Tor Vergata Hospital, University of Rome, Rome, Italy; <sup>4</sup>St Bartholemews Hospital, London, UK; <sup>5</sup>Clinic de Boli Infectioase si Tropicale, Bucharest, Romania; <sup>6</sup>St Stephen's Centre, Chelsea and Westminster Hospital, London, UK; <sup>7</sup>Liverpool University, Liverpool, UK; <sup>8</sup>Janssen, Tilburg, The Netherlands

**PO 29 NEW SWITCH STRATEGY WITH RALTEGRAVIR ASSOCIATED TO BOOSTED PI IN HIV PATIENTS**

S. Martini\*<sup>1</sup>, F. Di Martino<sup>1</sup>, A. Masiello<sup>2</sup>, A. Cascone<sup>1</sup>, A. Filippini<sup>1</sup>, P. Filippini<sup>1</sup>

<sup>1</sup> UOC Diagnosi e Terapia AIDS della AOU della Seconda Università degli Studi di Napoli, Naples, Italy; <sup>2</sup>AORN G. Moscati, Avellino, Italy

**PO 30 SWITCHING TO A NRTI- AND RITONAVIR-SPARING THERAPY: A VALID OPTION IN HIV POSITIVE EXPERIENCED-PATIENTS**

A. De Bona\*<sup>1</sup>, T. Bini<sup>1</sup>, F. Bai<sup>1</sup>, A. Di Biagio<sup>2</sup>, A. Parisini<sup>2</sup>, R. Visonà<sup>3</sup>, D. Ripamonti<sup>4</sup>, G. Travi<sup>5</sup>, A. Capetti<sup>6</sup>, A. d'Arminio Monforte<sup>1</sup>

<sup>1</sup>Department of Medicine, Surgery and Dentistry, University of Milan, Clinic of Infectious Diseases, "San Paolo" Hospital, Milan, Italy; <sup>2</sup>Infectious Diseases Clinic, University of Genoa, San Martino Hospital, Genoa, Italy; <sup>3</sup>Department of Infectious Diseases, Busto Arsizio Hospital, Busto Arsizio, Italy; <sup>4</sup>Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy; <sup>5</sup>Department of Infectious Diseases, Università Vita-Salute San Raffaele Scientific Institute, Milan, Italy; <sup>6</sup>Department of Infectious Diseases "Luigi Sacco" Hospital, Milan, Italy



- PO 31 ANALYSIS OF EFFICACY AND TOLERABILITY OF RALTEGRAVIR-BASED REGIMENS BY BACKGROUND THERAPY IN SALVAGE: A MULTICENTRE ITALIAN EXPERIENCE**  
S. Landonio\*<sup>1</sup>, A. Capetti<sup>1</sup>, P. Meraviglia<sup>2</sup>, A. Di Biagio<sup>3</sup>, S. Lo Caputo<sup>4</sup>, G. Sterrantino<sup>5</sup>, A. Ammassari<sup>6</sup>, B. Menzaghi<sup>7</sup>, M. Franzetti<sup>8</sup>, G. De Socio<sup>9</sup>, G. Pellicano<sup>10</sup>, E. Mazzotta<sup>11</sup>, S. Melzi<sup>1</sup>, P. Zucchi<sup>1</sup>, G. Rizzardini<sup>1</sup>  
<sup>1</sup> 1st Division of Infectious Diseases, "Luigi Sacco" Hospital, Milan, Italy; <sup>2</sup>2nd Division of Infectious Diseases, "Luigi Sacco" Hospital, Milan, Italy; <sup>3</sup>Infectious Diseases Clinic, "San Martino" Hospital, Genoa, Italy; <sup>4</sup>Infectious Diseases Clinic, "Santa Maria Annunziata" Hospital, Florence, Italy; <sup>5</sup> Division Infectious Diseases, "Careggi" Hospital, Florence, Italy; <sup>6</sup>3rd Division of Infectious Disease, "Lazzaro Spallanzani" Hospital, Rome, Italy; <sup>7</sup> Ospedale di Circolo, Division of Infectious Diseases, "Ospedale di Circolo", Busto Arsizio, Italy; <sup>8</sup>3rd Division of Infectious Diseases, "Luigi Sacco" Hospital, Milan, Italy; <sup>9</sup>Division of Infectious Diseases, "S Maria della Misericordia" Hospital, Perugia, Italy; <sup>10</sup>Division of Infectious Diseases, "Policlinico G. Martino", Messina, Italy; <sup>11</sup>Division of Infectious Diseases, "Ospedale Civile Spirito Santo", Pescara, Italy
- PO 32 IN VITRO CELL TOXICITY AND MATRIX METALLOPROTEINASE-9 INHIBITION BY ANTIRETROVIRAL DRUGS IN CULTURED PRIMARY ASTROCYTES**  
G.M. Liuzzi\*<sup>1</sup>, T. Latronico<sup>1</sup>, E. Raimondo<sup>1</sup>, G. Di Bari<sup>1</sup>, F. Mengoni<sup>2</sup>, M. Lichtner<sup>4</sup>, P. Riccio<sup>2</sup>, V. Vullo<sup>3</sup>, C.M. Mastroianni<sup>4</sup>  
<sup>1</sup>Department of Biochemistry and Molecular Biology, University of Bari, Bari, Italy; <sup>2</sup>Department of Biology D.B.A.F., University of Basilicata, Potenza, Italy; <sup>3</sup>"La Sapienza" University, Rome, Italy; <sup>4</sup>"La Sapienza" University, Polo Pontino, Latina, Italy
- PO 33 RENAL TOXICITY FOR SWITCHING FROM TENOFOVIR/EMTRICITABINE (TDF/FTC) TO ABACAVIR/LAMIVUDINE (ABC/3TC): AN ASSOCIATION TO BE CLARIFIED**  
L. Manzini\*<sup>1</sup>, V. Borghi<sup>1</sup>, S. Rusconi<sup>2</sup>, B. Vergani<sup>2</sup>, P. Bonfanti<sup>3</sup>, L. Calza<sup>4</sup>, P. Narciso<sup>5</sup>, F. Lenoci<sup>6</sup>, P. Maggi<sup>6</sup>, C. Mussini<sup>1</sup>  
<sup>1</sup> Clinica di Malattie Infettive Policlinico di Modena, Modena, Italy; <sup>2</sup>Istituto di Malattie Infettive Università di Milano, Ospedale L. Sacco, Milan, Italy; <sup>3</sup> Dipartimento di Malattie Infettive Ospedale L. Sacco, Milan, Italy; <sup>4</sup> Dipartimento di Malattie Infettive Università di Bologna, Bologna, Italy; <sup>5</sup> I.N.M.I. "L. Spallanzani", Rome, Italy; <sup>6</sup>Dipartimento di Malattie Infettive Università di Bari, Bari, Italy
- PO 34 SMOKING AS A RISK FACTOR FOR DETERIORATION OF RENAL FUNCTION IN A COHORT OF HIV-NAÏVE PATIENTS TREATED WITH TENOFOVIR**  
A. Uglietti\*<sup>1</sup>, C. Gervasoni<sup>2</sup>, S. Di Giambenedetto<sup>3</sup>, E. Gabrielli<sup>2</sup>, R. Cauda<sup>3</sup>, R. Esposito<sup>4</sup>, P. Grima<sup>5</sup>, G. Di Perri<sup>6</sup>, R. Maserati<sup>1</sup>, M. Galli<sup>2</sup>  
<sup>1</sup>Clinica di Malattie infettive, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>2</sup>Clinica di Malattie Infettive, Ospedale L. Sacco, Milan, Italy; <sup>3</sup>Clinica di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy; <sup>4</sup>Clinica di Malattie Infettive, Policlinico Universitario, Modena, Italy; <sup>5</sup>Malattie Infettive, Ospedale S. Caterina Novella, Galatina, Italy; <sup>6</sup>Clinica Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy
- PO 35 SAFETY OF FOS-AMPRENAVIR IN HIV INFECTED PATIENTS WITH CO-MORBIDITIES: A RETROSPECTIVE COHORT ANALYSIS**  
V. Esposito\*<sup>1</sup>, P. Chiodini<sup>2</sup>, N. Abrescia<sup>1</sup>, A. Chirianni<sup>1</sup>, M.G. Guida<sup>1</sup>, G. Parrella<sup>1</sup>  
<sup>1</sup>AO Monaldi-Cotugno-CTO, Naples, Italy; <sup>2</sup>Department of Medicine and Public Health, Second University of Naples, Naples, Italy
- PO 36 EFFICACY AND SAFETY OF ATAZANAVIR/RITONAVIR THERAPY IN A COHORT OF TREATMENT-EXPERIENCED PATIENTS**  
B.M. Celesia\*<sup>1</sup>, C. Coco<sup>1</sup>, M.C. Frasca<sup>1</sup>, R. La Rosa<sup>2</sup>, L. Nigro<sup>2</sup>, F. Bisicchia<sup>1</sup>, F. Palermo<sup>1</sup>, G. Nunnari<sup>1</sup>, M.T. Mughini<sup>1</sup>  
<sup>1</sup> U.O. Malattie Infettive Università di Catania ARNAS Garibaldi Catania, Catania, Italy; <sup>2</sup>U.O. Malattie Infettive P.O. Ferrarotto Azienda Policlinico OVE, Catania, Italy

- PO 37** HAART MODIFICATION IN VIROLOGICALLY SUPPRESSED PATIENTS  
 F. Castelnuovo\*<sup>1</sup>, A. Bergamasco<sup>1</sup>, R. Allegri<sup>1</sup>, I. El Hamad<sup>1</sup>, A. Scalzini<sup>1</sup>  
<sup>1</sup>Department of Infectious Diseases, <sup>1</sup> Division, Spedali Civili, Brescia, Italy
- PO 38** RALTEGRAVIR IN CLINICAL PRACTICE: RATES OF VIROLOGICAL FAILURE AT ONE YEAR IN AN OBSERVATIONAL COHORT OF TRIPLE-CLASS DRUG EXPERIENCED PATIENTS  
 L.E. Weimer\*<sup>1</sup>, M. Florida<sup>1</sup>, R. Bucciardini<sup>1</sup>, S. Baroncelli<sup>1</sup>, C. Galluzzo<sup>1</sup>, M.F. Pirillo<sup>1</sup>, V. Fragola<sup>1</sup>, G. D’Ettorre<sup>3</sup>, G. Ceccarelli<sup>3</sup>, S. Donnini<sup>1</sup>, M. Mirra<sup>1</sup>, M. Di Gregorio<sup>1</sup>, S. Lucattini<sup>1</sup>, L. Fucili<sup>1</sup>, F. Baldelli<sup>4</sup>, D. Francisci<sup>4</sup>, L. Martinelli<sup>4</sup>, S. Bastianelli<sup>4</sup>, G. Angarano<sup>5</sup>, N. Ladisa<sup>5</sup>, A. Volpe<sup>5</sup>, V. Vullo<sup>3</sup>, M. Andreoni<sup>6</sup>, L. Sarmati<sup>6</sup>, D. Delle Rose<sup>6</sup>, V. Tozzi<sup>7</sup>, P. Narciso<sup>7</sup>, N. Petrosillo<sup>7</sup>, R. Bellagamba<sup>7</sup>, R. Libertone<sup>7</sup>, S. Cicalini<sup>7</sup>, C. Tommasi<sup>7</sup>, F. Ghinelli<sup>8</sup>, L. Sighinolfi<sup>8</sup>, D. Segala<sup>8</sup>, O. Armignacco<sup>9</sup>, R. Preziosi<sup>9</sup>, C. Ferrari<sup>10</sup>, A. Degli Antoni<sup>10</sup>, A. Cavalli<sup>10</sup>, G. Parruti<sup>11</sup>, F. Sozio<sup>11</sup>, L. Cosentino<sup>11</sup>, A. Vivarelli<sup>12</sup>, P.E. Manconi<sup>13</sup>, F. Ortu<sup>13</sup>, M.L. Di Martino<sup>13</sup>, G. Verucchi<sup>14</sup>, B. Piergentili<sup>14</sup>, M.S. Mura<sup>15</sup>, M. Mannazzu<sup>15</sup>, G. Cattari<sup>15</sup>, R. Del Gobbo<sup>16</sup>, A. Mataloni Paggi<sup>16</sup>, A. Giacometti<sup>16</sup>, O. Cirioni<sup>16</sup>, E. Marchionni<sup>16</sup>, E. Gabrielli<sup>16</sup>, S. Sebastianelli<sup>16</sup>, G. Guaraldi<sup>17</sup>, G. Nardini<sup>17</sup>, B. Beghetto<sup>17</sup>  
<sup>1</sup> Istituto Superiore di Sanità, Roma; <sup>3</sup> “Sapienza” Università di Roma, Roma; <sup>4</sup> Azienda Ospedaliera di Perugia, Perugia; <sup>5</sup> Università di Bari, Bari; <sup>6</sup> Università di Roma “Tor Vergata”, Roma; <sup>7</sup> Istituto Nazionale delle Malattie Infettive “L. Spallanzani”, Roma; <sup>8</sup> Arcispedale S. Anna, Ferrara; <sup>9</sup> Ospedale Belcolle, Viterbo; <sup>10</sup> Ospedale Maggiore di Parma, Parma; <sup>11</sup> Presidio Ospedaliero Santo Spirito, Pescara; <sup>12</sup> Ospedale Civile di Pistoia, Pistoia; <sup>13</sup> Università di Cagliari, Cagliari; <sup>14</sup> Università degli Studi di Bologna, Bologna; <sup>15</sup> Università di Sassari, Sassari; <sup>16</sup> Ospedali Riuniti, Torrette, Ancona; <sup>17</sup> Università degli Studi di Modena e Reggio Emilia, Modena
- PO 39** METABOLIC PROFILE IN A COHORT OF HIV-1 POSITIVE PATIENTS TREATED WITH RAL-BASED SCHEME: RESULTS AFTER 48 WEEKS  
 P. Corsi\*<sup>1</sup>, C. Martinelli<sup>1</sup>, A. Carocci<sup>1</sup>, F. Leoncini  
<sup>1</sup> Infectious Diseases Unit AOU Careggi, Florence, Italy
- PO 40** ONE-PILL ONCE A DAY HAART: SIMPLIFICATION STRATEGY MAINTAINING ADHERENCE, EFFICACY AND IMPROVING PHYSICAL AND PSYCHOLOGICAL OUTCOMES IN A COHORT OF HIV-INFECTED ADOLESCENTS AND YOUTHS  
 V. Manfredini\*<sup>1</sup>, A. Viganò<sup>1</sup>, R. Murri<sup>2</sup>, C. Mameli<sup>1</sup>, S. Trotta<sup>1</sup>, G. De Matteis<sup>2</sup>, F. Di Nello<sup>1</sup>, V. Giacomet<sup>1</sup>, G.V. Zuccotti<sup>1</sup>  
<sup>1</sup>Pediatric Clinic, L. Sacco Hospital, University of Milan, Milan, Italy; <sup>2</sup>Department of Infectious Diseases, Catholic University of Rome, Rome, Italy
- PO 41** RESPONSES TO COMMON VACCINES IN ADOLESCENTS WITH HIV ACQUIRED PERINATALLY  
 R. Rosso<sup>1</sup>, L. De Hoffer<sup>1</sup>, A. Parisini<sup>1</sup>, L.A. Nicolini<sup>1</sup>, G. Secondo<sup>1</sup>, L. Taramasso<sup>1</sup>, E. Nicco<sup>1</sup>, A. Di Biagio\*<sup>1</sup>, C. Viscoli<sup>1</sup>  
<sup>1</sup> Department of Infectious Diseases, University of Genoa at San Martino Hospital, Genoa, Italy
- PO 42** SUCCESSFUL USE OF A DARUNAVIR/RITONAVIR IN FIVE PREGNANT WOMEN: PHARMACOKINETICS, EFFICACY AND SAFETY  
 J. Ivanovic\*<sup>1</sup>, R. Bellagamba<sup>1</sup>, M. Tempestilli<sup>1</sup>, F. Signore<sup>2</sup>, C. Vallone<sup>2</sup>, G. Pisani<sup>2</sup>, E. Nicastrì<sup>1</sup>, C. Tommasi<sup>1</sup>, A.L. Gallo<sup>1</sup>, R. Fezza<sup>1</sup>, L.P. Pucillo<sup>1</sup>, P. Narciso<sup>1</sup>  
<sup>1</sup>National Institute for Infectious Diseases ‘Lazzaro Spallanzani’, Rome, Italy; <sup>2</sup>Department of Obstetrics and Gynaecology, ‘San Camillo-Forlanini’ Hospital, Rome, Italy
- PO 43** FACTORS INFLUENCING THE ACCEPTANCE OF HIV TESTING IN PREGNANT WOMEN LIVING IN BISSAU  
 A. Riva\*<sup>1</sup>, G. Erika<sup>1</sup>, F. Rankin Bravo<sup>2</sup>, D. Da Silva Te<sup>2</sup>, M. Acurie Aquessuen<sup>2</sup>, A. Nanadje<sup>2</sup>, E. Mariani<sup>2</sup>, O. Bosisio<sup>2</sup>, F. Adorni<sup>3</sup>, F. Croce<sup>1</sup>, S. Rusconi<sup>4</sup>, M. Galli<sup>4</sup>  
<sup>1</sup> III Divisione di Malattie Infettive, Ospedale L. Sacco, Milan, Italy; <sup>2</sup> Associaçao Ceu e Terras, Bissau, Italy; <sup>3</sup>Institute of Biomedical

*Technologies, National Research Council, Segrate, Italy; <sup>4</sup>Dipartimento di Scienze Cliniche, Sezione di Malattie Infettive e Immunopatologia, Università di Milano, Milan, Italy*

- PO 44** **HYPOVITAMINOSIS D AND SECONDARY HYPERPARATHYROIDISM IN HIV-INFECTED PATIENTS: A CASE-CONTROL STUDY**  
E. Pontali<sup>1</sup>, A. Giusti<sup>2</sup>, G. Penco<sup>1</sup>, R. Piscopo\*<sup>1</sup>, M. Feasi<sup>1</sup>, A. Barone<sup>2</sup>, M. Razzano<sup>2</sup>, M. Pizzonia<sup>2</sup>, G. Cassola<sup>1</sup>, G. Pioli<sup>3</sup>  
*<sup>1</sup> Department of Infectious Diseases, E.O. Ospedali Galliera, Genoa, Italy; <sup>2</sup> Department of Geriatrics, E.O. Ospedali Galliera, Genoa, Italy; <sup>3</sup>ASMN Hospital, Reggio Emilia, Italy*
- PO 45** **IMMUNO-VIROLOGIC FACTORS INVOLVED IN CARDIOVASCULAR DISEASE (CVD) RISK IN HIV-INFECTED, ART-TREATED INDIVIDUALS**  
S. Parisotto\*<sup>2</sup>, S. Passerini<sup>1</sup>, P. Meraviglia<sup>1</sup>, M. Schiavini<sup>3</sup>, F. Niero<sup>1</sup>, P. Bonfanti<sup>1</sup>, D. Trabattoni<sup>2</sup>, G. Rizzardini<sup>1</sup>, M. Clerici<sup>2</sup>, S. Piconi<sup>1</sup>  
*<sup>1</sup>Infectious Disease Units, H. L. Sacco, Milan, Italy; <sup>2</sup>Chair of Immunology, University of Milan, Milan, Italy; <sup>3</sup>Endocrinologic Unit, H. L. Sacco, Milan, Italy*
- PO 46** **CARDIOVASCULAR RISK FACTORS AND CAROTID INTIMA-MEDIA THICKNESS ARE CORRELATED TO LOWER NEUROCOGNITIVE PERFORMANCE IN HIV-INFECTED PATIENTS**  
M. Fabbiani\*<sup>1</sup>, N. Ciccarelli<sup>1</sup>, M.C. Silveri<sup>1</sup>, M. Tana<sup>2</sup>, S. Farina<sup>1</sup>, E. Baldonero<sup>1</sup>, A. D'Avino<sup>1</sup>, A. Mondì<sup>1</sup>, L. Sidella<sup>1</sup>, E. Tamburrini<sup>1</sup>, R. Cauda<sup>1</sup>, P. Grima<sup>2</sup>, S. Di Giambenedetto<sup>1</sup>  
*<sup>1</sup> Catholic University of Sacred Heart, Rome, Italy; <sup>2</sup>S. Caterina Novella Hospital, Galatina, Italy*
- PO 47** **DYSREGULATION OF ADIPOKINES IN HIV-INFECTED PATIENTS UNDER HAART IS A MARKERS FOR CARDIOVASCULAR RISK?**  
G. Ceccarelli\*<sup>1</sup>, G. D'Ettore<sup>1</sup>, S. Baroncelli<sup>2</sup>, C. Rizza<sup>1</sup>, F. Tierno<sup>1</sup>, P. Massetti<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, S. Vella<sup>2</sup>, V. Vullo<sup>1</sup>  
*<sup>1</sup> Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy; <sup>2</sup>Department of Drug Evaluation Italian Institute of Health ISS Rome, Italy*
- PO 48** **ABACAVIR AND TENOFOVIR IMPACT ON ENDOTHELIAL G. Guaraldi\*<sup>1</sup>, S. Zona<sup>1</sup>, A. Roverato<sup>2</sup>, G. Orlando<sup>1</sup>, F. Carli<sup>1</sup>, A. Lattanzi<sup>1</sup>, L. Manzini<sup>1</sup>, L. Bisi<sup>1</sup>, A. Cicognani<sup>1</sup>, R. Rossi<sup>1</sup>**  
*<sup>1</sup>University of Modena and Reggio Emilia, Modena, Italy; <sup>2</sup>University of Bologna, Bologna, Italy*
- PO 49** **PLASMA CONCENTRATIONS OF SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR AND LIPID METABOLISM CHANGE WITH HIV-RNA AND CD4 CELL COUNTS IN MULTI-EXPERIENCED HIV-1+ PATIENTS TREATED WITH MARAVIROC-BASED ART**  
S. Nozza<sup>1</sup>, E.M. Faioni<sup>2</sup>, M. Pogliaghi\*<sup>1</sup>, G. Fontana<sup>2</sup>, C. Razzari<sup>2</sup>, S. Chiappetta<sup>1</sup>, L. Galli<sup>1</sup>, V. Spagnuolo<sup>1</sup>, G. Tambussi<sup>1</sup>  
*<sup>1</sup>San Raffaele Scientific Institute, Milan, Italy; <sup>2</sup>Università degli Studi di Milano and Az. Ospedaliera San Paolo, Medicina III, Dipartimento di Medicina, Chirurgia e Odontoiatria, Milan, Italy*
- PO 50** **MENOPAUSE IN HIV INFECTED PATIENTS: WOMEN IN A MIDLIFE POLYPATHOLOGY CRISIS**  
C. Berardi\*<sup>1</sup>, R. Rossi<sup>1</sup>, S. Zona<sup>1</sup>, G. Orlando<sup>1</sup>, F. Carli<sup>1</sup>, C. Casalgrandi<sup>1</sup>, A. Bedini<sup>1</sup>, S. Cocchi<sup>1</sup>, M.G. Modena<sup>1</sup>, G. Guaraldi<sup>1</sup>  
*<sup>1</sup> University of Modena and Reggio Emilia, Modena, Italy*
- PO 51** **THE SENSE TRIAL: ETRAVIRINE SHOWS LOWER PREVALENCE AND SEVERITY OF NEUROPSYCHIATRIC ADVERSE EVENTS COMPARED TO EFAVIRENZ IN TREATMENT-NAÏVE PATIENTS**  
A. Uglietti\*<sup>1</sup>, G. Carosi<sup>2</sup>, A. Castagna<sup>3</sup>, M. Andreoni<sup>4</sup>, H. Stellbrink<sup>5</sup>, S. Rugina<sup>6</sup>, C. Zagler<sup>7</sup>, S. Esser<sup>8</sup>, B. Gazzard<sup>9</sup>, A. Hill<sup>10</sup>, Y. van Delft<sup>11</sup>, S. Marks<sup>11</sup>  
*<sup>1</sup> S.Matteo Hospital, University of Pavia, Pavia, Italy; <sup>2</sup> Brescia Civili Hospital, University of Brescia, Brescia, Italy; <sup>3</sup> Fondazione San Raffaele,*

Milan, Italy; <sup>4</sup> Tor Vergata Hospital, University of Rome, Rome, Italy; <sup>5</sup> Infektionsmedizinisches Centrum, Hamburg, Germany; <sup>6</sup> Spitalul Clinic de Boli Infectioase, Constanta, Romania; <sup>7</sup> SMZ Baumgartner, Vienna, Austria, Vienna; <sup>8</sup> Universita'tsklinikum, Essen, Germany; <sup>9</sup> St Stephens Centre, Chelsea and Westminster Hospital, London, UK; <sup>10</sup> Liverpool University and Tibotec BVBA, Liverpool, UK; <sup>11</sup> Janssen-Cilag, Tilburg, The Netherlands

- PO 52** THE EFFECTS OF LIPOIC ACID EYE DROPS IN HIV-POSITIVE PATIENTS  
 A. Uglietti\*<sup>1</sup>, S. Pezzotta<sup>2</sup>, E. Antoniazzi<sup>2</sup>, R. Maserati<sup>1</sup>  
<sup>1</sup> Clinica Malattie Infettive-Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>2</sup> Clinica Oculistica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- PO 53** EVALUATION OF ENDOTHELIAL FUNCTION AND ACTIVATION MARKERS IN HIV-1 INFECTED PATIENTS ON SUPPRESSIVE HAART AFTER SWITCHING TO ABACAVIR / LAMIVUDINE FIXED DOSE: PRELIMINARY RESULTS  
 A. Esposito\*<sup>1</sup>, D. Pastori<sup>2</sup>, R. Carnevale<sup>2</sup>, L. Perri<sup>2</sup>, C. Fimiani<sup>1</sup>, M. Schillizzi<sup>2</sup>, C. Calabrese<sup>2</sup>, A. Fantauzzi<sup>1</sup>, S. Basili<sup>2</sup>, I. Mezzaroma<sup>1</sup>  
<sup>1</sup> Dipartimento di Medicina Clinica, "Sapienza", Università di Roma, Rome, Italy; <sup>2</sup> Dipartimento di Medicina Interna e Specialità Mediche, "Sapienza", Università di Roma, Rome, Italy
- PO 54** EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN A SINGLE CENTER COHORT  
 M. Colafigli\*<sup>1</sup>, M. Proserpi<sup>1</sup>, M. Fabbiani<sup>1</sup>, M. Doino<sup>1</sup>, S. Farina<sup>1</sup>, A. Mondì<sup>1</sup>, A. D'Avino<sup>1</sup>, I. Fanti<sup>1</sup>, R. Cauda<sup>1</sup>, S. Di Giambenedetto<sup>1</sup>  
<sup>1</sup> Università Cattolica del Sacro Cuore, Rome, Italy
- PO 55** BONE MINERAL DENSITY (BMD) FOLLOW UP AMONG HIV-INFECTED SUBJECTS: PREDICTORS OF LOW BMD AT BASELINE  
 M. Feasi\*<sup>1</sup>, G. Penco<sup>1</sup>, A. Giusti<sup>2</sup>, M. Pizzonia<sup>2</sup>, M. Razzano<sup>2</sup>, A. Barone<sup>2</sup>, R. Piscopo<sup>1</sup>, E. Pontal<sup>1</sup>, G. Cassola<sup>1</sup>, G. Pioli<sup>3</sup>  
<sup>1</sup> Department of Infectious Diseases, E.O. Ospedali Galliera, Genoa, Italy; <sup>2</sup> Department of Geriatrics, E.O. Ospedali Galliera, Genoa, Italy; <sup>3</sup> ASMN Hospital, Reggio Emilia, Italy
- PO 56** VITAMIN D AND CARDIOVASCULAR RISK IN HIV+ PATIENTS  
 K. Falasca\*<sup>1</sup>, J. Di Biase<sup>1</sup>, C. Ucciferri<sup>1</sup>, P. Mancino<sup>1</sup>, F. Vignale<sup>1</sup>, M. Vannucci<sup>1</sup>, E. Pizzigallo<sup>1</sup>, J. Vecchiet<sup>1</sup>  
<sup>1</sup> Clinical Infectious Diseases, "G. d'Annunzio" University Chieti-Pescara, Chieti, Italy
- PO 57** LONG-TERM SAFETY OF A DUAL REGIMEN OF RALTEGRAVIR AND RITONAVIR-BOOSTED PROTEASE INHIBITOR IN ARV-EXPERIENCED PATIENTS WITH CHRONIC KIDNEY DISEASE  
 D. Segala\*<sup>1</sup>, R. Roda<sup>1</sup>, M. Libanore<sup>1</sup>, L. Sighinolfi<sup>1</sup>  
<sup>1</sup> U.O. Malattie Infettive, Ferrara, Italy
- PO 58** PREVALENCE AND INCIDENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIV-INFECTED PATIENTS: A PROSPECTIVE COHORT STUDY  
 S. Cicalini\*<sup>1</sup>, P. Chinello<sup>1</sup>, P. Piselli<sup>1</sup>, M. Musso<sup>1</sup>, E. Grilli<sup>1</sup>, A. Agresta<sup>1</sup>, N. Petrosillo<sup>1</sup>  
<sup>1</sup> National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
- PO 59** CAN ADAPTED PHYSICAL ACTIVITY HELP TO CONTROL AND PREVENT THE LIPODYSTROPHIC SYNDROME IN HIV INFECTION? WALKING TO HEALTH PROTOCOL AT AMEDEO DI SAVOIA HOSPITAL IN TURIN  
 M. Guastavigna\*<sup>1</sup>, M. Tettoni<sup>1</sup>, G. Orofino<sup>1</sup>, D. Penoncelli<sup>1</sup>, P. Martinoglio<sup>1</sup>, D. Demarie<sup>1</sup>, P. Desiderato<sup>1</sup>, R. Di Frenna<sup>1</sup>, M. Zignin<sup>2</sup>, C. Zignin<sup>2</sup>  
<sup>1</sup> Ambulatorio Lipodistrofie e Dismetabolismi HIV correlati, ASLTO2, Turin, Italy; <sup>2</sup> SUIISM, Turin, Italy

- PO 60** SWITCHING TO DARUNAVIR/RITONAVIR FROM LOPINAVIR/RITONAVIR OR FOSAMPRENAVIR/RITONAVIR IMPROVES METABOLIC ASSESSMENT IN HIV POSITIVE PATIENTS  
F. Vignale\*<sup>1</sup>, K. Falasca<sup>1</sup>, C. Ucciferri<sup>1,2</sup>, P. Mancino<sup>1</sup>, M. Vannucci<sup>1</sup>, E. Pizzigallo<sup>1</sup>, J. Vecchiet<sup>1</sup>  
<sup>1</sup>Infectious Disease Clinic, Department of Medicine and Science of Aging, "G. d'Annunzio" University, Chieti; <sup>2</sup>Department of Health Sciences, Infectious Disease Unit, School of Medicine, University of Molise, Campobasso, Italy
- PO 61** THE PERFORMANCE OF INTERFERON-G RELEASE ASSAYS (IGRAS) FOR TB DETECTION IS IMPAIRED IN HIV LATE PRESENTATION  
I. Sauzzullo\*<sup>2</sup>, F. Mengoni<sup>2</sup>, R. Rossi<sup>2</sup>, A. Ermocida<sup>2</sup>, M. Lichtner<sup>1</sup>, G. D'Ettore<sup>2</sup>, V. Vullo<sup>2</sup>, C.M. Mastroianni<sup>1</sup>  
<sup>1</sup>Sapienza Università, Polo Pontino, Latina, Italy; <sup>2</sup>Sapienza Università di Roma, Unità di Malattie Infettive, Rome, Italy
- PO 62** HCV OCCULT INFECTION IN HIV POSITIVE SUBJECTS: DOES IT EXIST?  
F. Di Martino<sup>1</sup>, N. Coppola<sup>2</sup>, S. Martini\*<sup>1</sup>, M. Pisaturo<sup>2</sup>, G. Tonziello<sup>2</sup>, A. Masiello<sup>3</sup>, A. Filippini<sup>1</sup>, A. Cascone<sup>1</sup>, E. Sagnelli<sup>2</sup>, P. Filippini<sup>1</sup>  
<sup>1</sup>UOC Diagnosi e Terapia AIDS della AOU della Seconda Università degli Studi di Napoli, Naples, Italy; <sup>2</sup>Clinica di Malattie Infettive della AOU della Seconda Università degli studi di Napoli, Naples, Italy; <sup>3</sup>AORN G. Moscati, Avellino, Italy
- PO 63** EPSTEIN-BARR VIRUS LOAD AND IMMUNE ACTIVATION IN HIV-1 INFECTED PATIENTS  
M.R. Petrara\*<sup>1</sup>, A.M. Cattelan<sup>2</sup>, M. Zanchetta<sup>3</sup>, R. Freguja<sup>1</sup>, K. Giancesin<sup>1</sup>, F. Carmona<sup>3</sup>, A. De Rossi<sup>1</sup>  
<sup>1</sup>Dipartimento di Scienze Oncologiche e Chirurgiche, AIDS Reference Centre, Università degli Studi di Padova, Padova, Italy; <sup>2</sup>Divisione di Malattie Infettive, Ospedale di Rovigo, Rovigo, Italy; <sup>3</sup>Istituto Oncologico Veneto, Padova, Italy
- PO 64** EFFECT OF HCV THERAPY ON IMMUNOLOGICAL HOMEOSTASIS IN HIV/HCV CO-INFECTED PATIENTS  
M. Airoidi\*<sup>1</sup>, P. Nasta<sup>2</sup>, F. Maggiolo<sup>3</sup>, S. Di Gianbenedetto<sup>4</sup>, N. Ladisa<sup>5</sup>, F. Gatti<sup>2</sup>, F. Suter<sup>3</sup>, M. Fabbiani<sup>4</sup>, A. Bandera<sup>1</sup>, A. Gori<sup>1</sup>  
<sup>1</sup>Division of Infectious Diseases, San Gerardo Hospital, University of Milan-Bicocca, Monza, Italy; <sup>2</sup>Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy; <sup>3</sup>Ospedali Riuniti di Bergamo, USC Malattie Infettive, Bergamo, Italy; <sup>4</sup>Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy; <sup>5</sup>Institute of Infectious Diseases, University of Bari, Bari, Italy
- PO 65** VISCERAL LEISHMANIASIS: DEMOGRAPHIC, CLINIC AND THERAPEUTIC PREDICTORS OF INFECTION RECURRENCES  
E. Nicastrì\*<sup>1</sup>, C. Tommasi<sup>1</sup>, M. Viscione<sup>1</sup>, R. Bellagamba<sup>1</sup>, J. Ivanovic<sup>1</sup>, M.G. Paglia<sup>1</sup>, P. Ghirga<sup>1</sup>, A. Corpolongo<sup>1</sup>, A.L. Gallo<sup>1</sup>, P. Narciso<sup>1</sup>  
<sup>1</sup>National Institute for Infectious Diseases, IRCCS, "Lazzaro Spallanzani", Rome, Italy
- PO 66** TUBERCULAR GLUTEUS ABSCESES: A RETURN TO THE EARLY 20TH CENTURY, OR A CONSEQUENCE OF NEW, UNPRECEDENTED BEHAVIORS?  
E.M. Gabrielli\*<sup>1</sup>, F. Zanini<sup>1</sup>, S. Merli<sup>2</sup>, A. Riva<sup>1</sup>, M. Galli<sup>1</sup>, C. Gervasoni<sup>1</sup>  
<sup>1</sup>Clinical Science Department, Section of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy; <sup>2</sup>II Division of Infectious Diseases, L.Sacco Hospital, Milan, Italy
- PO 67** SYPHILITIC HEPATITIS IN A COHORT OF HIV-INFECTED SUBJECTS: INCIDENCE AND RISK FACTORS  
R. Rossotti\*<sup>1</sup>, C. Molteni<sup>1</sup>, P. Bonfanti<sup>1</sup>, A. Orani<sup>1</sup>  
<sup>1</sup>SC Malattie Infettive e Tropicali, AO "A. Manzoni", Lecco, Italy
- PO 68** WHAT ABOUT BACTERIAL PNEUMONIA AFTER MORE THAN A DECADE OF HAART?  
M. Carugati\*<sup>1</sup>, F. Zanini<sup>1</sup>, C. Schirotti<sup>1</sup>, L. Tocalli<sup>2</sup>, F. Franzetti<sup>1</sup>  
<sup>1</sup>Clinica di Malattie Infettive A.O. - Polo Universitario "L. Sacco", Milan, Italy; <sup>2</sup>Laboratorio di Microbiologia A.O. Polo Universitario "Luigi Sacco", Milan, Italy

- PO 69** EFFECTS OF CADMIUM AND GC-MACROPHAGE ACTIVATING FACTOR (GCMF) ON INTRACELLULAR HIV TARGETS IN NORMAL AND TRANSFORMED HUMAN BREAST CELLS  
G. Morucci<sup>1</sup>, T. Punzi<sup>1</sup>  
<sup>1</sup>Department of Anatomy, Histology and Forensic Medicine, University of Firenze, Florence, Italy
- PO 70** ANAL MALIGNANCIES ASSOCIATED TO CONDYLOMA ACUMINATA: DIFFERENCES BETWEEN HIV+ AND HIV-PATIENTS  
M. Mistrangelo<sup>1</sup>, I. Dal Conte<sup>2</sup>, P. Cassoni<sup>3</sup>, R. Senetta<sup>3</sup>, S. Delmonte<sup>4</sup>, V. Ghisetti<sup>3</sup>, S. Rondoletti<sup>4</sup>, R. Brustia<sup>1</sup>, A. Rosanò<sup>1</sup>, G. Gavello<sup>1</sup>, S. Volpato<sup>1</sup>, M. Morino<sup>1</sup>  
<sup>1</sup> Digestive and Coloproctological Surgical Department and Centre of Minimally Invasive Surgery, University of Turin, Molinette Hospital, Turin, Italy; <sup>2</sup>Infectious Diseases Department, University of Turin, Amedeo di Savoia Hospital, Turin, Italy; <sup>3</sup>Department of Biomedical Sciences and Human Oncology, University of Turin, Molinette Hospital, Turin, Italy; <sup>4</sup>Dermatological Department, University of Turin, Turin, Italy
- PO 71** BREAST CANCERS AND LUNG CANCERS IN HIV-POSITIVE PATIENTS FROM 1999 TO 2009 IN THE INSTITUTE OF INFECTIOUS DISEASES OF BRESCIA: LESSONS LEARNED FROM CLINICAL CASES  
A. Vavassori<sup>1</sup>, A. Ferraresi<sup>1</sup>, A. Calabresi<sup>1</sup>, I. Izzo<sup>1</sup>, F. Castelnuovo<sup>1</sup>, I. El Hamad<sup>1</sup>, M. Mendeni<sup>1</sup>, E. Focà<sup>1</sup>, G. Cristini<sup>1</sup>, C. Torti<sup>1</sup>, E. Quiros Roldan<sup>1</sup>  
<sup>1</sup> Department of Infectious Diseases, University and Spedali Civili of Brescia, Brescia, Italy
- PO 72** NON-HODGKIN LYMPHOMA IN HIV PATIENTS: INFECTIOUS COMPLICATIONS AND SURVIVAL RATE  
S. Grignolo<sup>1</sup>, E. Nicco<sup>1</sup>, A. Parisini<sup>1</sup>, M. Bassetti<sup>1</sup>, A. Di Biagio<sup>1</sup>, F. Ballerini<sup>1</sup>, C. Viscoli<sup>1</sup>  
<sup>1</sup>Department of Infectious Diseases, University of Genoa, San Martino Hospital, Genoa, Italy
- PO 73** ORAL HPV-RELATED MALIGNANCIES IN HIV POSITIVE INDIVIDUALS: A CLINICAL CASE  
F. Vignale<sup>1</sup>, C. Ucciferri<sup>1</sup>, K. Falasca<sup>1</sup>, P. Mancino<sup>1</sup>, M. Vannucci<sup>1</sup>, E. Pizzigallo<sup>1</sup>, J. Vecchiet<sup>1</sup>  
<sup>1</sup> Infectious Disease Clinic, Department of Medicine and Science of Aging "G. d'Annunzio" University, Chieti, Italy
- PO 74** SEXUAL TRANSMISSION OF A DRUG HIV1 VIRUS: DATING OF THE INFECTION BY PHYLOGENETIC ANALYSIS  
A.R. Pignataro<sup>1</sup>, F. Cossarini<sup>2</sup>, F. Canducci<sup>1</sup>, M. Sampaolo<sup>1</sup>, V. Spagnuolo<sup>2</sup>, A. Castagna<sup>2</sup>, M. Clementi<sup>3</sup>, E. Boeri<sup>1</sup>  
<sup>1</sup> Diagnostica e Ricerca San Raffaele, Milan, Italy; <sup>2</sup> Dipartimento di Malattie Infettive San Raffaele, Milan, Italy; <sup>3</sup> Università Vita e Salute San Raffaele, Milan, Italy
- PO 75** CMV RELATED UVEITIS AND KS IN AN AIDS PRESENTER PATIENT WITH NHL TREATED WITH RITUXIMAB: CASE REPORT  
A. Franco<sup>1</sup>, L. Aprea<sup>1</sup>, C. Dell'Isola<sup>1</sup>, T. Garofano<sup>2</sup>, E. Manzillo<sup>1</sup>, V. Montesarchio<sup>2</sup>, T. Pizzella<sup>1</sup>, F. Simioli<sup>1</sup>, C.M. Izzo<sup>1</sup>  
<sup>1</sup> VIII Department of Infectious Diseases, Monaldi-Cotugno-CTO Hospital, Naples, Italy; <sup>2</sup> Oncology Unit, Monaldi-Cotugno-CTO Hospital, Naples, Italy
- PO 76** PROTEASE INHIBITORS AND HIV-RELATED DEMYELINATING POLYNEUROPATHIES: A NEW POSSIBLE TREATMENT?  
G. Ceccarelli<sup>1</sup>, A. Clemenzi<sup>2</sup>, G. Antonini<sup>2</sup>, C. Rizza<sup>1</sup>, G. D'Ettore<sup>1</sup>, V. Vullo<sup>1</sup>  
<sup>1</sup> Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Italy; <sup>2</sup> Department of Neurological Science, II "Sapienza" University of Rome, Rome, Italy
- PO 77** KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS/HUMAN HERPESVIRUS TYPE 8-POSITIVE CUTANEOUS LYMPHOMAS  
S. Migliore<sup>1</sup>, N. Storaci<sup>1</sup>, G. Gambuzza<sup>1</sup>, A. Famà<sup>1</sup>, A. Iacono<sup>1</sup>  
<sup>1</sup> UOC Malattie Infettive, Ragusa, Italy

- PO 78** SEVERE OSTEOPOROSIS IN A YOUNG HIV-INFECTED MAN TREATED WITH TERIPATIDE  
 R. Marocco\*<sup>1</sup>, C. Del Borgo<sup>1</sup>, R. Cesareo<sup>2</sup>, V.S. Mercurio<sup>1</sup>, V. Belvisi<sup>1</sup>, M. Lichtner<sup>1</sup>, C.M. Mastroianni<sup>1</sup>  
<sup>1</sup>Infectious Disease Unit, SM Goretti Hospital Latina, Italy;  
<sup>2</sup>Endocrinology, SM Goretti Latina, Latina, Italy
- PO 79** PROGRESSIVE DISSEMINATED HISTOPLASMOSIS DETECTED BY A RAPID AND AGGRESSIVE DIAGNOSTIC APPROACH  
 G. Montorzi\*<sup>1</sup>, L. Zammarchi<sup>1</sup>, J. Nocentini<sup>1</sup>, F. Baragli<sup>1</sup>, D. Magnelli<sup>1</sup>, L. Attala<sup>1</sup>, A. Bartoloni<sup>1</sup>  
<sup>1</sup>Clinica Malattie Infettive, Università di Firenze, Florence, Italy
- PO 80** AVASCULAR NECROSIS OF THE BONE IN HIV-INFECTED PATIENTS: A POSSIBLE RULE OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME  
 F. Prati<sup>1</sup>, E. Barchi\*<sup>1</sup>, G. Zoboli<sup>1</sup>, G. Magnani<sup>1</sup>  
<sup>1</sup>U.O. Malattie Infettive ASMN, Reggio Emilia, Italy
- PO 81** CLINICAL SIGNIFICANCE AND MANAGEMENT OF SEVERE HYPONATREMIA IN A CRITICALLY ILL AIDS PRESENTER  
 V. Belvisi\*<sup>1</sup>, A. Vetica<sup>1</sup>, P. Fabietti<sup>1</sup>, C. Del Borgo<sup>1</sup>, R. Citton<sup>1</sup>, V. Mercurio<sup>1</sup>, T. Tieghi<sup>1</sup>, C.M. Mastroianni<sup>1</sup>  
<sup>1</sup>Infectious Disease Unit, SM Goretti Hospital Sapienza University, Latina, Italy
- PO 82** THE MIGRATION PROJECT IN VENETO REGION: EVALUATION OF THE EPIDEMIOLOGICAL IMPACT OF TUBERCULOSIS, HIV, HBV, HCV INFECTIONS AND SYPHILIS (MARCO POLO PROJECT)  
 E. Morelli\*<sup>1</sup>, M. Disegna<sup>2</sup>, N. Gennaro<sup>2</sup>, C. Gallo<sup>2</sup>, A.M. Cattelan<sup>3</sup>, M.G. Cecchetto<sup>3</sup>, G. Pelizzer<sup>4</sup>, M. Conforto<sup>4</sup>, C. Facchin<sup>4</sup>, P.G. Scotton<sup>5</sup>, F. Farina<sup>5</sup>, R. Rinaldi<sup>6</sup>, S. Tisato<sup>6</sup>, L. Falcone<sup>6</sup>, P. Rovere<sup>7</sup>, V. Mondardini<sup>8</sup>, F. Marangoni<sup>9</sup>, R. Ferretto<sup>9</sup>, E. Concia<sup>10</sup>, R. Valentinotti<sup>10</sup>, E. Raise<sup>1</sup>  
<sup>1</sup>U.O.di Malattie Infettive, Ospedale SS Giovanni e Paolo, Venezia e Ospedale dell'Angelo, Zelarino (Mestre), Italy; <sup>2</sup>Agenzia Regionale Socio Sanitaria del Veneto, Venezia, Italy; <sup>3</sup>U.O.di Malattie Infettive, Ospedale Santa Maria della Misericordia, Rovigo, Italy; <sup>4</sup>U.O. di Malattie Infettive, Ospedale San Bortolo, Vicenza, Italy; <sup>5</sup>U.O.di Malattie Infettive, Ospedale Cà Foncello, Treviso, Italy; <sup>6</sup>U.O.di Malattie Infettive, Azienda Ospedaliera di Padova, Padua, Italy; <sup>7</sup>U.O.di Malattie Infettive, Ospedale di Legnago, Italy; <sup>8</sup>U.O.di Malattie Infettive, Ospedale San Martino, Belluno, Italy; <sup>9</sup>U.O.di Malattie Infettive, Ospedale di Schio; <sup>10</sup>U.O.di Malattie Infettive, Azienda Ospedaliera di Verona, Italy

## EPIDEMIOLOGY AND SOCIAL SCIENCES

- PO 83** HIV PREVALENCE AMONG PATIENTS WITH SEXUALLY TRANSMITTED INFECTIONS IN ITALY 1991-2007  
 V. Regine\*<sup>1</sup>, M.C. Salfa<sup>1</sup>, M. Raimondo<sup>1</sup>, L. Camoni<sup>1</sup>, M. Giuliani<sup>1</sup>, B. Suligoi<sup>1</sup> and the Italian STI Surveillance Working Group<sup>2</sup>  
<sup>1</sup>Centro Operativo AIDS, Istituto Superiore di Sanità, Rome, Italy;  
<sup>2</sup>G. Angelini (Bari), N. Aste (Cagliari), M. Cusini (Milan), A. D'Antuono (Bologna), S. Delmonte (Turin), A. Di Carlo (Rome), I. El-Hamad (Brescia), A. Matteelli (Brescia), G. Moise (Gorizia), L. Priano (Genoa), F. Urbani (Trento), G. Zucatti (Florence) - Italy
- PO 84** HIV INFECTION IN A COHORT OF ADULT MIGRANTS  
 N. Marino\*<sup>1</sup>, C. Blè<sup>1</sup>, P. Pierotti<sup>1</sup>, P. Zagli<sup>1</sup>, A. Poggi<sup>1</sup>, F. Mazzotta<sup>1</sup>  
<sup>1</sup>Azienda Sanitaria Firenze, Florence, Italy
- PO 85** SURVEILLANCE SYSTEM FOR HIV INFECTION IN TUSCANY  
 V. Casotto\*<sup>1</sup>, F. Voller<sup>1</sup>, E. Balocchini<sup>2</sup>, F. Cipriani<sup>1</sup>  
<sup>1</sup>Regional Health Agency of Tuscany, Florence, Italy; <sup>2</sup>Tuscany Region, Florence, Italy

- PO 86** 20-YEAR (1990-2009) CHANGING PATTERN OF PERSONS ATTENDING AT ITALIAN NATIONAL INSTITUTE FOR INFECTIOUS DISEASES (INMI) "LAZZARO SPALLANZANI" FOR HIV COUNSELLING AND TESTING IN ROME  
 F.M. Fusco<sup>1</sup>, S. Pittalis\*<sup>1</sup>, A. Navarra<sup>1</sup>, G. De Carli<sup>1</sup>, N. Orchi<sup>1</sup>, P. Scognamiglio<sup>1</sup>, C. Angeletti<sup>1</sup>, E. Girardi<sup>1</sup>, V. Puro<sup>1</sup>, G. Nurra<sup>1</sup>, G. Ippolito<sup>1</sup>  
<sup>1</sup>Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani", Rome, Italy
- PO 87** RESULTS OF EPIDEMIOLOGICAL SURVEILLANCE OF AIDS CASES IN TUSCANY  
 J.J.V. Branca\*<sup>2</sup>, S. Pacini<sup>2</sup>, M. Ruggiero<sup>3</sup>  
<sup>2</sup> Department of Anatomy, Histology and Forensic Medicine, University of Firenze, Florence, Italy; <sup>3</sup>Department of Experimental Pathology and Oncology, University of Firenze, Florence, Italy
- PO 88** HIV / AIDS: UNA MALATTIA DIMENTICATA  
 S. Corso\*<sup>1</sup>, A. Poggi<sup>2</sup>, D. Romeo<sup>3</sup>, A. Alecci<sup>4</sup>, S. Franciolini<sup>5</sup>, A. Campani<sup>5</sup>, C. Bartolozzi<sup>5</sup>, F. Bacherini<sup>5</sup>, B. Di Giacomo<sup>5</sup>, F. Polverini<sup>6</sup>, S. Lo Caputo<sup>2</sup>, F. Mazzotta<sup>2</sup>  
<sup>1</sup>LILA-Toscana, Florence, Italy; <sup>2</sup>UOC Malattie Infettive-Azienda Sanitaria Firenze, Florence, Italy; <sup>3</sup>UO Medicina di Comunità-Azienda Sanitaria Firenze, Florence, Italy; <sup>4</sup>Dipartimento di Patologia Clinica-Azienda Sanitaria Firenze, Florence, Italy; <sup>5</sup>UO Assistenza Infermieristica Territoriale-Azienda Sanitaria Firenze, Florence, Italy; <sup>6</sup>Dipartimento di Statistica-Università di Firenze, Florence, Italy
- PO 89** TOWARD IMPROVEMENTS IN HIV EPIDEMIOLOGY  
 M. Prayer Galletti\*<sup>1</sup>, S. Pacini<sup>2</sup>, G. Morucci<sup>2</sup>, H.H. Bauer<sup>3</sup>  
<sup>1</sup>Department of Experimental Pathology and Oncology, University of Firenze, Florence, Italy; <sup>2</sup>Department of Anatomy, Histology and Forensic Medicine, University of Firenze, Florence, Italy; <sup>3</sup>Virginia Polytechnic Institute & State University, Blacksburg, VA, USA
- PO 90** META-ANALYSIS AND UPDATE ON THE GENERAL AIDS EPIDEMICS PREDICTED FOR AFRICA  
 P.H. Duesberg<sup>1</sup>, D. Mandrioli<sup>1</sup>, A. McCormack<sup>1</sup>, J.M. Nicholson<sup>2</sup>, C. Del Popolo\*<sup>3</sup>, D. Rasnick<sup>4</sup>, C. Fiala<sup>5</sup>, C. Koehnlein<sup>6</sup>, H.H. Bauer<sup>7</sup>  
<sup>1</sup> University of California, Berkeley, USA; <sup>2</sup> Virginia Tech, Blacksburg, USA; <sup>3</sup> Department of Anatomy, Histology and Forensic Medicine, Florence, Italy; <sup>4</sup> Oakland, California, USA; <sup>5</sup> Gynmed Ambulatorium, Vienna, Austria; <sup>6</sup> Internistische Praxis, Kiel, Germany; <sup>7</sup> Virginia Tech, Blacksburg, USA
- PO 91** ACTIVE IN-THE-FIELD SURVEILLANCE REVEALS HIGH RATES OF HIV AND HEPATITIS INFECTION AMONG AN IMMIGRATE POPULATION  
 G. Stornaiuolo<sup>1</sup>, V. Cuniato<sup>2</sup>, G. Cuomo\*<sup>1</sup>, E. Nocera<sup>2</sup>, G. Brancaccio<sup>1</sup>, M. De Rosa<sup>2</sup>, A. Pontarelli<sup>1</sup>, R.F. Natale<sup>2</sup>, G.B. Gaeta<sup>1</sup>  
<sup>1</sup>UOC Malattie Infettive ed Epatiti Virali, Seconda Università degli Studi di Napoli, Naples, Italy; <sup>2</sup>Associazione di Volontariato "Jerry Essan Masslò", Castelvolturno, CE, Italy
- PO 92** A WANDERING BUS FOR THE PREVENTION OF HIV AND SEXUALLY TRANSMITTED DISEASES: THE PROJECT "PARLIAMONETOUR" (LET'S TALK TOUR) OF THE COTUGNO HOSPITAL  
 A. Franco<sup>1</sup>, E. Guidetti<sup>1</sup>, M. Figoni<sup>1</sup>, C. Dell'Isola\*<sup>1</sup>  
 for "PARLIAMONETOUR" Group co-authors, A. Giordano<sup>1</sup>  
<sup>1</sup> Monaldi-Cotugno-CTO Hospital, Naples, Italy
- PO 93** HIV SELF-REPORTED PREVALENCE AND OTHER INDICATORS ON HIV TESTING AND PREVENTION AMONG MSM IN ITALY. DATA FROM EMIS PROJECT  
 M. Breveglieri\*<sup>1</sup>, M. Furegato<sup>1</sup>, R. Lelleri<sup>2</sup>, L. Pietrantoni<sup>2</sup>, R. Zini<sup>4</sup>, B. Suligoi<sup>3</sup>, M. Mirandola<sup>1</sup>  
<sup>1</sup>Regional Centre for Health Promotion - Regione Veneto, Verona, Italy; <sup>2</sup>Dipartimento di Scienze dell'Educazione - Università di Bologna, Bologna, Italy; <sup>4</sup>Arcigay - Associazione Lesbica e Gay Italiana, Bologna; <sup>5</sup>Istituto Superiore Sanità, Rome, Italy



## Informazioni Scientifiche

### LINGUE UFFICIALI

Lingue ufficiali del Congresso: italiano e inglese. Non è previsto un sistema di traduzione simultanea.

### SVOLGIMENTO DEI LAVORI

Tutti gli oratori dovranno attenersi rigorosamente ai tempi assegnati per assicurare un corretto svolgimento delle varie Sessioni.

### COMUNICAZIONI ORALI

Ad ogni Comunicazione saranno concessi 10 minuti per l'esposizione e 2 per la discussione.

### SHORT COMMUNICATIONS

Ad ogni Short Communication saranno concessi 8 minuti per l'esposizione e 2 per la discussione

### POSTERS E POSTER PRESENTATIONS

Misure dei Poster: cm. 70 di larghezza – cm. 100 di altezza.

Il materiale per il montaggio sarà disponibile presso l'area di affissione. L'affissione dei Poster potrà essere effettuata a partire dalle ore 12.00 di Domenica 27 Marzo 2011 secondo la numerazione predisposta dalla Segreteria, alla quale si prega attenersi.

Alla discussione dei Poster è richiesta la presenza di uno degli Autori.

### ICAR 2011 ON-LINE

Tutte le presentazioni del Congresso, autorizzate dagli Autori, saranno disponibili *on-time* sul sito [www.icar2011.it](http://www.icar2011.it)

### SUPPORTI INFORMATICI E CENTRO SLIDE

È prevista la proiezione computerizzata. Al fine di evitare problemi di interfacciamento tra i portatili dei Relatori e il proiettore della Sala e per rendere più veloce il susseguirsi delle relazioni, non sarà possibile collegare i propri computer portatili nella Sala. Si raccomanda ai Relatori di voler consegnare la propria relazione al Centro Slide, se possibile, il giorno prima o almeno 2 ore prima dell'inizio della Sessione per permettere ai tecnici di duplicare la presentazione e per consentire un migliore svolgimento dei lavori. I files delle presentazioni dovranno essere preparati con il Programma Power Point.

### ISCRIZIONE DEGLI AUTORI

Il pagamento della quota di iscrizione è condizione indispensabile per poter presentare il proprio contributo selezionato come Comunicazione o Poster.

### ATTI DEL CONGRESSO

Gli Atti del Congresso sono pubblicati su *Infection* (Supplemento con gli Abstracts selezionati)

### ICAR 2011 AWARDS

Verranno assegnati ai migliori contributi scientifici selezionati per qualità, originalità e rilevanza dell'argomento trattato, i seguenti Premi:

Premio Scientifico "G.B. Rossi"- Anlaids; Premio Fondazione Aviralia; Premio SIMIT "R. Rosso", Premio SIVIM e Premio SIMIT.

**CREDITI FORMATIVI ECM**

Il Congresso e i Pre-Congress Courses sono stati accreditati dalla Commissione Nazionale per la Formazione Continua in Medicina del Ministero della Salute.

**BADGE ELETTRONICO NOMINATIVO**

A tutti i Partecipanti regolarmente iscritti verrà consegnato un badge elettronico nominativo che dovrà essere sempre indossato per poter accedere alle Sessioni scientifiche ed al Programma congressuale. Il badge consente, inoltre, la rilevazione delle presenze per l'attribuzione dei crediti formativi. Per ottenere i crediti ECM è necessario: partecipare alle Sessioni Scientifiche, compilare le schede ECM dedicate a ICAR 2011 e consegnarle alla Segreteria al termine del Congresso. Il certificato ECM verrà inviato a mezzo mail.

**ATTESTATO DI PARTECIPAZIONE**

Un Attestato di Partecipazione verrà rilasciato, su richiesta, al termine del Congresso.

**Informazioni Generali****SEDE DEL CONGRESSO**

Palazzo dei Congressi  
Piazza Adua 1 – 50123 Firenze

**CERIMONIA INAUGURALE**

Palazzo Vecchio – Salone dei Cinquecento  
Piazza della Signoria 1 – 50122 Firenze

**SEGRETARIA ICAR 2011**

La Segreteria Organizzativa sarà a disposizione dei Partecipanti in Sede Congressuale durante i seguenti orari:

|  |               |
|--|---------------|
| Domenica 27 Marzo 2011 – Palazzo dei Congressi | 12.30 – 17.00 |
| Domenica 27 Marzo 2011 – Palazzo Vecchio       | 16.30 – 21.00 |
| Lunedì 28 Marzo 2011 – Palazzo dei Congressi   | 07.30 – 19.30 |
| Martedì 29 Marzo 2011 – Palazzo dei Congressi  | 07.30 – 19.00 |

**CYBER POINT**

Sarà a disposizione dei congressisti un servizio di Internet Point (accesso al servizio in osservanza dell'art. 7 D.L. 144/2005).

**ESPOSIZIONE TECNICO SCIENTIFICA**

Nell'ambito del Congresso sono previsti Meeting-Information-Point riservati alle Aziende Farmaceutiche, alle Società scientifiche ed alle Associazioni per incontri con i Congressisti.

**TAXI**

Radio Taxi Firenze: tel. 055.4390

**COFFEE & MEALS****Coffee Stations**

Nell'area congressuale saranno a disposizione dei congressisti delle *Coffee Stations* con bevande calde.

**Refreshments & Light Lunches**

Dalle 13.00 alle 14.00 saranno messi a disposizione dei congressisti i tipici "salati toscani", bevande e soft drinks per un *light lunch*.

---

Servizi bar e caffetteria saranno disponibili all'interno del Palazzo dei Congressi; nelle immediate vicinanze, tipici Ristoranti sono facilmente raggiungibili dalla Sede Congressuale.



ACKNOWLEDGEMENTS  
WITH UNRESTRICTED EDUCATIONAL GRANTS OF

## Sponsor Platinum

---



## Altri Sponsor

---





## **Patrocini**

**Sotto l'Alto Patronato del Presidente della Repubblica**

**Ministero della Salute**

**Comune di Firenze • Provincia di Firenze • Regione Toscana**

**Università degli Studi di Firenze • Università degli Studi di Roma Tor Vergata**

**Azienda Sanitaria di Firenze • Azienda Ospedaliero-Universitaria Careggi**

**AIFA • Fondazione Aviralta Onlus • AIMI**